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A.    Theoretical Part 
 
1.    Introduction 
 
1.1    Drug discovery  
 
1.1.1    History of important drugs derived from plants 
 
In 1785, Whitering published the use of Digitalis purpurea, and this eventually led to 
the isolation of digoxin, a cardiotonic agent [1]. In 1816, Sertürner isolated the 
analgesic, morphine, from Papaver somniferum, and the isolation of the antimalarial 
drug, quinine, from the bark of Cinchona pubescens was reported in 1820. Some 
other discovery highlights were the isolation of atropine from Atropa belladona in 
1831, cocaine from Erythroxylum coca in 1860, and ephedrine from Ephedra sinica in 
1887 [2]. The alkaloids vinblastine and vincristine from the Madagascar periwinkle 
Catharanthus roseus became available in the 1960’s and are now extensively used 
in the treatment of different cancer disease types [3]. Another promising anticancer 
drug is taxol, which was isolated from Taxus brevifolia in 1971. In the early 1970’s 
artemisinin, a potent and essentially non-toxic antimalarial agent was isolated from 
Artemisia annua, a Chinese medicinal plant [4].  
 
 
1.1.2    Strategy in the search of new biologically active plant constituents 
 
Of the estimated 250.000-500.000 plant species around the globe, only a small 
percentage has been investigated phytochemically and the fraction subjected to 
biological or pharmacological screening is even lower [5]. The approach to obtain an 
exploitable pure plant constituent involves interdisciplinary work in botany, 
pharmacognosy, pharmacology, chemistry and toxicology and can be formulated as 
follows [6] : 
1) Selection, collection, proper botanical identification and drying of the plant 
material 
2) Preparation of appropriate extracts 
3) Biological screening (in vitro assays) of the crude extracts 
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4) Chromatographic separation of pure bioactive constituents  
(bioassay-guided fractionation) 
5) Verification of the purity of the isolated compounds 
6) Structure elucidation by chemical and physicochemical methods 
7) Partial or total synthesis 
8) Preparation of derivatives/analogues for the investigation of structure-activity 
relationships 
9) Large-scale isolation for further pharmacological and toxicological tests 
 
The work presented in the present thesis involved the steps 1) to 6); the procedure is 
summarized in scheme 1. 
 
Sample acquisition 
Ethnobotanical and random 
approach 
 
Botanical 
identification 
 
Extraction 
 
Bioassays 
Antiprotozoal screening and 
receptor-binding studies 
 
Separation 
Bioassay-guided fractionation 
 
Pure constituents 
 
Structure elucidation 
 
               Bioassays 
Determination of IC50 values for 
activity and cytotoxicity and  
electrophysiological 
investigations 
 
Scheme 1 : Procedure to obtain biologically active plant constituents. 
 
One of the most delicate steps in any drug discovery program from higher plants is 
the selection of plant species to be collected for investigation. Possible approaches 
are described in the following : 
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Random approach 
This involves collection of plants in a given locality to generate a large number of 
plant materials. This will provide a great chemical diversity, which increases the 
chance of obtaining a biologically active molecule [7].  
 
Chemotaxonomic approach 
In the chemotaxonomic approach, the plant is chosen based on taxonomic 
relationships to plants which have already been reported to contain compounds of 
biological interest [8]. 
 
Ecological approach 
The survival of any organism depends on its ability to adapt to its ecosystem. It is 
believed, that some of the essential plant constituents have been produced by the 
plants either for their own physiological process or as a defense against predators. 
Careful observations of plant-animal interaction within a given ecosystem can serve 
as indicator for possible activity [7]. 
 
Ethnopharmacological approach 
Ethnopharmacology can be defined as the interdisciplinary scientific exploration of 
biologically active agents traditionally employed or observed by man [9]. The idea of 
this approach is that the indigenous use of medicinal plants can offer indications to 
the biological activities of those plants.  
 
 
1.2    Medicinal plants 
 
Medicinal plants also known as herbs, herbal medicines, pharmacologically active 
plants or phytomedicinals, are the dominant form of medicine in most countries. 
Upwards of three-fourths of the population of the planet is primarily dependent on raw 
plant products to meet daily health care needs [10].  
 
 
 
 
 4 
 
1.2.1    Reports on medicinal plants in Tanzania 
 
Although various plants from the local flora of Tanzania are used as remedies, only a 
small number of these plants have been identified. Haerdi [11] identified 625 plants 
used by healers in villages around the town of Ifakara in central Tanzania. Kokwaro 
[12] listed over 1000 East African medicinal plants which are used by traditional 
healers in Kenya and/or Tanzania. Hedberg et al. [13-15] listed 153 plants which are 
used in the northeastern part of Tanzania. Chhabra et al. [16, 17] mentioned 146 
plants used by healers in five regions of eastern Tanzania, Coast, Dar Es Salaam, 
Kilimanjaro, Morogoro and Tanga. Some Tanzanian medicinal plants have been 
screened for antiprotozoal activity and active plant extracts have been investigated 
phytochemically [18-22]. 
 
 
1.2.2    Antiprotozoal natural products from medicinal plants 
 
There is a need to develop new antiprotozoal drugs which have novel structures and 
novel mode of action. Protozoa are responsible for several diseases which are of 
world wide importance, including amoebiasis, giardiasis, leishmaniasis, malaria and 
trypanosomiasis [23]. A selection of natural products with antiprotozoal activity is 
shown in table 1. 
 
Table 1 : Natural products with antiprotozoal activity. 
Natural product  
class 
Compound Protozoa/Disease Isolated from  
Medicinal plant/References 
A. Terpenoids    
Sesquiterpenes Artemisinin Plasmodium falciparum / 
Malaria 
Artemisia annua [24] 
    
 Yingzaosu A, C 
 
Plasmodium falciparum / 
Malaria 
Artobotrys unicatus [25, 26]  
    
 Parthenin Plasmodium falciparum / 
Malaria 
Parthenium hysterophorus 
[27, 28] 
   
 
 Dehydrozaluzanin C Leishmania promastigotes / 
Leishmaniasis 
Trypanosoma cruzi / 
American trypanosomiasis 
Munnozia maronii [29] 
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Table 1  (continued)    
Natural product  
class 
Compound Protozoa/Disease Isolated from  
Medicinal plant/References 
Quassinoids Brusatol 
Bruceine D 
Plasmodium falciparum / 
Malaria 
Brucea javanica [30] 
 
B. Alkaloids    
Isoquinolines Tetrandrine Plasmodium falciparum / 
Malaria 
Cylea barbata [31] 
 
    
Indoles Vinblastine Trypanosoma cruzi / 
American trypanosomiasis 
Catharanthus roseus [32] 
 
    
C. Quinones Jacaranone Leishmania amazonensis / 
Leishmaniasis 
Jacaranda copaica [33] 
 
    
D. Flavonoids Artemetin 
Casticin 
Plasmodium falciparum / 
Malaria 
Artemisia annua [34] 
 
 
 
1.3    Traditional medicine 
 
Traditional medicine is a medical system based on cultural beliefs and practices 
handed down from generation to generation. In many rural communities of 
developing countries, the use of remedies based on traditional medicine form the 
basic core of health care. The concept includes mystical and magical rituals, herbal 
therapy, and other treatments, which may not be explained by modern medicine. 
Traditional systems in general have had to meet the needs of local communities for 
many centuries. 
 
Over the years, the World Health Assembly has adopted a number of resolutions 
drawing attention to the fact that most of the populations in various developing 
countries around the world depend on traditional medicine for primary health care, 
that the work force represented by practitioners of traditional medicine is a potentially 
important resource of the delivery of health care and the medicinal plants are of great 
importance to the health of individuals and communities [35].  
 
The reasons for inclusion of traditional healers in primary health care are manifold : 
the healers know the sociocultural background of the people; they are highly 
respected and experienced in their work; economic considerations; the distances to 
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be covered in some countries; the strength of traditional beliefs, the shortage of 
health professionals, particularly in rural areas [36].   
 
 
1.3.1    Traditional African medicine 
 
Traditional African medicine can be characterised as by the following attributes [37]  : 
 
a) Unwritten knowledge. The body of knowledge pertaining to traditional African 
medicine is largely unwritten. Until recently, most of the practitioners were 
illiterate and the ideas upon which its practice is based have never been 
subjected to systematic critical evaluation.  
 
b) Empiricism. The system is not based on any recognised scientific framework, but 
rather on the accumulated experience of what has proved effective. Empirical 
knowledge thus derived has been handed down from generation to generation 
through apprenticeship or family lineage. 
 
c) The role of supernatural forces. The practice of traditional African medicine 
assumes the existence and participation of supernatural forces − gods, spirits 
etc. − in the causation of disease or other human misfortune.  
 
 
1.3.2    Traditional medicine in Tanzania 
 
Traditional medicine is an important part of the health-care system of Tanzania. In 
spite of an extensive program to create health centers and to train Rural Medical Aids 
and Medical Assistants, the traditional healer is still the only medical practitioner 
available, within reasonable distance, to many Tanzanians living in the rural part of 
the country. The number of traditional healers has been estimated to about 30.000 to 
40.000, in comparison with about 600 Western-trained doctors, most of whom are 
working in hospitals in the big cities [13].  
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1.4    Tropical diseases with special reference to Africa 
 
Epidemic diseases are not new to mankind, yet outbreaks continue to pose a threat. 
Reasons which attributed to Africa’s current situation include : poverty, urbanization, 
civil strife, mass movements leading to overcrowding, collaps of public health 
infrastructure and environmental disasters.  
The most important parasites under which Africa moans are summarised in table 2.     
However, the numbers listed are often underestimated due to poor availability or 
applicability of data. Some diseases like tuberculosis and malaria break out with so 
far unknown ferocity, others are resistant to drugs and almost untreatable and new 
deadly diseases like Ebola haemorrhagie fever emerge [38, 39]. 
 
Table 2 : African infectious diseases [38, 39]. 
Parasites Disease Occurence Mortality 
Plasmodium spp. Malaria 23 million 0.5-3 million 
Trypanosoma spp. Trypanosomiasis 300.000  
Leishmania spp. Leishmaniasis 12 million  
Entamoeba histolytica Amoebiasis 5 million 5000 
Onchocerca volvulus Filariasis 18 million  
Ascaris lumbricoides Ascariasis > 200 million  
Schistosoma spp. Schistosomiasis 100 million  
 
 
1.4.1    Trypanosomiasis 
 
1.4.1.1    Introduction 
 
Trypanosomes are classified under the subkingdom of Protozoa and the phylum 
Sarcomastigophora. They belong to the order Kinetoplastida and the family 
Trypanosomatidae. Common features of trypanosomatids are a flagellum and a 
kinetoplast, a small organelle consisting of a condensed network of circular DNA. All 
members of the Trypanosomatidae family parasitise a very diverse range of hosts, 
including vertebrates, invertebrates, plants and other protists [40].  
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1.4.1.2    African trypanosomiasis (sleeping sickness) 
 
1.4.1.2.1     Introduction 
 
African trypanosomiasis, also known as sleeping sickness, ranks among the top 
contenders for title of greatest neglected disease of mankind [41]. There are two 
forms of African trypanosomiasis caused by two morphologically identical parasites : 
Trypanosoma brucei gambiense causes primarily a human chronic disease and is 
endemic in west and central African countries, T. b. rhodesiense has a huge animal 
reservoir and is primarily zoonotic. It causes acute illness in people in eastern and 
southern African countries [42]. The disease was largely controlled in the 1960’s, but 
it re-emerged in the 1980’s and today 60 million people are exposed to it. 36.000 
cases were reported in 1998, but only 3-4 million people are under surveillance and it 
is estimated that 300.000 people are infected [43]. 
 
 
1.4.1.2.2    The parasite 
 
T. b. gambiense and T. b. rhodesiense are morphologically indistinguishable. It is a 
highly pleomorphic organism, frequently showing in a single blood smear a variety of 
forms ranging from slender-bodied organisms with a long free flagellum, reaching a 
length of 30 µm or more, to fatter, stumpier forms without a free flagellum which 
average about 15 µm in length [44]. 
 
 
1.4.1.2.3    Transmission and infection 
 
The life cycle of T. b. rhodesiense is similar to that of T. b. gambiense. The infective 
stage is the metacyclic trypomastigote, which lives within the salivary gland of the 
tsetse fly. Infection occurs when an individual is bitten by an infected tsetse fly. 
Important vectors include Glossina morsitans, G. pallidipes, G. fuscipes and G. 
palpalis. The metacyclic trypomastigotes rapidly transform into bloodstream 
trypomastigotes within the extracellular spaces in the subcutaneous tissue. The 
trypomastigotes eventually find their way into the bloodstream and the lymphatics, 
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where they continue the replication cycle. Invasion of the cerebrospinal fluid also 
occurs, but does not contribute to the life cycle. The tsetse fly becomes infected 
when it ingests the trypomastigote while taking a blood meal from an infected 
individual. The trypomastigote transform into the procyclic trypomastigote and after 
several cycles of cell division it migrates to the insect’s salivary glands, where it 
differentiates further into the epimastigote form. Epimastigotes develop within the 
salivary gland into metacyclic trypomastigotes, the infective stage for the mammalian 
host. Wild animals and cattle are important reservoir hosts for T. b. rhodesiense. For 
T. b. gambiense the main reservoir are humans [45]. 
 
 
1.4.1.2.4    Clinical manifestation 
 
Initially the trypanosomes are present extracellularly in the subcutaneous tissue at 
the site of the bite of the tsetse fly and give rise to papular and later ulcerating lesion, 
often called a chancre. In the first stage trypanosomes enter the bloodstream and 
multiply there. This stage is accompanied by fever and lymphoid hyperplasia leading 
to enlargement of the spleen and especially of the cervical lymph nodes. The second 
stage involves central nervous invasion associated with intermittent fever. 
Trypanosomes in the cerebrospinal fluid produce diffuse meningoencephalitis. The 
central nervous system lesions are accompanied by headache, apathy, wasting of 
musculature, tremors, inability to walk and eventually to somnolescence, paralysis, 
coma and death, usually after a course of 1-3 years [46]. 
 
 
1.4.1.2.5    Treatment and its limitations 
 
The drugs currently used for the treatment of sleeping sickness are suramin (1), 
pentamidine (2), melarsoprol (3), eflornithine (4), and nifurtimox (5). 
Suramin (1) was introduced in the early 1920’s and to this day remains the drug of 
choice for treatment of the early phase of T. b. rhodesiense infections. The mode of 
action is still a complete mystery [47]. 
Pentamidine (2) was first introduced in 1949. The drug is only used as the second-
line drug when therapy with suramin (1) is contraindicated [48]. The mechanism of 
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action is not well understood. It is known that the drug is taken up by at least three 
transporters [49, 50] and then binds to negative-charged cellular components, and 
disrupts the structure of kinetoplasts DNA [51]. 
Melarsoprol (3) was introduced in 1949 for the treatment of late-stage sleeping 
sickness. The drug causes a serious reactive encephalopathy in 5-10 % of the cases, 
half of which are fatal [48]. Other common side effects include vomiting, abdominal 
colic and peripheral neuropathy. The mechanism of action could be the combination 
of  trypanothione depletion and the inhibition of trypanothione reductase [47]. 
Eflornithine (4) is the drug of choice for treatment of late-stage sleeping sickness 
caused by T. b. gambiense. The drug is not recommended for T. b. rhodesiense 
infections. The inhibition of polyamine biosynthesis by eflornithine (4) triggers a wide 
range of downstream biochemical effects, but opinion is divided as to which of these 
are responsible for the trypanocidal effect [52]. 
Nifurtimox (5) is currently registered for the treatment of chagas disease. Side-
effects are extremly common and 50 % of patients are unable to complete a full 
course of treatment. Nevertheless, nifurtimox (5) has been used in the treatment of 
late-stage sleeping sickness where eflornithine (4) or melarsoprol (3) are ineffective 
[53]. For the mode of action see chapter 1.4.1.3.5 
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1.4.1.3    American trypanosomiasis (chagas disease) 
 
1.4.1.3.1    Introduction 
 
Chagas disease, caused by Trypanosoma cruzi, is a major public health problem in 
Latin America [54]. The disease is a zoonosis, which afflicts a large variety of small 
mammals. The parasite is transmitted among its hosts by hematophagus reduviid 
bugs. Human disease occurs, when the bugs establish a habitat in human dwellings 
[55]. Currently, there are 18-20 million people infected and another 40 million people 
are at risk of aquiring the disease [56, 57]. 
 
 
1.4.1.3.2    The parasite 
 
T. cruzi is an organism which differs from other trypanosomes infecting man in that it 
has an intracellular amastigote stage in cardiac muscle and other tissues, as well as 
trypomastigote forms in the circulating blood. The trypomastigotes average 20 µm in 
length. The nucleus is usually positioned centrally and the large oval kinetoplast is 
located posteriorly. In stained blood films they characteristically assume a C or U 
shape [44]. 
 
 
1.4.1.3.3    Transmission and infection 
 
The infective stage of T. cruzi is the metacyclic trypomastigote. It is 15 µm in length 
and possesses a single nucleus and flagellum [45]. The most frequent way of 
transmission is by reduviid bugs (Rhidnius spp.; Triatoma spp.) [46]. Infection occurs 
shortly after an infected bug takes a blood meal. Its feces contain the infective 
trypomastigotes. The host experiences a mild itching sensation and rubs the 
trypomastigotes into the bite wound. Trypomastigotes enter a wide variety of cells 
and transform into amastigotes. The amastigote is 3-5 µm in diameter and does not 
possess an external flagellum. The host becomes hypersensitive to the parasite as 
the result of the cellular destruction at the site of initial infection. Some amastigotes 
transform into trypomastigotes, and after being released into the peripheral blood, 
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they infect other sites in the body. The bug becomes infected, when it takes a blood 
meal from an individual harbouring trypomastigotes. Trypomastigotes transform into 
epimastigotes within the midgut of the bug. Epimastigotes differentiate into 
metacyclic trypomastigotes within the hindgut. This is the infective stage of the 
parasite [45]. 
 
 
1.4.1.3.4    Clinical manifestation 
 
Acute disease manifestation 
T. cruzi may mark its point of entry into human body by inflammation, and when this 
occurs in the eye there may be conjunctivitis, unilateral palpebral oedema, and 
satellite adenopathy. Manifestations of generalised infection occur with fever, 
tachycardia, lymphadenopathy, and oedema. The acute congenital phase may be 
symptomless or may be associated with jaundice, skin haemmorrhages, and 
neurological signs.  
 
Chronic disease manifestation 
After 2-4 months the acute clinical manifestation disappears and the disease enters 
the chronic phase, generally starting with a long period of clinical latency, which lasts 
10-30 years or throughout life. After this period many infected patients present 
manifestations related to the involvement of certain organs such as heart, 
oesophagus, colon, and nervous system. 
 
Cardiac involvement 
Heart involvement is the major aspect of chagas disease because of its 
characteristics, frequency, and consequences, and is also the source of most 
controversies. About 20-30 % of the total chagasic population in endemic areas has 
symptomless heart disease and these patients may live for many years. Heart 
disease worsens in some of them, with increasing arrythmias or heart failure [58].  
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1.4.1.3.5    Treatment and its limitations 
 
The drugs used for the treatment of chagas disease are nitroheterocyclic 
compounds, a nitrofuran, nifurtimox (5) and benznidazole (6), a nitroimidazole 
derivative.  
Nifurtimox (5) acts via the reduction of the nitro group to unstable nitroanion 
radicals, which in turn react to produce highly toxic, reduced oxygen metabolites [59]. 
Benznidazole (6) seems to act via a different mechanism (reductive stress), which 
involves covalent modification of macromolecules by nitroreduction intermediates 
[60]. Both nifurtimox (5) and benznidazole (6) have significant activity in the acute 
phase, with up to 80 % parasitological cures in treated patients [61]. However their 
efficacy varies according to the geographical area, probably due to differences in 
drug susceptibility among different T. cruzi strains [62, 63]. 
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1.4.2    Malaria 
 
1.4.2.1    Introduction 
 
Malaria is the world’s most important parasitic infection, ranking among the major 
health and developmental challenges for the poor countries of the world [64]. Four 
parasite species of the genus Plasmodium infect human beings. Nearly all malaria 
deaths are caused by Plasmodium falciparum [65], which is transmitted by the most 
efficient of the malaria vector mosquitos, Anopheles gambiae [66]. More than a third 
of the world’s population live in malaria-endemic areas, and 1 billion people are 
estimated to carry parasites at any one time. In Africa alone, there are an estimated 
200-450 million cases of fever in children infected with malaria parasites each year 
[67]. Estimates for annual malaria mortality range from 0.5 to 3.0 million people [68]. 
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1.4.2.2    The parasite 
 
The agents of human malaria are members of the genus Plasmodium and the 
suborder Haemosporina [69]. The problem with the definition is the unusual biology 
of these organisms. P. falciparum, the agent of malaria tropica, is an exceedingly 
small, haploid, but genomically complicated eukaryote, able to constantly change its 
gene expression [70]. 
 
 
1.4.2.3    Transmission and infection  
 
Natural transmission is dependent on a complex interaction between host, vector, 
parasite and environment. The anopheline mosquito is infected via blood from an 
infected host (human); the parasite then matures to the sporozoit stage in the vector, 
and invades its salivary glands. The mosquito infects other people by injecting 
sporozoites in the salvia while feeding on their blood [71]. The sporozoites are then 
carried to the liver, where they leave the blood circulation system. Each sporozoite 
penetrates a “building block” cell of the liver tissue and invades hepatocytes. Whithin 
the liver cell, the sporozoite rounds up and transforms into a “spore”-like form. During 
the succeeding two weeks, this spore replicates into thousands of merozoites (cyst-
like structures) and the host liver cell is destroyed in the process. The merozoites 
then invade the red blood cells and increase in a series of two- to three-day cycles. 
The first clinical attack of intense rigour and sweating with high fever develops when 
a large number of red cells are infected and burst. As they continue to flood into the 
blood stream, the resulting merozoites attach to the surface of other red blood cells 
and create a continuous cycle of replication [72]. 
 
 
1.4.2.4    Clinical manifestation 
 
It is important to distinguish between the disease caused by malaria parasites and 
the frequently asymptomatic infection caused by the same parasites. It is important to 
recognize that one may be infected without having the disease [73]. The clinical 
manifestations of malaria are extremly diverse in terms of onset of signs and 
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symptoms, severity and complications. However, common characteristic symptoms 
are alternating episodes of fever and asymptomatic phases associated with 
symptoms like chills, headache, myalgia, joint pains, sweating and anaemia. Rigors 
are common and splenomegaly is a frequent consequence. Almost exclusively 
people infected with P. falciparum malaria may develop severe and complex 
symptoms which will usually lead to death if not treated [74]. 
 
 
1.4.2.5    Treatment and its limitations 
 
Currently ten drugs are available for the treatment of malaria. These are artemisinin 
(7) and derivatives, atovaquone (8), benflumetol (9), chloroquine (10), halofantrine 
(11), mefloquine (12), primaquine (13), proguanil (14) (and chloroproguanil (15)), 
pyrimethamine (16) and quinine (17). 
Artemisinin (7) and derivatives are used for both uncomplicated and severe P. 
falciparum malaria. The most commonly used compounds are artemether and 
artesunate. Artemisinins probably work by generation of free radicals in parasitised 
red blood cells, followed by alkylation of parasite proteins [75]. 
Atovaquone (8) is thought to inhibit mitochondrial respiration in the parasite [76] and 
is used orally in synergistic combination with proguanil (14) to treat uncomplicated P. 
falciparum malaria [77]. 
Benflumetol (9) is exclusively used in combination with artemether to treat 
uncomplicated P. falciparum malaria. Its mode of action is unknown [78]. 
Chloroquine (10) remains the most widely used antimalarial drug world wide. It 
works by joining with the ferriprotoporphyrin IX in the parasite, thereby antagonising 
the polymerisation of this toxic metabolic product into inert crystals of haemozoin 
[79]. 
Halofantrine (11) seems to have a mechanism of action similar to that of chloroquine 
(10). It is used for uncomplicated cases of multiresistant P. falciparum malaria [78]. 
Mefloquine (12) is also thought to work in much the same way as chloroquine (10) 
[80]. 
Primaquine (13) is given orally to eradicate the liver hypnozoites of P. vivax and P. 
ovale; it is normally given when the treatment with chloroquine (10) has been 
completed and the patient is recovering. 
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Proguanil (14) (and chloroproguanil (15)) are metabolised to active metabolites 
which inhibit parasite dihydrofolate reductase (DHFR). 
Pyrimethamine (16) is a selective, competitive inhibitor of parasite DHFR, and is 
only used in synergistic combination with a sulfonamide [78]. 
Quinine (17) is reliable in the face of chloroquine-resistant P. falciparum. World wide, 
quinine (17) is used mainly as a parenteral drug for severe P. falciparum malaria.  
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1.4.3    Leishmaniasis 
 
1.4.3.1    Introduction 
 
Leishmaniasis is a group of infections caused by the trypanosomid parasites, 
Leishmania spp. There are 350 million people residing in regions endemic to the 
disease. Annually, 12 million people, in at least 74 countries, are infected by the 
parasites [81]. The number of new cases of cutaneous leishmaniasis each year in the 
world is thought to be about 1.5 million. The number of new cases of visceral 
leishmaniasis is thought to be about 500.000 [82]. Leishmaniasis is endemic to many 
densely populated regions of the world including the Persian Gulf, the Mediterranean, 
Northern Africa, Asia, and Central and South America [83]. 
 
 
1.4.3.2    The parasite 
 
Leishmaniasis is caused by hemoflagellated intracellular parasites belonging to the 
genus Leishmania. Basic anatomy and physiology include a single free flagellum, 
rod-shaped kinetoplasts, a single nucleus, mitochondrion and rough endoplasmatic 
reticulum. The size of the parasite varies not only between species, but also between 
amastigote and promastigote forms. The size of promastigotes (form in the insect 
vector) ranges from 10 to 20 µm long and 2 to 5 µm in major diameter. Amastigote 
cells are smaller, generally 2-3 µm in diameter and obligate intracellular [84].  
 
 
1.4.3.3    Transmission and infection 
 
Transmission begins with either the female Phlebotomus spp. or the Lutzomyia spp. 
sandfly taking up the pathogenic Leishmania spp. from an infected vertebrate host. 
These host reservoirs include sloths, horses, dogs, rats and other rodents [85]. Once 
the sandfly has been infected, the amastigote migrates to the alimentary canal of the 
insect where it attaches to local epidermal cells. The parasites mature and 
differentiate into motile promastigotes. Then they transit away from the midgut region 
to the pharynx and/or the proboscis of the sandfly. Upon a subsequent blood meal, 
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the promastigotes are injected into the blood stream of the victim and there they will 
be phagocytized [86]. The parasite is equipped to evade the digestive enzymes 
present in the vacuole. Leishmania spp. have a membrane bound molecule known 
as the lipophosphoglycan (LPG). The LPG permits intracellular survival [87, 88]. 
Once inside the macrophage, the parasite resides in the phagolysosomal or the 
parasitophorous vacuole. Here it transforms back into the infectious amastigote. 
Amastigotes replicate and are released back into the blood stream where similar 
cycles commence. Parasites are known to infect macrophages within the skin, 
viscera and blood tissues. Dissemination of the disease is local or systemic 
depending on the distinct Leishmania spp. involved [89]. 
 
 
1.4.3.4    Clinical manifestation  
 
Three common clinical manifestations and two rare forms of leishmaniasis exist : 
 
Cutaneous leishmaniasis (oriental sore) 
The manifestation results in external lesions in the outer epidermal layers. The 
infection cures itself spontaneously in 4-6 months, except in the case of diffuse 
cutaneous leishmaniasis, which is incurable. Cutaneous leishmaniasis is primarily 
associated with the L. mexican complex, L.  tropica and L. major [90]. 
 
Mucocutaneous leishmaniasis (espundia, chicler’s ulcer) 
This form results in ulcers within the pharyngeal and nasal mucosa and also self 
cures in a matter of months. The extensive scarring and degradation of tissues never 
completely heal. Mucocutaneous leishmaniasis is most commonly encountered in the 
forested areas of Central and South America and is primarily associated with the L. 
braziliensis complex [91]. 
 
Visceral leishmaniasis (kala-azar, black fever, black sickness) 
This manifestation effects the lymph nodes and the internal mesentery of the liver 
and spleen and results in inflammation of local visceral tissues. Anemia, portal 
hypertension and ascites are all symptomatic of advanced infection. L. chagasi and 
L. donovani are responsible for this form of leishmaniasis. The disease is fatal unless 
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treated early. Many parasites causing visceral leishmaniasis are known to be 
resistant to modern chemotherapy [90]. 
 
There are two other rare forms of leishmaniasis. Recidua leishmaniasis (chronic 
relapsing) is a cutaneous manifestation that is responsible for the presence of chronic 
lesions in the epidermis. L. tropica is most often associated with this disease. Post-
Kala Azar Dermal leishmaniasis is often encountered after a successful recovery 
from visceral leishmaniasis [89]. 
 
 
1.4.3.5    Treatment and its limitations 
 
The drugs recommended for the treatment of leishmaniasis include the pentavalent 
antimonials sodium stibogluconate (pentostam), the structure of which is still not 
known, despite its use for over 50 years [92], and meglumine antimoniate 
(glucantime (18)), amphotericin B (19), and pentamidine (2). A more modern drug is 
miltefosine (20) [93]. 
The antimonials remain effective treatments, but the requirement for up to 28 days 
of parenteral administration, the variable efficacy against visceral and cutaneous 
leishmaniasis, and the emergence of significant resistance are all factors underlining 
the limitations of these drugs.  
The polyene antibiotic amphotericin B (19) has proved to be highly effective for the 
treatment of antimonial-resistant L. donovani visceral leishmaniasis [94], but is an 
unpleasant drug because of its toxicity and the need for slow infusion parenteral 
administration over four hours.  
The usefulness of the diamidine pentamidine (2) has been limited by its toxicity.  
Perhaps the most significant recent advance has been the effective oral treatment of 
visceral leishmaniasis by using miltefosine (20), an alkylphosphocholine orginally 
developed as an anticancer drug [92]. 
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1.5    The GABAA receptor 
 
1.5.1    Introduction 
 
The γ-aminobutyric acid type-A (GABAA) receptor is a ligand-gated anion-selective 
ion channel, that exists as a pentameric complex of structurally homologous subunits 
[95, 96]. Four families of subunits, termed α, β, γ, and δ, whose members may co-
assemble to create GABAA receptors with differential biophysical and 
pharmacological properties, are currently recognized [97-99]. GABAA receptor 
isoforms mediate the majority of the inhibitory action of GABA within the central 
nervous system (CNS), the activation of postsynaptically located GABAA receptors 
resulting in an increase in membrane conductance, predominantly to chloride ions, 
which shunts the influence of excitatory neurotransmitters, such as glutamate [100]. 
GABAA receptor-mediated inhibition represents a key process in which information 
transfers within the CNS can be modulated by therapeutic agents. Facilation of 
GABAA-ergic transmission by drugs from diverse chemical classes can produce a 
broad spectrum of behavioral effects that include anxiolytic, anticonvulsant, sedative, 
and most profundly, general anaesthetic actions [95]. 
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1.5.2    GABA 
 
γ-Aminobutyric acid (GABA) is an inhibitory neurotransmitter and present in the brain 
abundantly. The major pathway of GABA synthesis is decarboxylation of glutamate 
catalyzed by L-glutamate decarboxylase (GAD), while GABA degradation is 
catalyzed by GABA-α-ketoglutarase transaminase (GABA-T). The activity of GAD is 
also high in the neuronal tissues. Some non-neuronal tissues also have high 
concentration of GABA and high GAD activity, which are comparable to those of the 
brain. One of such tissues is the pancreatic islet. Especially B cells of the islet 
possess extremly high concentration of GABA and GAD activity [101, 102]. 
 
 
1.5.3    Molecular structure of GABAA receptors 
 
As members of the ligand-gated ion channel family, GABAA receptors share 
structural and functional similarities with the nicotinic acetylcholine receptor, the 
glycine receptor and the 5-HT3 receptor, which include a pentameric 
pseudosymmetrical transmembrane subunit structure with a central pore. Each 
subunit is composed of a large N-terminal putatively extracellular domain, thought to 
mediate ligand-channel interactions, and four putative transmembrane domains with 
a large intracellular loop [103-105]. In vivo, fully functional GABAA receptors generally 
are assembled from a combination of α-, β-, and γ2- subunits [106, 107]. The subunit 
stochiometry has been proposed to be two α-subunits, one β-subunit, and two γ-
subunits [108, 109]. 
 
 
1.5.4    Drugs acting at the GABAA receptor 
 
GABAA receptors are the site of action of a variety of pharmacologically important 
drugs, including benzodiazepines, barbiturates, neurosteroids and ethanol [110, 111].  
The clinically used benzodiazepines, e.g. valium (diazepam (21)), act as positive 
allosteric modulators and have sedative, hypnotic, anxiolytic, muscle-relaxant and 
anticonvulsant effects. Benzodiazepines act by increasing the frequency of channel 
openings [112]. The benzodiazepine-binding site is located at the interface between 
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the α and the γ subunit [113]. A great diversity in benzodiazepine pharmacology is 
generated by the existence of receptor isoforms containing different α and γ subunit 
forms. Barbiturates, e.g. phenobarbital (22), enhance the actions of GABA by 
increasing the average channel open time [112], in addition, at high concentrations, 
they directly increase channel openings, even in the absence of GABA. 
Several steroids, among them the anaesthetic alfaxalone (23), have been described 
to enhance receptor function, whereas others, e.g. pregnanolone (24), inhibit the 
GABA response. Neurosteroids might be endogenous modulators of the GABAA 
receptor [114]. Whether or not ethanol can directly act on the GABAA receptor is 
discussed very controversially. It was shown to enhance receptor function [115] as 
well as not altering it [116]. 
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2.    Aim of the thesis 
 
The aim of the present thesis was to isolate, identify, elucidate and evaluate 
antiparasitic and GABAA receptor stimulating constituents from African medicinal 
plants. The aim was divided into three parts :  
 
1. Biological screening of plant extracts 
Extracts of selectively collected African medicinal plants were screened for 
antitrypanosomal (African trypanosomes) and antiplasmodial activity and for 
cytotoxicity. In addition, the extracts were tested for GABAA receptor stimulation 
using receptor binding assays. The goal of this screening was the evaluation of the 
most promising plant extracts in regard to the subsequent isolation of bioactive 
constituents. 
 
2. Chemical investigation of selected active plant extracts 
The second part was the bioassay-guided fractionation of those plant extracts which 
showed significant antiparasitic activity and/or GABAA receptor stimulation in the 
preliminary screening and the structure elucidation of the isolated compounds. 
 
3. Further biological investigation of the isolated compounds 
In addition to the mentioned tests the isolated compounds were tested for further 
antiparasitic activity including antitrypanosomal (American trypanosomes) and 
antileishmanial activity. The cytotoxicity was determined and the compounds were 
investigated electrophysiologically. 
 
 
 
 
 
 
 
 
 
 
 24 
 
3.    Plant species 
 
3.1    Selection 
 
The selection of the plant species was based on the information obtained from two 
Ph.D. theses [20, 21], the availability of the plant species in Tanzania and on the 
information obtained from the search in the Chemical Abstracts. In addition, some 
plant species were selected randomly based on availability.  
Gessler [20] obtained ethnobotanical information by interviewing traditional healers in 
Tanzania and by analyzing ethnobotanical literature regarding antimalarial plants. 
Freiburghaus [21] selected some rare Tanzanian medicinal plants randomly. 
Samples of the appropriate plants were collected, extracts produced and screened 
for antitrypanosomal or antiplasmodial activity.  
 
Based on the obtained results, plant species were selected for the present thesis, 
whose extracts fulfilled the following criterions : 
a) antitrypanosomal activity (T. b. rhodesiense) : IC50 ≤ 10 µg/ml 
b) antiplasmodial activity (P. falciparum) : IC50 ≤ 5 µg/ml 
 
Of the plant species where the extracts fulfilled these criterions not all parts have 
been collected and screened by Gessler and Freiburghaus. For the present thesis it 
was decided to collect all available parts of these plants except those whose extracts 
had shown no activity. It was also decided to screen all plant species for both 
activities, antitrypanosomal and antiplasmodial. 
 
The Chemical Abstract search, then, provided the necessary chemical knowledge 
known about the selected plant species, and heavily investigated plants were 
removed from the selection.  
 
 
3.2    Collection and identification 
 
Plant species were collected at the end of the wet season in June and July 2001 from 
Pugu forest (50 km west of Dar Es Salaam) and Chalinze region (100 km west of Dar 
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Es Saalam) in Tanzania. The plants were botanically identified by Mr. L. B. 
Mwasumbi of the Institute of Botany of the University of Dar Es Salaam and voucher 
specimens were deposited at the Herbarium of the University of Dar Es Salaam, 
Tanzania. The collected plant species are shown in table 3 and 4.   
 
Table 3 : Plant species collected from Pugu forest (*) and Chalinze region (**), selected based  
on the information obtained from two Ph.D. theses [20, 21]. 
Plant species Synonyms Family Plant part 
Hymenocardia 
ulmoides Oliv.*/** 
[117] 
H. poggei Pax. 
H. ulmoides Oliv. 
var. capensis 
H. capensis (Pax.) 
Euphorbiaceae stembark 
rootbark 
root 
rootbark (Chalinze) 
 
Albizia gummifera 
(J.F. Gmel.) 
C.A. Sm.* [118] 
Sassa gummifera 
Inga sassa Willd. 
A. sassa (Willd.) 
A. mearnsi De Wild. 
A. laevicorticata Zimm. 
Mimosaceae 
 
stembark (large tree) 
stembark (small tree) 
root (small tree) 
rootbark (small tree) 
 
 
Foetidia africana 
Verdc.** [119] 
- Lecythidaceae root 
rootbark 
stembark 
 
Salacia 
madagascariensis 
(Lam.)** [120] 
Hippocratea 
madagascariensis Lam. 
H. verticillata Steud 
var. madagascariensis 
H. senegalensis Lam.  
var. madagascariensis 
Tonsella  
madagascariensis (Lam.) 
Salacia simtata Loes. 
 
Celastraceae root 
rootbark 
stembark 
leaves 
Asteranthe asterias  
(S. Moore) 
Engl. & Diels** [121] 
Uvaria asterias  
S. Moore 
Asteranthopsis asterias 
(S. Moore) 
Annonaceae rootbark 
root 
stembark 
leaves 
 
Cussonia zimmermannii 
Harms* [122] 
 
- 
 
Araliaceae 
 
rootbark 
stembark 
 
Commiphora  
eminii Engl.* [123] 
 
C. puguensis sensu Wild 
 
Burseraceae 
 
stembark 
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Table 4 : Plant species collected from Pugu forest (*) and Chalinze region (**), selected randomly, 
based on availability. 
Plant species Synonyms Family Plant part 
Bridelia  
micrantha (Hochst.) Baill.* 
[117] 
B. speciosa Muell. Arg. 
var. trichoclada Muell. Arg. 
B. stenocarpa Muell. Arg. 
B. zanzibarensis  
Vatke & Pax 
B. abyssinica Pax 
B. abyssinica Pax 
var. densiflora Gehrm. 
B. mildbraedii Gehrm. 
Candelabria 
micrantha Hochst. 
 
Euphorbiaceae stembark 
root 
rootbark 
Commiphora  
fulvotomentosa 
Engl.* [123] 
C. boiviniana Engl. 
C. sp. near C. trollii  
Mattick sensu 
C. torrei Mendes 
 
Burseraceae stembark 
Vangueria  
infausta  
Burchell* [124]  
 
V. tomentosa Hochst. Rubiaceae rootbark 
Vernonia spp.* 
 
- Compositae leaves 
Bridelia  
cathartica  
Bertol. f.* [117] 
 
 
 
 
 
 
 
 
 
 
 
 
B. melanthesoides  
(Baill.) Klotzsch 
B. fischeri Pax 
B. lingelsheimii Gehrm. 
B. niedenzui Gehrm. 
B. fischeri Pax 
var. lingelsheimii (Gehrm.) 
B. schlechteri Hutch. 
B. cathartica Bertol. 
f. subsp. Melanthesoides (Baill.) 
Pentameria melanthesoides Baill. 
 
Euphorbiaceae stembark 
rootbark 
root 
Combretum 
harissii */a) 
- Combretaceae root 
stem 
leaves 
fruits 
a) New plant species [125]. 
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3.3    Extraction 
 
The dried plant material was hackled with a chaffcutter and powdered with a coffee 
grinder. The ground material was then sequentially extracted with four different 
solvents, starting with petroleum ether, then dichloromethane, methanol and at the 
end water. Thereby four extracts of different polarity were obtained from each 
sample. The extraction procedure is shown in scheme 2 and the yields of the crude 
extracts are listed in table 5. The crude extracts were then screened for biological 
activity. 
 
Dried and ground plant material 
 
Extraction with petroleum ether 
 
 
Cake  Filtrate 
 
Extraction with dichloromethane  Dry, weigh, store 
 
 
Cake  Filtrate 
 
Extraction with methanol  Dry, weigh, store 
 
 
Cake  Filtrate 
 
Extraction with water  Dry, weigh, store 
 
 
Discard  Filtrate 
 
  Dry, weigh, store 
 
Scheme 2 : Extraction procedure. 
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Table 5 : Yields of the extracts obtained with different solvents from the ground plant material.  
Plant species Part Quantity   
[g] 
                 Extracts [mg] 
  
   Petroleum 
   ether 
CH2Cl2 
 
 MeOH 
 
Water 
 
Hymenocardia ulmoides  stembark 34.6     207   178   3917   870 
 rootbark 34.7     145   119   7783   690 
 root 33.3       25     50   1294   460 
 rootbark (Chalinze) 34.6     148   110   5746   450 
Albizia gummifera stembark (large tree) 34.4       65   103   1212 1810 
 stembark (small tree) 34.0       84   129   1291 2770 
 root (small tree) 33.5     172   165   1601   550 
 rootbark (small tree) 34.2       74   124   2606 3800 
Foetidia africana root 34.8       59     94   1338   340 
 rootbark 34.3     472   185   6804 1600 
 stembark 34.6     338   321   4153 1340 
Salacia madagascar. root 34.9     139 1507   3246   430 
 rootbark 34.8     523 2350   7415 1250 
 stembark 34.9     685 2251   5747 1080 
 leaves 35.0   1584   641   8397 2650 
Asteranthe asterias  rootbark 34.9     676   688   1476   690 
 root 35.1       54     27   1005   490 
 stembark 34.9     298   456   1505 1010 
 leaves 35.9   1032   648   4146 1810 
Cussonia zimmermannii rootbark 35.1     220   218   3125 3520 
 stembark 35.6     129   172   1261 2780 
Commiphora eminii  stembark 35.9     697   324   2827   920 
Bridelia micrantha  stembark 34.5     173   115   8506   620 
 root 35.2       56     66   2045   730 
 rootbark 34.9     135     73   7466   790 
Commiphora fulvo. stembark 34.6     197   479   1790 1030 
Vangueria infausta  rootbark 35.4       88   128   2289 1670 
Vernonia spp. leaves 37.3     589 1051   3927 3710 
Bridelia cathartica  stembark 35.1     150   143   4050   790 
 rootbark 35.7     149   103   7020   710 
 root 35.1     145     72   2484   650 
Combretum harissii root 28.7       41     52   1951   400 
 stem 36.1       48     51   2269   420 
 leaves 35.7   2141   487   8537   900 
 fruits 35.5     600   385 10900 1210 
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4.    Biological testing 
 
4.1    Methodology 
 
4.1.1    Antitrypanosomal activity testing 
 
The assays for T. b. rhodesiense and T. cruzi were based on the LILIT (long 
incubation low inoculation test) [126] with minor modifications. The fluorometric 
evaluation of the Alamar Blue assay [127] was determined as shown by Kaminsky 
and Brun [128] and the concentration at which the parasite growth was inhibited by 
50 % (IC50) was estimated by linear interpolation between the two adjacent drug 
concentrations above and below the 50 % incorporation line [129]. T. cruzi assays 
were performed using reporter gene transfected parasites and photometric 
evaluation. 
 
 
4.1.2    Antiplasmodial activity testing 
 
The drug sensitivity assay was performed as previously described by Desjardins et 
al. [130]. The assay uses the uptake of [3H]hypoxanthine by parasites as an indicator 
for viability. The IC50 values were calculated according to Hills et al. [129]. 
 
 
4.1.3    Antileishmanial activity testing 
 
The assay for L. donovani was performed as described by Neal and Croft [131]. IC50 
values were calculated by linear regression analysis [128]. 
 
 
4.1.4    Cytotoxicity testing 
 
Cytotoxicity assays were performed using an Alamar Blue assay as described by 
Pagé et al. [132] with the modification of Ahmed et al. [133]. 
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4.1.5    GABAA receptor binding assay 
 
Modulatory effects of the ion channel GABAA receptor were performed as described 
by Karobath and Sperk [134] and Simmen et al. [135]. The stimulation of 
[3H]flunitrazepam binding to rat cortex at a selected extract concentration was 
determined as a primary screen. Subsequent EC50 values of purified compounds 
were graphically determined.    
 
 
4.1.6    Electrophysiological investigations 
 
Electrophysiological investigations were performed using Xenopus laevis oocytes. 
The oocytes were prepared, injected, defolliculated and currents recorded as 
described by Sigel [136] and Sigel et al. [137]. 
 
 
4.2    Results 
 
4.2.1    Crude plant extracts 
 
4.2.1.1    Antitrypanosomal activity testing (African trypanosomes) 
 
Definition of test score 
Active : IC50 ≤ 10 µg/ml 
Moderate activity : 1 µg/ml ≤ IC50 ≤ 10 µg/ml 
High activity : IC50 < 1 µg/ml 
 
The summary of the results of the in vitro testing of the crude plant extracts on STIB 
900 strain of T. b. rhodesiense is presented in table 6. All samples were tested in 
duplicate (n = 2). The standard drug melarsoprol exhibited an IC50 value of 0.0042 
µg/ml. 
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Table 6 : IC50 values of the crude extracts. All values as µg/ml. 
Plant species Part                     Extracts 
  Petroleum  
    ether 
  CH2Cl2    MeOH    Water 
Hymenocardia ulmoides  stembark     49.8 23.1   6.21   6.51 
 rootbark     70.4 19.1   5.01 18.5 
 root     61.9 15.3   8.61 32.5 
 rootbark (Chalinze) > 100 53.3   6.51 26.6 
Albizia gummifera stembark (large tree)     88.6 19.5 15.4 48.4 
 stembark (small tree)     64.6 22.4 17.8 23.3 
 root (small tree)     58.0   5.01   9.81 52.7 
 rootbark (small tree)     55.8   9.61 24.1 37.4 
Foetidia africana root     57.2   7.11   3.81 22.1 
 rootbark     59.5 25.1   7.31 58.5 
 stembark     81.2 27.9   4.61 58.8 
Salacia madagascariensis root       4.01 16.9 13.2 19.6 
 rootbark       0.152   1.71 18.0 51.0 
 stembark       0.212   1.61 28.9 15.2 
 leaves     18.3 45.3 27.7 14.9 
Asteranthe asterias  rootbark       6.21   2.91 14.0 11.4 
 root       2.61   5.41 10.7 42.4 
 stembark       6.21   6.51 13.9 42.0 
 leaves     27.8   4.81 10.8 38.0 
Cussonia zimmermannii rootbark       4.81 21.1 59.6 58.9 
 stembark       8.81 14.8 23.0 18.0 
Commiphora eminii  stembark       4.31   3.91 16.1 52.7 
Bridelia micrantha  stembark       0.702 14.6   2.21 17.0 
 root       1.21   8.21   4.51 11.7 
 rootbark       0.682 20.1   4.21 29.2 
Commiphora fulvotomentosa stembark       2.11   6.51 13.1 34.1 
Vangueria infausta  rootbark       1.51   3.01 15.4 56.6 
Vernonia spp. leaves       4.31   1.81 60.3 24.1 
Bridelia cathartica  stembark     59.6 10.9   7.91 18.3 
 rootbark       5.01   2.01   5.01 18.6 
 root       1.51   2.21   3.91 17.1 
Combretum harissii root     80.3   9.61 26.5 56.2 
 stem     19.9 13.6 20.6 52.3 
 leaves     76.0 25.5 15.9   9.71 
 fruits     20.1 22.3   7.61 21.9 
bold : Active extracts 
1
 : Moderate activity 
2           : High activity 
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From the antitrypanosomal screening of the crude plant extracts it could be found 
that of a total of 140 extracts from 35 samples of 13 plant species, 89 (64 %) showed 
no activity and 51 (36 %) exhibited significant activity against T. b. rhodesiense STIB 
900 strain. Of the 51 active extracts 47 (92 %) showed moderate activity and 4 (8 %) 
showed high activity. 17 (49 %) of the petroleum ether extracts, 17 (49 %) of the 
dichloromethane, 15 (43 %) of the methanol and 2 (8 %) of the water extracts were 
found to be active. The most active extracts were the petroleum ether extracts of the 
rootbark and the stembark of Salacia madagascariensis and the rootbark and the 
stembark of Bridelia micrantha. Their IC50 values of 0.15 and 0.21 µg/ml were 
compared with the standard drug melarsoprol (IC50 = 0.0042 µg/ml) and found about 
36 respectively 50-fold higher. 
 
 
4.2.1.2    Antiplasmodial activity testing 
 
Definition of test score 
Active : IC50 ≤ 5 µg/ml 
Moderate activity : 0.5 µg/ml ≤ IC50 ≤ 5 µg/ml 
High activity : IC50 < 0.5 µg/ml 
 
The summary of the results of the in vitro testing of the crude plant extracts on K1 
strain of P. falciparum is presented in table 7. All samples were tested in duplicate (n 
= 2). The standard drugs chloroquine and artemisinin exhibited an IC50 value of 0.036 
µg/ml and 0.0023 µg/ml, respectively. 
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Table 7 : IC50 values of the crude extracts. All values as µg/ml. 
Plant species Part  Extracts   
    Petroleum  
     ether 
  CH2Cl2 
 
MeOH 
 
Water 
 
Hymenocardia ulmoides stembark    13.1      7.8 > 20    11.4 
 rootbark    13.9      3.21 > 20 > 20 
 root > 20    13.4 > 20 > 20 
 rootbark (Chalinze) > 20      5.4 > 20 > 20 
Albizia gummifera stembark (large tree)    15.5    11.0 > 20      6.6 
 stembark (small tree) > 20    15.3 > 20 > 20 
 root (small tree) > 20      2.61      1.61 > 20 
 rootbark (small tree) > 20    11.2 > 20 > 20 
Foetidia africana root > 20    17.7    16.1 > 20 
 rootbark > 20    11.0 > 20 > 20 
 stembark    16.8      5.4 > 20 > 20 
Salacia madagascariensis root      0.961 > 20 > 20 > 20 
 rootbark      0.0532      0.731 > 20 > 20 
 stembark      0.0872      1.01 > 20 > 20 
 leaves > 20 > 20 > 20 > 20 
Asteranthe asterias rootbark      2.11      0.881    17.9 > 20 
 root      2.41      2.81 > 20 > 20 
 stembark      1.31      1.21 > 20 > 20 
 leaves > 20      3.31 > 20 > 20 
Cussonia zimmermannii rootbark      3.31      5.9 > 20 > 20 
 stembark    13.6      6.4 > 20 > 20 
Commiphora eminii stembark      6.0      2.81 > 20 > 20 
Bridelia micrantha stembark    14.5    13.8 > 20 > 20 
 root > 20    11.5    12.1 > 20 
 rootbark > 20    15.0 > 20 > 20 
Commiphora fulvotomentosa stembark      7.0      9.3 > 20 > 20 
Vangueria infausta rootbark > 20      8.3 > 20 > 20 
Vernonia spp. leaves > 20      3.21 > 20 > 20 
Bridelia cathartica stembark > 20      8.3 > 20 > 20 
 rootbark > 20      6.9 > 20 > 20 
 root > 20 > 20      7.4 > 20 
Combretum harissii root > 20      6.2 > 20 > 20 
 stem > 20    10.9 > 20 > 20 
 leaves > 20    12.4 > 20 > 20 
 fruits    17.7      7.6    12.6 > 20 
bold : Active extracts 
1
 : Moderate activity 
2           : High activity 
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From the antiplasmodial screening of the crude plant extracts it could be found that of 
a total of 140 extracts from 35 samples of 13 plant species, 122 (87 %) showed no 
activity and 18 (13 %) exhibited significant activity against P. falciparum K1 strain. Of 
the 18 active extracts 16 (89 %) showed moderate activity and 2 (11 %) showed high 
activity. 7 (20 %) of the petroleum ether extracts, 10 (29 %) of the dichloromethane, 1 
(3 %) of the methanol and none of the water extracts were found to be active.  
The most active extracts were the petroleum ether extracts of the rootbark and the 
stembark of Salacia madagascariensis. Their IC50 values of 0.053 and 0.087 µg/ml 
were compared with the standard drugs chloroquine (IC50 = 0.036 µg/ml) and 
artemisinin (IC50 = 0.0023 µg/ml) and found about 1.5 and 23, and 2.4 and 38-fold 
higher. 
 
 
4.2.1.3    Summary of the antiparasitic and the cytotoxicity testings 
 
51 crude plant extracts which showed significant activity either in the 
antitrypanosomal and/or in the antiplasmodial testing were tested for cytotoxicity.  
The results of the antiparasitic and the cytotoxicity testings of the active crude 
extracts and the appropriate selectivity indices are summarised in table 8. All 
samples were tested in duplicate (n = 2).    
 
Table 8 : Summary of the antiparasitic and cytotoxicity test results of the active extracts.  
Standard drugs/ 
Plant species 
     Part  Extract IC50 
T.b. rhod. 
[µg/ml] 
  IC50 
  P. falc. 
  [µg/ml] 
  IC50 
  Cytotox. 
  [µg/ml] 
   SI 
   T.b. 
   rhod. 
 SI 
  P. 
  falc. 
Standard drugs        
Melarsoprol      0.0042     
Mefloquine             1.7   
Chloroquine         0.036    
Artemisinin         0.0023    
Plant species        
Salacia madagascar. rb PE 0.15      0.053         0.34       2.3    6.4 
Salacia madagascar. sb PE 0.21      0.087         0.45       2.1    5.2 
Bridelia micrantha rb PE 0.68 > 20       40.0     58.8  
Bridelia micrantha sb PE 0.70    14.5       12.8     18.3    0.9 
Bridelia micrantha r PE 1.2 > 20  > 100  > 83  
Vangueria infausta rb PE 1.5 > 20       20.7     13.8  
Bridelia cathartica r PE 1.5 > 20       12.0       8.0  
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Table 8 (continued)        
Standard drugs/ 
Plant species 
     Part Extract IC50 
T.b. rhod. 
[µg/ml] 
  IC50 
  P. falc. 
  [µg/ml] 
  IC50 
  Cytotox. 
  [µg/ml] 
   SI 
   T.b. 
   rhod. 
 SI 
  P. 
  falc. 
Salacia madagascar. sb CH2Cl2 1.6      1.0         5.7       3.6    5.7 
Salacia madagascar. rb CH2Cl2 1.7      0.73         2.6       1.5    3.6 
Vernonia spp. l CH2Cl2 1.8      3.2         3.0       1.6    0.94 
Bridelia cathartica rb CH2Cl2 2.0      6.9         0.85       0.43    0.12 
Commiphora fulvo. sb PE 2.1      7.0       45.0     21.4    6.4 
Bridelia cathartica r CH2Cl2 2.2 > 20         6.0       2.7  
Bridelia micrantha sb MeOH 2.2 > 20       60.0     27.1  
Asteranthe asterias r PE 2.6      2.4       50.1     19.3  20.9 
Asteranthe asterias rb CH2Cl2 2.9      0.88       17.1       5.9  19.4 
Vangueria infausta rb CH2Cl2 3.0      8.3       33.2     11.1    4.0 
Foetidia africana r MeOH 3.8    16.1       51.0     13.4    3.2 
Commiphora eminii sb CH2Cl2 3.9      2.8       15.4       3.9    5.5 
Bridelia cathartica r MeOH 3.9      7.4       23.7       6.1    3.2 
Salacia madagascar. r PE 4.0      0.96       15.3       3.8  15.9 
Bridelia micrantha rb MeOH 4.2 > 20       62.0     14.8  
Commiphora eminii sb PE 4.3      6.0       29.3       6.8    4.9 
Vernonia spp. l PE 4.3 > 20       73.8     17.2  
Bridelia micrantha root MeOH 4.5    12.1       28.8       6.4    2.4 
Foetidia africana sb MeOH 4.6 > 20       51.2     11.1  
Asteranthe asterias l CH2Cl2 4.8      3.3       22.9       4.8    6.9 
Cussonia zimmerm. rb PE 4.8      3.3         6.9       1.4    2.1 
Bridelia cathartica rb PE 5.0 > 20       16.1       3.2  
Bridelia cathartica rb MeOH 5.0 > 20         8.7       1.7  
Hymenocardia ulmo. rb MeOH 5.0 > 20       37.6       7.5  
Albizia gummifera 
(small tree) 
r CH2Cl2 5.0      2.6       57.8     11.6  22.2 
Asteranthe asterias r CH2Cl2 5.4      2.8       26.3       4.9    9.4 
Hymenocardia ulmo. sb MeOH 6.2 > 20       43.2       7.0  
Asteranthe asterias rb PE 6.2      2.1       15.8       2.5    7.5 
Asteranthe asterias sb PE 6.2      1.3       14.4       2.3  11.1 
Hymenocardia ulmo. sb MeOH 6.5    11.4       26.4       4.1    2.3 
Hymenocardia ulmo. 
(Chalinze) 
rb MeOH 6.5 > 20       51.2       7.9  
Asteranthe asterias sb CH2Cl2 6.5      1.2       16.8       2.6  14.0 
Commiphora fulvo. sb CH2Cl2 6.5      9.3       15.4       2.4    1.7 
Foetidia africana r CH2Cl2 7.1    17.7       67.4       9.5    3.8 
Foetidia africana rb MeOH 7.3 > 20       54.1       7.4  
Combretum harissii f MeOH 7.6    12.6       79.0     10.4    6.3 
Bridelia cathartica sb MeOH 7.9 > 20         1.9       0.24  
Bridelia micrantha r CH2Cl2 8.2    11.5  > 100  > 12.2  
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Table 8 (continued)        
Standard drugs/ 
Plant species 
      Part Extract IC50 
T.b. rhod. 
[µg/ml] 
  IC50 
  P. falc. 
  [µg/ml] 
  IC50 
  Cytotox. 
  [µg/ml] 
   SI 
   T.b. 
   rhod. 
 SI 
  P. 
  falc. 
Hymenocardia ulmo. r MeOH 8.6 > 20       64.3       7.5  
Cussonia zimmerm. sb PE 8.8    13.6       88.4     10.0    6.5 
Albizia gummifera 
(small tree) 
rb CH2Cl2 9.6    11.2       77.7       8.1    6.9 
Combretum harissii r CH2Cl2 9.6      6.2       11.8       1.2    1.9 
Combretum harissii l Water 9.7    15.0       75.2       7.8    5.0 
Albizia gummifera 
(small tree) 
r MeOH 9.8      1.6       49.7       5.1  31.1 
SI : selectivity index = IC50 cytotoxicity / IC50 activity 
 
l : leaves 
rb : rootbark 
 
f : fruits 
sb : stembark 
 
PE : petroleum ether 
r : root 
   
 
The selectivity indices (SI) of the extracts with antitrypanosomal activity were in the 
range from 0.24 to > 83 and the SI of the extracts with antiplasmodial activity were in 
the range from 0.12 to 31.1. 
 
 
4.2.1.4    GABAA receptor binding assay 
 
Definition of test score 
Enhanced binding : relative specific binding ≥ 120 % 
Moderate enhanced binding : 120 % ≤ relative specific binding ≤ 140 %  
High enhanced binding : relative specific binding > 140 % 
 
The summary of the results of the crude plant extracts in the [3H]flunitrazepam 
binding assay to rat cortex membranes is presented in table 9. The extract 
concentration tested was 50 µg/ml. All samples were tested in triplicate (n = 3). The 
standard compound GABA exhibited a relative specific binding of 124 % at a 
concentration of 10 µM. 
 
Specific binding  : Total binding − non specific binding 
Relative specific binding : Specific binding (%) = 100 % 
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Table 9 : Relative specific binding of the crude plant extracts. All values as %. 
Plant species Part                             Extracts   
  Petroleum  
   ether 
CH2Cl2 
 
MeOH 
 
Water 
 
Hymenocardia ulmoides stembark   89   93   74   95 
 rootbark   92 100   98 115 
 root   84   98 102 1201 
 rootbark (Chalinze)   82   75 1412 116 
Albizia gummifera stembark (large tree) 104 117 1201   93 
 stembark (small tree) 1422   92 118   86 
 root (small tree) 118   58 115   97 
 rootbark (small tree) 104   96   92   67 
Foetidia africana root   96 103 107 105 
 rootbark 107 108   82 117 
 stembark   91   97   87 107 
Salacia madagascar. root   87   72 102 104 
 rootbark 100   93   89 1211 
 stembark   96   96 116 112 
 leaves 109   89 1241 1331 
Asteranthe asterias rootbark 1432 105 1351 107 
 root 100   89   70   90 
 stembark 103   65 1301 1412 
 leaves 1241 103 107 119 
Cussonia zimmermannii rootbark 1512 1432 116 1201 
 stembark 1482   81 100   87 
Commiphora eminii stembark   94   81 1291 103 
Bridelia micrantha stembark   86   72 103   99 
 root 1231   83 103   98 
 rootbark   87   92   98 118 
Commiphora fulvo. stembark   90 104   93 105 
Vangueria infausta rootbark 100   74   84   81 
Vernonia spp. leaves   54   81 112   72 
Bridelia cathartica stembark   99   91 100   88 
 rootbark   88   79 101   97 
 root   95   63   93   85 
Combretum harissii root   82 1221   96   91 
 stem 108   93 112 101 
 leaves   86   84   91   97 
 fruits   45   69 101   72 
bold : Extracts with enhanced binding at the GABAA receptor 
1
 : Moderate enhanced binding 
2
 : High enhanced binding 
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From the GABAA receptor binding assay of the crude plant extracts it could be found 
that of a total of 140 extracts from 35 samples of 13 plant species, 121 (86 %) 
showed no effect on the relative specific binding, while 19 (14 %) exhibited a 
significant effect on the relative specific binding. Of the 19 active extracts 12 (63 %) 
showed moderate enhanced binding and 7 (37 %) showed high enhanced binding. 6 
(17 %) of the petroleum ether extracts, 2 (8 %) of the dichloromethane, 6 (17 %) of 
the methanol and 5 (14 %) of the water extracts were found to bind at the GABAA 
receptor. 
 
The most active extracts were the petroleum ether extracts of the rootbark and the 
stembark of Cussonia zimmermannii Harms with an enhanced relative specific 
binding of 151 and 148 %, respectively. 
 
 
4.2.2    Fractions 
 
4.2.2.1    Rootbark extract of Cussonia zimmermannii Harms 
 
The results of the antiparasitic (n = 2) and the GABAA receptor binding assays (n = 3) 
of the fractions of the petroleum ether extract of the rootbark of Cussonia 
zimmermannii Harms are presented in table 10. Only those fractions are listed which 
exhibited an increase or at least the same activity compared to the previous fraction. 
After two fractionation steps only the main fractions were investigated further. For the 
procedure of the bioassay-guided fractionation see chapter 5.2.1. 
 
The crude petroleum ether extract exhibited the following antiparasitic avtivities and 
relative specific binding at the GABAA receptor : 
 
- T. b. rhodesiense : IC50 4.8 µg/ml 
- P. falciparum  : IC50 3.3 µg/ml 
- GABAA receptor : enhanced relative specific binding 151 % (conc. 50 µg/ml) 
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Table 10 : Results of the antiparasitic and the GABAA  
receptor binding assays of the fractions of Cussonia  
zimmermannii Harms rootbark petroleum ether extract. 
Fraction IC50 
T.b. rhod. 
[µg/ml] 
IC50 
P. f. 
[µg/ml] 
rel. spec. 
binding 
[%] 
F3 1.7 1.0 156 
F4 2.7 0.90 173 
F5  2.1  
F6  1.7  
    
F3.4  0.33  
F3.6 0.48 0.91 156 
F3.7 1.5   
    
F4.7 1.1 0.81 172 
 
 
4.2.2.2    Stembark extract of Commiphora fulvotomentosa Engl. 
 
The results of the in vitro testing of the fractions of the petroleum ether extract of the 
stembark of Commiphora fulvotomentosa Engl. on STIB 900 strain of T. b. 
rhodesiense are presented in table 11. Only those fractions are listed which exhibited 
an increase or at least the same activity compared to the previous fraction.  
 
After three fractionation steps the fractions did no longer show any activity, therefore 
no further investigation was performed. For the procedure of the bioassay-guided 
fractionation see chapter 5.2.1. All samples were tested in duplicate (n = 2). 
 
The crude petroleum ether extract exhibited the following antitrypanosomal activity : 
 
- T. b. rhodesiense : IC50 2.1 µg/ml 
 
Table 11 : IC50 values (µg/ml) of the fractions of C. fulvotomentosa  
rootbark petroleum ether extract determined with STIB 900 strain  
of T. b. rhodesiense. 
Fraction IC50 
F2 1.5 
F3 0.57 
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4.2.3    Isolated pure compounds of Cussonia zimmermannii Harms 
 
4.2.3.1    Antiparasitic and cytotoxicity testing  
 
The results of the antiparasitic (T. b. rhodesiense, P. falciparum, T. cruzi and L. 
donovani axenic and in infected macrophages) and the cytotoxicity testing of the 
isolated pure compounds MS-1 (25), MS-2 (26) and MS-4 (27) of Cussonia 
zimmermannii Harms (Isolation and structure elucidation see chapter 5.2.1 and 5.2.2) 
and the selectivity indices of the compounds MS-2 (26) and MS-4 (27) are 
summarised in table 12. All samples were tested in duplicate (n = 2). The isolated 
compound MS-5 (28) was not tested because of small quantity. 
 
Formulas of the compounds MS-1 (25), MS-2 (26), and MS-4 (27) (see chapter 
5.2.2).       
 
                              
OH
O
O
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O
O
O
O
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 41 
 
Table 12 : Summary of the antiparasitic and cytotoxic test results of the isolated pure compounds of 
Cussonia zimmermannii Harms. 
Standard drugs/ 
compounds 
IC50  
T. b. 
rhod. 
[µg/ml] 
IC50  
P.  
falc. 
[µg/ml] 
IC50  
T.  
cruzi 
[µg/ml] 
IC50 
L. dono. 
axenic 
[µg/ml] 
IC50  
L. dono. 
inf. mac. 
[µg/ml] 
IC50  
Cytotox. 
 
[µg/ml] 
SI1 
T. 
cruzi 
SI1 
L. dono. 
inf. mac. 
Standard drugs         
Melarsoprol 0.0023        
Chloroquine  0.027       
Artemisinin  0.0012       
Benznidazole   0.62      
Miltefosine    0.18 0.29    
Mefloquine        1.9   
Compounds         
   MS-1 (25) 5.4 5.9 7.9 2.4 > 3 16.5   
   MS-2 (26) 0.14 0.44 0.2 0.039 0.098   3.6   18.0   36.7 
   MS-4 (27) 0.42 0.84 0.15 0.054 0.85 21.8 145.3  
1
 : SI = Selectivity index : IC50 cytotoxicity / IC50 activity 
bold : IC50 values of isolated pure compounds < IC50 values of standard drugs 
  (higher activity than the standard drug) 
 
 
4.2.3.2    GABAA receptor binding assay 
 
The summary of the results of the isolated pure compounds MS-1 (25), MS-2 (26), 
and MS-4 (27) of Cussonia zimmermannii Harms obtained from the [3H]flunitrazepam 
binding assay to rat cortex membranes are presented in table 13 and figure 1.  
The isolated compound MS-5 (28) was not tested because of small quantity. The 
compounds were tested at concentrations from 20 to 0.1 µg/ml. Compound MS-1 
(25) (n = 9) and MS-2 (26) and MS-4 (27) (n = 3). The standard compound GABA led 
to a relative specific binding of 120 % at a concentration of 10 µM. 
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Table 13 : Summary of the results of the pure compounds  
isolated from Cussonia zimmermannii Harms obtained from  
the GABAA receptor binding assay. 
        Rel. spec. binding of 
      [3H]flunitrazepam [%] 
              Compound 
Tested 
concentrations 
[µg/ml] 
  MS-1 (25)   MS-2 (26)   MS-4 (27) 
     20 138 152 158 
     10 140 132 132 
       5 138 137 142 
       2 126 125 121 
       1 113 113 113 
       0.1 101 112 100 
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Figure 1 : Stimulation of [3H]flunitrazepam binding by MS-1 (25), MS-2 (26), and MS-4 (27). Specific 
binding stimulated by MS-1 (25) (■), MS-2 (26) (), and MS-4 (27) () is shown relative to control 
binding in the absence of drugs. Data are expressed as mean ± SEM of three to nine individual 
experiments.   
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4.2.3.3    Electrophysiological investigations 
 
Positive allosteric modulation 
 
Functional effects of the isolated compounds MS-1 (25), MS-2 (26), and MS-4 (27) 
were investigated in electrophysiological studies at recombinant GABAA receptors 
expressed in Xenopus laevis oocytes. For reasons of solubility the compounds were 
only used up to a concentration of 30 µM. GABA was always used at concentrations 
eliciting 2-6 % of the maximal current amplitude in the corresponding GABAA receptor 
type. 30 µM of each tested compound elicited at the α1β2γ2 receptor type by itself tiny 
currents amounting to < 0.1 % of the maximal current elicited by GABA. But all 
compounds exhibited a potent positive allosteric modulatory effect by enhancing the 
GABA-stimulated current at α1β2γ2. This concentration dependent stimulation is 
documented for MS-1 (25) at α1β2γ2 with a GABA concentration of 7 µM (figure 2). 
Maximum stimulation at α1β2γ2 was achieved with about 10 µM MS-1 (25). It was also 
tested whether 10 µM MS-1 (25) stimulated currents elicited by GABA concentrations 
eliciting near maximal current amplitudes. In the presence of 500 µM GABA, 10 µM 
MS-1 (25) did not significantly affect the current amplitudes (97.7 ± 2.5 % of the 
control (n = 3)). 
 
Subunit specificity of MS-1 (25) 
 
Figure 3A shows an averaged concentration response curve of this type of 
experiment for the α1β2γ2 receptor type. Maximal stimulation was about 450 % and 
half-maximal stimulation was observed at a concentration (EC50) of about 1.5 µM. 
Replacement of the α1 subunit in this combination by one of the other α subunit 
isoforms (α2, α3, α5, or α6) resulted in little effect on EC50, that varied between 0.6 
and 1.0 µM, but had in some cases a drastic effect on the maximal stimulation. 
Extent of stimulation was α1β2γ2 ≈ α3β2γ2 > α2β2γ2 > α5β2γ2 ≈ α6β2γ2. Figure 3B shows 
the effect of the β subunit isoform and the lacking effect of omitting γ2 from α1β2γ2. 
Replacing β2 in α1β2γ2 by β1 or β3 drastically reduced maximal stimulation from 450 % 
to 80 % and 150 %, respectively. Introducing the point mutation β2N265S, which is 
known to strongly reduce stimulatory effects by loreclezole [138] into α1β2γ2, had only 
a relatively weak effect in this case, reducing maximal stimulation to about 65 %. 
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Subunit specificity of MS-2 (26) and MS-4 (27)  
 
Figures 4 and 5 show subunit specificities of MS-2 (26) and MS-4 (27), respectively. 
Again replacement of the α1 subunit in α1β2γ2 by one of the other α subunit isoforms 
(α2, α3, α5, or α6) resulted in little effect on EC50, that varied between 0.8 and 1.3 µM 
for MS-2 (26) and 1.4 and 3.5 µM for MS-4 (27), but had in some cases a drastic 
effect on the maximal stimulation. Maximal stimulation was about 300 % for MS-2 
(26) and about 110 % for MS-4 (27). The following specificity in this respect was 
observed for MS-2 (26) α1β2γ2 ≈ α3β2γ2 ≈ α1β2 > α2β2γ2 ≈ α6β2γ2 ≈ α5β2γ2 > α1β1γ2, and 
for MS-4 (27) α1β2γ2 ≈ α1β2 ≈ α5β2γ2 ≈ α3β2γ2 ≈ α2β2γ2 > α6β2γ2 » α1β1γ2.  
 
Lack of inhibition by the benzodiazepine antagonist Ro15-1788 
 
It was tested whether MS-1 (25) would act at a known site on the GABAA receptor. 
Currents elicited by 2-7 µM GABA were stimulated by 10 µM MS-1 (25) 361 ± 117 % 
(n = 6). When 1 µM of the benzodiazepine antagonist Ro15-1788 was co-applied, 
stimulation was not significantly altered with 391 ± 156 % (n = 3). In contrast the 
antagonist of the ROD site [139], ROD178B, significantly reduced stimulation to 134 
± 16 % (n = 3) at a concentration of 100 µM (figure 6). 
 
Effect of MS-1 (25) on the apparent affinity of picrotoxin 
 
Currents elicited by 3 or 4 µM GABA were inhibited by increasing concentrations of 
the channel pore blocker picrotoxin. The half-maximal concentration of picrotoxin for 
current inhibition was 1.2 ± 0.3 µM (n = 3) in the absence and 3.3 ± 0.9 µM in the 
presence of 10 µM MS-1 (25) (n = 3). MS-1 (25) seems to decrease apparent 
picrotoxin affinity about three-fold (figure 7). 
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Ion selectivity is maintained and stimulation is potential independent 
 
The reversal potential and the potential dependence of the current elicited by GABA 
were both not altered in the presence of 10 µM MS-1 (25). The reversal potential was 
–29 ± 1 mV (n = 3) in the absence of 10 µM MS-1 (25) and was not altered in its 
presence (not shown). 
 
   
 
Figure 2 : Concentration dependence of allosteric stimulation by MS-1 (25) at α1β2γ2 GABAA 
receptors. Recombinant α1β2γ2 GABAA receptors were expressed in Xenopus leavis oocytes and 
exposed to either 7 µM GABA alone or in combination with increasing concentrations of MS-1 (25). 
The experiment was repeated twice on oocytes of two different batches with similar results. 
 
 
 
 
Figures 3A/B : Subunit isoform specificity of MS-1 (25). (A) Recombinant α1β2γ2 (), α2β2γ2 (), α3β2γ2 
(■), α5β2γ2 (□) and α6β2γ2 (▲) and (B) α1β2γ2 (), α1β2 (), α1β2N265Sγ2 (x), α1β3γ2 (+), and α1β1γ2 ().  
GABAA receptors were expressed in Xenopus leavis oocytes and exposed to either GABA alone or in 
combination with increasing concentrations of MS-1 (25). Data are given as mean ± SEM (≤ 3 oocytes 
from two different batches). 
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Figure 4 : Subunit isoform specificity of MS-2 (26). Recombinant α1β2γ2 (), α1β2 (), α2β2γ2 (), 
α3β2γ2 (■), α5β2γ2 (□), α6β2γ2 (▲) and α1β1γ2 (). GABAA receptors were expressed in Xenopus leavis 
oocytes and exposed to either GABA alone or in combination with increasing concentrations of MS-2 
(26). Data are given as mean ± SD (≥ 3 oocytes from two different batches). 
   
 
       
 
Figure 5 : Subunit isoform specificity of MS-4 (27). Recombinant α1β2γ2 (), α1β2 (), α2β2γ2 (), 
α3β2γ2 (■), α5β2γ2 (□), α6β2γ2 (▲) and α1β1γ2 (). GABAA receptors were expressed in Xenopus leavis 
oocytes and exposed to either GABA alone or in combination with increasing concentrations of MS-4 
(27). Data are given as mean ± SEM (≥ 3 oocytes from two different batches). 
 
 47 
 
       
 
Figure 6 : Lack of inhibition by the benzodiazepine antagonist Ro15-1788 and reduction of the 
stimulation by the ROD site antagonist ROD178B. Recombinant α1β2γ2 GABAA receptors were 
exposed to either GABA in combination with 10 µM MS-1 (25), to GABA in combination with 10 µM 
MS-1 (25) and 1 µM Ro15-1788, or to GABA in combination with 10 µM MS-1 (25) and 100 µM 
ROD178B. Data are given as mean ± SEM (≥ 3 oocytes from two different batches). 
 
 
      
 
Figure 7 : MS-1 (25) affects inhibition by picrotoxin. Recombinant α1β2γ2 GABAA receptors were 
exposed to either GABA alone (■) or in combination with 10 µM MS-1 (25) (). Currents were inhibited 
by increasing concentrations of picrotoxin. Data are given as mean ± SEM (3 oocytes from two 
different batches). 
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4.3    Discussion and conclusions of the results of the crude plant extracts 
 
Summary of the antiparasitic and the cytotoxicity testings 
The most active extracts in both antiparasitic assays were the petroleum ether 
extracts of the rootbark and the stembark of Salacia madagascariensis. But the 
cytotoxicity was also high and the selectivity indices in a moderate range of 2-6. 
Promising results showed the petroleum ether extract of the rootbark of Bridelia 
micrantha with an IC50 value of 0.68 µg/ml against T. b. rhodesiense and a SI of 
about 60. Other parts of this plant showed also interesting results. Some constituents 
of this plant are known. Also promising results showed the petroleum ether extract of 
the stembark of Commiphora fulvotomentosa with an IC50 value of 2.1 µg/ml against 
T. b. rhodesiense and a SI of 21.4. Of this plant no consituents are known. Also the 
petroleum ether extract of the rootbark of Vangueria infausta with an IC50 value of 1.5 
µg/ml against T. b. rhodesiense and a SI of 13.8 was interesting, unfortunately only a 
small quantity of about 200 g of plant material could be collected. 
 
GABAA receptor binding assay 
The most promising results showed the petroleum ether and the dichloromethane 
extract of the rootbark and the petroleum ether extract of the stembark of Cussonia 
zimmermannii. Interesting was the fact that the plant is used in traditional medicine 
for the treatment of epilepsy [11] and mental illness [16]. Also remarkable was that in 
contrast to the antiparasitic results many water extracts exhibited a significant 
enhanced relative specific binding at the GABAA receptor.  
 
Selection of the extracts for bioassay-guided fractionation 
Many extracts showed promising activities in the antiparasitic and GABAA receptor 
binding testings. Because not all of them could be investigated phytochemically, a 
selection had to be made. The selected plant extract should show high activities in 
the preliminary screening and of the plant, from which it was extracted, no  
constituents should be known. Therefore Salacia madagascariensis, Bridelia 
micrantha and Vangueria infausta were excluded from further investigation.  
For the bioassay-guided fractionation the petroleum ether extract of the stembark of 
Commiphora fulvotomentosa and the petroleum ether extract of the rootbark of 
Cussonia zimmermannii were selected because of the following reasons : 
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Petroleum ether extract of the stembark of C. fulvotomentosa : 
- low IC50 value of 2.1 µg/ml against T. b. rhodesiense 
- high selectivity index of 21.4 
- no known constituents 
- enough plant material at hand (1039 g)  
 
Petroleum ether extract of the rootbark of C. zimmermannii : 
- acceptable IC50 value of 4.8 µg/ml against T. b. rhodesiense 
- good IC50 value of 3.3 µg/ml against P. falciparum 
- high relative specific binding at the GABAA receptor of 151 % 
- traditionally used for the treatment of epilepsy and mental illness 
- no known constituents 
- enough plant material at hand (717 g) 
 
The main reason for the selection of Cussonia zimmermannii for further investigation 
was the fact, that its rootbark extract showed activity in all three performed assays 
and that the plant is known to be used in traditional medicine not only for the 
treatment of malaria but also for epilepsy and mental illness. This could be due to 
constituents with GABAA receptor stimulating properties, because benzodiazepines 
which also act at the GABAA receptor are used as antiepileptics. 
 
 
5.    Constituents of Cussonia zimmermannii Harms 
 
5.1    Introduction 
 
5.1.1    Botany 
 
Cussonia zimmermannii Harms belongs to the genus Cussonia of the family  
Araliaceae. Local names are msopole (Kihehe, Kisagara), mtumbitumbi (Kingindo) 
and mutolondo. No synonyms are known [11]. It is a tree to 25 m tall with greenish-
grey fissured bark. Leaves digitately compound; petiole up to 53 cm long and 5 mm 
diameter, but generally considerably smaller, glabrous apart from some crisped hairs 
in stipular region and at junction with leafets; leafets 5-7 (-9), sessile, chartaceous to 
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coriaceous, lanceolate to oblanceolate, narrowly ovate and narrowly obovate, up to 
25 cm long by 8 cm wide, but generally considerably less, caudate to acute, with a 
narrowly cuneate to much attenuated base with crenate to subentire margins, 
glabrous above, glabrous to slightly puberulous beneath. Flowering spikes up to 
about 12 together, up to 34 cm long [122]. It blooms from October to November [11]. 
The plant occurs in Kenya (Kwale- and Tana River District) and Tanzania (Tanga-, 
Uzaramo- and Lindi District). It grows in lowland rain forest, lowland dry evergreen 
forest and woodlands of 0 - 400 m [122]. 
 
 
5.1.2    Use in traditional medicine 
 
In traditional medicine a decoction of the root of Cussonia zimmermannii Harms is 
used to treat malaria. The marrow of the stem and branches are eaten to treat 
epilepsy and a decoction of the root is taken as a remedy for labour pain [11]. An 
infusion of the leaves is used as a wash for people suffering from fever or the ague. 
A decoction of the roots is taken as a remedy for gonorrhoea [12]. Roots of Cussonia 
zimmermannii Harms along with roots of Deinbollia borbonica Scheff. f. are cooked 
with chicken and the resulting soup is ingested for hypertensive encephalopathy, 
post-partum haemorrhage and mental illness [16]. 
 
 
5.1.3    Known constituents of the genus Cussonia 
 
Of the genus Cussonia 51 compounds from 10 different species are described in 
literature. They belong to eight classes of natural products. Most compounds belong 
to the classes of triterpenoid saponins and diterpenoid glycosides. There is only one 
species which is known to contain polyacetylenes and from another species 
stigmasterol has been isolated.  
 
The known constituents of the genus Cussonia are summarised in table 14. The 
structures of the known polyacetylenes from the genus Cussonia are shown in 
scheme 3. 
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Table 14 : Known constitutents of the genus Cussonia. 
Class of natural products Constituent Plant species/ 
References 
Polyacetylenes (+)-9(Z),17-Octadecadiene-12,14-diyne-1,11(S), 
16(S)-triol (29) 
(+)-9(Z),17-Octadecadiene-12,14-diyne-1,11(S), 
16(S)-triol-1-acetate (30) 
 
C. barteri [140] 
 
 
Quinic acid esters 1’-O-Chlorogenoylchlorogenic acid 
1’-O-Chlorogenoylneochlorogenic acid 
 
C. barteri [141] 
 
Triterpenoid saponins 3-O-(α-L-Arabinopyranosyl)-23-hydroxyursolic acid 
3-O-(β-D-Glucopyranosyl)-23-hydroxyursolic acid  
 
28-O-[α-L-Rhamnopyranosyl-(1→4)-β-D-glucopyranosyl-
(1→6)-β-D-glucopyranosyl]-23-hydroxyursolic acid ester 
 
Cussosaponins A-E 
 
[(α-L-Arabinofuranosyl-(1→4)-β-D-glucuronopyranosyl-
(1→3)]-3β-hydroxyolean-12-en-28-oic acid 
[(α-L-Arabinofuranosyl-(1→4)-β-D-galactopyranosyl-
(1→2)]-β-D-glucuronopyranosyl-(1→3)]-3β-hydroxyolean-
12-en-28-oic acid 
 
Cussonoside A and B 
C. bancoensis [142] 
 
 
C. bancoensis [143]  
 
 
C. racemosa [144]  
C. spicata [145]  
 
 
 
 
 
C. barteri [146]  
   
Steroids Stigmasterol C. bancoensis [142]  
   
Triterpenoid carbocyclic  
acids and esters 
 
 
 
 
 
 
 
 
 
 
 
Diterpenoid glycosides 
 
 
Ursolic acid 
23-Hydroxyursolic acid  
3β-Hydroxylup-20(29)-en-28-oic acid 
 
23-Hydroxy-3-oxo-urs-12-en-28-oic acid 
 
Hederagenin 
 
 
 
Oleanolic acid 
Oleanolic acid methyl ester acetate 
 
Paniculoside IV 
 
 
 
C. bancoensis [142]  
 
 
 
C. natalensis [147] 
 
C. holstii [148] 
C. bojeri [149] 
C. corbisieri [150] 
 
C. corbisieri [150] 
 
 
C. vantsilana [151] 
C. bojeri [152] 
C. racemosa [153] 
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Table 14 (continued)   
Class of natural products Constituent Plant species/ 
References 
Diterpenoid glycosides Cussovantoside A-D 
Suavioside E 
Cussovacoside C 
 
β-D-Glucopyranosyl,17-hydroxy-ent-kauran-19-oate- 
16-O-β-D-glucopyranoside 
β-D-Glucopyranosyl 16β,17-dihydroxy-(−)-kauran-19-oate 
 
Cussoracosides A-F 
 
β-D-Glucopyranosyl-ent-16β,17-dihydroxykauran-19-oate 
Cussosides A-D (cleorodane glycosides) 
Cussoside E (labdane glycoside) 
C. vantsilana [151] 
 
 
 
C. bojeri [153]  
 
 
 
C. racemosa [153]  
 
C. racemosa [154]  
   
Diterpenoid carbocyclic acids Cussovantonin A and B 
Kaur-16-en-18-oic acid 
 
16β,17-Dihyroxy-kauran-19-oic acid  
 
C. vantsilana [151] 
 
 
C. bojeri [153] 
Flavonoids Rutin  
 
 
 
Kaempferol rutinoside 
C. vantsilana [151] 
C. bojeri [153]  
C. barteri [141] 
 
C. vantsilana [151] 
 
                      
29, (+)-9(Z),17-Octadecadiene-12,14-diyne-1,11(S),16(S)-triol
OHH
H OH
Z OH
OHH
H OH
Z O
O
30, (+)-9(Z),17-Octadecadiene-12,14-diyne-1,11(S),16(S)-triol-1-acetate
(S)
(S)
(S)
(S)
             
 
Scheme 3 : Structures of the known polyacetylenes (29) and (30) from the genus Cussonia.  
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5.2    The polyacetylenes and stigmasterol 
 
The polyacetylenes 
 
Polyacetylenes (polyynes) are compounds with very diverse structures containing 
several C/C triple bonds. In addition they often also contain C/C double bonds, allene 
units, thiophene and furan rings. "Polyacetylenes" is used as a collective name even 
when only one C/C triple bond is present in the molecule. They are produced mainly 
by fungi (basidomycetes) and plants of the families Asteraceae, Apiaceae, and 
Araliaceae [155]. In some species they are not constitutively present, but were 
induced after fungal attack, for example in certain Fabaceae and Solanaceae (e.g. 
falcarindiol (31) production by Cladosporium-infected tomatoes). More than one 
thousand natural polyacetylenes are known in higher plants [156]. Naturally occurring 
polyacetylenes are formed biogenetically from unsaturated fatty acids such as oleic 
and linoleic acids by further dehydrogenation of their cis-alkene bonds and 
subsequent shortening of the carbon chain. Compounds with an odd number of 
carbon atoms develop by decarboxylation and α-oxydation. They can occur in all 
plant organs and are localized in oil channels [157].  
 
For the isolation of polyacetylenes generally, careful solvent extraction at room 
temperature is performed. They normally are concentrated in oil channels, therefore, 
extractions with ether-petroleum ether mixtures are sufficient. Repeated column 
chromatography and finally TLC are usually successful in isolation of the acetylenes. 
Structure elucidation methods are mostly spectroscopic, important is the infrared 
spectroscopy, although the acetylenic stretching frequency is usually weak. Important 
is also mass spectroscopy but the most important method has become NMR 
spectroscopy. The position of the signals of triple bond-methyl groups is located 
around 2 ppm, which is very little changed by the number of triple bonds and the 
couplings across triple bonds are unusually large [158] :  
 
H3C C
H
(C C)
n
 
n = 1 : J = ~ 3 Hz 
n = 2 : J = ~ 1 Hz 
n = 3 : J = 0.3 Hz 
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Polyacetylenes are known to possess antifungal, insecticidal, antibiotic (e.g. 
Helicobacter pylori), molluscicidal and local anaesthetic activities. Further biological 
properties are inhibition of  5-lipoxygenase, phototoxicity, neurotoxicity and hemolytic 
activity. Some polyacetylenes can also cause allergic and irritant contact dermatitis. It 
has been shown that the antifungal activity of e.g. falcarindiol (31) is due to 
destruction of the plasma membrane of dermatophytes.  
The trivial names, biological activities and origin of some typical polyacetylenes from 
plant species of the families Apiaceae and Asteraceae and from basidomycete 
cultures are shown in table 15, their structures and molecular folmulas are shown in 
scheme 4. 
 
Table 15 : Trivial names, biological activities and origin of some typical polyacetylenes from  
Apiaceae, Asteraceae and basidomycete cultures. 
Trivial names Biological activties Origin Ref. 
Mycomycin (32) antibiotic Basidomycete 
cultures 
[155] 
 
Cicutoxin (33) highly toxic (neurotoxicity) Cicuta virosa 
(Apiaceae) 
[156]  
 
Œanthotoxine (34) highly toxic (neurotoxicity) Œanthus crocata 
(Apiaceae) 
[156]  
 
Wyerone (35) antifungal, phytoalexin Vicia faba 
(Asteraceae) 
[159]  
 
Tonghaosu (36) antifeedant activity towards insects Chrysanthemum segetum 
(Asteraceae) 
[155]  
 
HO
EE E (R)
OH33, cicutoxin
C17H22O2
HO2C
E Z
32, mycomycin
C13H10O2
34, oenanthotoxine
C13H14
O COOH
O35, wyeroneC15H14O4
O
O
36, tonghaosu
C13H12O2
 
 
Scheme 4 : Structures and molecular formulas of some typical polyacetylenes.  
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From the family Araliaceae (where Cussonia zimmermannii Harms belongs to) over 
thirty different polyacetylenes have been isolated. The trivial names, CA index 
names, biological activities and origin of some selected polyacetylenes closely 
related to the ones isolated from Cussonia zimmermannii are shown in table 16, their 
structures and molecular formulas are shown in scheme 5. 
 
Table 16 :  Names, biological activities and origin of some polyacetylenes, isolated from plants of the 
family Araliaceae.  
Trivial names/CA index names Biological activities Origin Ref. 
Falcarinol (37, 1,9-Heptadecadiene- 
4,6-diyn-3-ol (3R, 9Z)) 
Causes allergic and irritant contact 
dermatitis 
Inhibition of Helicobacter pylori growth 
and vacuolation 
Antifungal 
Local anaesthetic 
Panax ginseng 
Hedera helix 
[160]  
[161]  
[162]  
[163]  
 
 
 
Falcarindiol (31, 1,9-Heptadecadiene- 
4,6-diyn-3,8-diol (3S, 8S, 9Z)) 
 
Inhibitory activity on 5-lipoxygenase 
Local anaesthetic 
Destroys the plasma membrane 
 
Schefflera  
digitata 
 
[160]  
[164]  
 
 
Heptadeca-1-en-4,6-diyn-3,9-diol (38) 
 
n.d. 
 
Panax ginseng 
 
[160]  
 
Panaxytriol, Falcarintriol  
(39, 1-Heptadecene-4-6-diyn-3,9,10- 
triol (3R, 9R, 10R))  
Inhibition of Helicobacter pylori growth 
and vacuolation 
Panax ginseng [160]  
[162]  
 
 
8-Heptadecene-4,6-diyn-3,10-diol,  
10 acetate (40) 
 
n.d. 
 
Panax  
vietnamensis 
 
[165]  
 
 
1,9-Heptadecadiene-4,6-diyn-3-ol, 
acetate [R-(Z)] (41) 
 
n.d 
 
Didymopanax 
spp. 
 
[166] 
n.d. : not determined 
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Z
O
O
41, 1,9-heptadecadiene-4,6-diyn-3-ol, acetate
C19H26O2
OH
37, falcarinol
C17H24O
Z
(R)
OH
OH
31, falcarindiol
C17H24O2
(S)
OH
OH
38, heptadeca-1-en-4,6-diyn-3,9-diol
C17H26O2
OH
OH
OH
39, panaxytriol
C17H26O3
OH
O
O
40, 8-heptadecene-4,6-diyn-3,10-diol, 10-acetate
C19H28O3
Z
(S)
(R)
(R) (R)
(R)
 
 
Scheme 5 : Structures and molecular formulas of some polyacetylenes closely related to 
polyacetylenes isolated from Cussonia zimmermannii. 
 
 
Stigmasterol 
 
Stigmasterol (24-ethyl-cholest-5,22-dien-3β-ol) (42) belongs to the sterols, a group of 
naturallly occurring steroids derived from cholesterol that possess a 3β-hydroxy 
group and a 17β-aliphatic side chain normally with 8-10 carbon atoms. Sterols are 
widely distributed in the animal and plant kingdom as cell components either in the 
free form or as esters or glycosides. Depending on their occurrence, they are 
distinguished as zoosterols of the animal kingdom or phytosterols of the plant 
kingdom. The non-saponifiable part of soy bean oil contains 12-25 % stigmasterol 
(42) [167]. Stigmasterol (42) is used as starting material for the partial synthesis of 
hormones [157].  
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5.2.1    Isolation 
 
The polyacetylenes and stigmasterol were obtained from the petroleum ether extract 
from 717 g of Cussonia zimmermannii Harms rootbark. The extract was subjected to 
bioassay-guided fractionation by preparative scale chromatography : MPLC and 
HPLC methods as described in chapter 4.1.1.2. Thus 36.5 mg of MS-1 (25), 81.2 mg 
of MS-2 (26), 17.3 mg of stigmasterol (42), 221.7 mg of MS-4 (27), and 1.4 mg of 
MS-5 (28) were obtained. 
 
For the activities of the crude extract and the fractions see chapter 4.2.1.1, for the 
activities of the isolated pure compounds see chapters 4.3.1.1, 4.3.1.2, and 4.3.1.3. 
The procedure of the bioassay-guided fractionation of the petroleum ether extract 
from Cussonia zimmermannii Harms is shown in schemes 6-15. The footnotes stand 
for the following : bold frames : fractions investigated further; 1 : fractions with activity 
against T. b. rhodesiense; 2 : fractions with activity against P. falciparum and 3 : 
tested fractions that stimulate GABAA receptor binding. For the isolation methods see 
chapter 4.1.1.2 in the experimental part. 
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Cussonia 
zimmermannii 
rootbark 
717 g 
 
  
   Extraction with petroleum ether  
  
crude 
extract 
4.7 g 
 
  
               MPLC Method 1  
  
      
  F1 
  90.7 mg 
  F2 
1014.7 mg 
     F31/2/3 
1011.0 mg 
     F41/2/3 
945.6 mg 
  F52 
101.7 mg 
  F62 
168.5 mg 
 F7 
689.5 mg 
        
                                                Scheme 7        Scheme 13      Scheme 14       Scheme 15  
 
Scheme 6 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from plant material to fraction F3, F4, F5 and F6). 
 
 
       
                                              Scheme 8                          Scheme 9     Scheme 10 
 
Scheme 7 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3 to fraction F3.4, F3.6 and F3.7). 
 
                                               
 
   F31/2/3 
1000 mg 
 
        MPLC Method 2 
 
          
F3.1 
11.8 mg 
 F3.2 
8.6 mg 
 F3.3 
6.6 mg 
 F3.42 
14.1 mg 
 F3.5 
163.6 mg 
 F3.61/2/3 
311.7 mg 
 F3.71 
106.4 mg 
 F3.8 
185.3 mg 
 F3.9 
42.5 mg 
 F3.10 
100.3 mg 
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Scheme 8 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3.4 to fraction F3.4.1 and F3.4.2). 
 
 
    F3.61/2/3 
310 mg 
 
      MPLC Method 3 
 
    
F3.6.1 
4.9 mg 
 F3.6.2 
1.7 mg 
 F3.6.3 
7.8 mg 
 F3.6.4 
9.3 mg 
 F3.6.5 
276.8 mg 
 
 
                 Prep. HPLC Method 2 
 
        
F3.6.5.1 
15.6 mg 
 F3.6.5.2 
8.3 mg 
 F3.6.5.3 
5.8 mg 
 F3.6.5.4 
12.5 mg 
 F3.6.5.5 
11.3 mg 
 F3.6.5.6 
95.8 mg 
 F3.6.5.7 
47.6 mg 
 F3.6.5.8 
17.6 mg 
 F3.6.5.9 
11.3 mg 
    
    
                            Prep. HPLC Method 3     Prep. HPLC Method 4 
     
 F3.6.5.6.2 
MS-2 (26) 
76.4 mg 
 F3.6.5.7.2 
MS-1 (25) 
36.5 mg 
 
 
Scheme 9 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3.6 to MS-1 (25) and MS-2 (26)). 
 
 F3.42 
14 mg 
 
                                                               Recrystallisation from Hexane 
 
 
 
F3.4.1 
8.0 mg 
   F3.4.2 
5.3 mg 
   
  
         Prep. HPLC Method 1              No further investigation 
  
       
 
  16 Fractions,  
no main fraction 
  
   
 
    No further investigation 
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 F3.71 
102 mg 
 
              MPLC Method 4   
 
     
F3.7.1 
2.9 mg 
 F3.7.2 
1.7 mg 
 F3.7.3 
19.0 mg 
 F3.7.4 
60.6 mg 
 F3.7.5 
13.3 mg 
 F3.7.6 
1.5 mg 
      
 
                                                                     Scheme 11  Scheme 12 
 
Scheme 10 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3.7 to fraction 3.7.3 and 3.7.4). 
 
F3.7.3 
19 mg 
 
                            Prep. HPLC Method 5 
 
        
F3.7.3.1 
0.4 mg 
 F3.7.3.2 
0.3 mg 
 F3.7.3.3 
1.4 mg 
 F3.7.3.4 
0.6 mg 
 
F3.7.3.5 
7.8 mg 
 F3.7.3.6 
0.2 mg 
 F3.7.3.7 
2.6 mg 
 F3.7.3.8 
0.5 mg 
 F3.7.3.9 
0.5 mg 
 
                    Prep. HPLC Method 6 
 
F3.7.3.5.2 
MS-2 (26) 
4.8 mg 
 
Scheme 11 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3.7.3 to MS-2 (26)). 
 
F3.7.4 
60 mg 
 
                                                                Recrystallisation from Hexane 
 
  
F3.7.4.1 
29.1 mg 
   F3.7.4.2 
28.4 mg 
   
      Prep. HPLC Method 7               Prep. HPLC Method 8   
     
  
 
F3.7.4.1.6 
Stigmasterol (42) 
17.3 mg 
  F3.7.4.2.9 
MS-5 (28) 
1.4 mg 
  
 
Scheme 12 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F3.7.4 to stigmasterol (42) and MS-5 (28)). 
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                                                                                  Prep. HPLC Method 9 
 
F4.7.7 
267.3 mg 
 
                                                                                  Prep. HPLC Method 10 
 
F4.7.7.2 
MS-4 (27) 
221.7 mg 
 
Scheme 13 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F4 to MS-4 (27)). 
 
F5 
100 mg 
 
                                                            MPLC Method 6 
 
              
F5.1 
4.9 mg 
 F5.2 
0.9 mg 
 F5.3 
2.9 mg 
 F5.4 
1.3 mg 
 F5.5 
8.1 mg 
 F5.6 
1.8 mg 
 F5.7 
15.5 mg 
 
              
              
F5.8 
5.0 mg 
 F5.9 
19.7 mg 
 F5.10 
11.5 mg 
 F5.11 
1.6 mg 
 F5.12 
1.1 mg 
 F5.13 
21.2 mg 
 F5.14 
2.5 mg 
 
 
Scheme 14 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F5 to fraction F5.1-F5.14). 
 
Scheme 15 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Cussonia zimmermannii Harms rootbark (from fraction F6 to fraction F6.1-F6.11). 
     F41/2/3 
940 mg 
 
           MPLC Method 5 
 
           
F4.1 
7.6 mg 
 F4.2 
6.2 mg 
 F4.3 
2.9 mg 
 F4.4 
0.8 mg 
 F4.5 
31.6 mg 
 F4.6 
144.9 mg 
 F4.71/2/3 
551.0 mg 
 F4.8 
20.8 mg 
 F4.9 
17.2 mg 
 F4.10 
116.8 mg 
 F4.11 
23.7 mg 
 F4.12 
2.9 mg 
 
F6 
165 mg 
 
                                                          MPLC Method 7 
 
           
F6.1 
5.5 mg 
 F6.2 
1.4 mg 
 F6.3 
3.0 mg 
 F6.4 
1.2 mg 
 F6.5 
0.5 mg 
 F6.6 
9.4 mg 
 F6.7 
1.6 mg 
 F6.8 
34.1 mg 
 F6.9 
7.3 mg 
 F6.10 
37.4 mg 
 F6.11 
22.2 mg 
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5.2.2    Structure elucidation of the polyacetylenes 
 
5.2.2.1    8-Hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)), a novel diyne 
 
Preparative HPLC (see scheme 9) yielded 36.5 mg of a yellowish viscous oil with a  
negative optical rotation ([α]D –94.5). The oil was analyzed by EI-MS, HR-EI-MS, 
UV/VIS- and IR-spectroscopy, 1H-NMR, 13C-NMR, DEPT135, 1H-1H COSY, HMQC 
and HMBC. 
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The EI-MS measurement of MS-1 (25) showed a [M]+ peak at m/z 306 and the 
molecular formula was determined as C19H30O3 from its HR-EI-MS measurement 
(m/z [M]+ calc.: 306.21950; found : 306.21971). The UV spectrum suggested a 
conjugated diyne [158]. IR absorption bands indicated the presence of hydroxyl 
groups (3424 cm-1), alkanes (2926 cm-1, 2855 cm-1, 1464 cm-1 and 1372 cm-1), 
acetylenes (2253 cm-1 and 2156 cm-1) and esters/acetates (1746 cm-1 and 1231    
cm-1). The 13C-NMR spectrum (figure 8) showed 19 resonances, which corresponded 
to the molecular formula derived from HR-EI-MS. The DEPT135 spectrum (figure 8) 
showed 14 resonances, five methyls or methines (δC 65.3, 62.9, 20.9, 14.1 and 9.3) 
and nine methylenes (δC 37.5, 31.9, 29.51, 29.48, 29.29, 29.21, 27.8, 25.0 and 22.7). 
Therefore it could be concluded that the molecule must contain five quaternary 
carbon atoms (δC 169.9, 80.6, 76.7, 69.3 and 68.8) which was also confirmed by 
HMQC. The quaternary carbon atom at δC 169.9 was identified as that of an ester 
carbonyl group and the other four had to be connected by conjugated triple bonds. 
The suggestion of a diyne structure also was in agreement with the acetylene bands 
in the IR spectrum, the UV bands and the comparison with literature data [140].
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Figure 8 : 13C-NMR and DEPT135 of 8-hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) in CDCl3.
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The crosspeaks in the HMQC spectrum (figure 9) and the corresponding integrals 
from the 1H-NMR spectrum (figure 10) showed that the carbon atoms at δC 65.3 and 
62.9 were methines and those at δC 20.9, 14.1 and 9.3 were methyls. Therefore the 
molecule must contain the following structure components :  
1x COO 
4x C (conjugated triple bonds) 
2x CH 
3x CH3  
9x CH2  
= C19H29O2. The difference to the found molecular formula was OH which 
corresponded to the hydroxyl band in the IR spectrum.  
Furthermore the carbon atoms at δC 65.3 and 62.9 were identified as oxygen-bearing. 
 
The 1H-NMR spectrum (figure 10) showed two oxygen-bearing methines at δH 5.35 (t, 
J = 6.5) and 4.42 (t, J = 6.6), three methyls at δH 1.02 (t, J = 7.4), 0.88 (t, J = 7.0) and 
2.09 (s), a hydroxyl at δH 1.75 (d, J = 5.8), and three methylenes at δH 1.82-1.77 (m), 
1.72-1.69 (m) and 1.43 (broad q, J = 7.3) and an overlapped methylene envelope at 
δH 1.31-1.26 (m). A 1H-1H COSY experiment (figure 11) showed two separate spin 
systems. The first showed a methyl at δH 1.02 (t) that was coupled to a methylene at 
δH 1.82-1.77 (m) that was further coupled to an oxygen-bearing methine at δH 5.35 (t) 
marking the end of this spin system. The second spin system began at the second 
oxygen-bearing methine at δH 4.42 (t) which was coupled to a hydroxyl proton at δH 
1.75 (d) and a methylene at δH 1.72-1.69 (m) that was coupled to a further methylene 
at δH 1.43 (broad q). Beyond this, the spin system extended to the overlapped 
methylene envelope at δH 1.31-1.26 (m) and could not be traced further with 
certainty.  
 
Then the 13C resonances were correlated with the corresponding 1H resonances by 
HMQC (figure 9) and the structure components were linked using an HMBC 
experiment (figure 12). Key correlations were that of the carbonyl carbon atom at δC 
169.9 with the methyl protons at δH 2.09 which indicated an acetate. The correlation 
observed between the carbonyl carbon atom at δC 169.9 and the methine proton at 
δH 5.35 indicated an acetoxy group at the C-atom with δC 65.3. 
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Figure 9 : HMQC of 8-hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) in CDCl3.
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Figure 10 : 1H-NMR of 8-hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) in CDCl3. (∗ water). 
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Figure 11 : 1H-1H COSY of 8-hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) in CDCl3.
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Figure 12 : HMBC of 8-hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) in CDCl3 (with detail).
 69 
The acetylene carbon atom at δC 80.6 showed crosspeaks with the proton of the 
hydroxyl-bearing methine at δH 4.42 and the methylene protons at δH 1.72-1.69, 
which placed the carbinol-C with δC 62.9 adjacent to the acetylene-C at δC 80.6. On 
the opposite side of the diyne, a correlation was observed between the acetylene 
carbon atom at δC 76.7 and the methine proton at δH 5.35 and the methylene protons 
at δH 1.82-1.77 which placed this acetylene carbon next to the acetoxy-bearing C at 
δC 65.3. A strong correlation between one of the inner alkyne carbon atoms at δC 
69.3 and the methine proton at δH 5.35, and a weak correlation with the methine 
proton at δH 4.42 placed this acetylene carbon next to that at δC 76.7. The second 
inner alkyne carbon atom at δC 68.8 correlated strongly with the methine proton at δH 
4.42 and weakly with the methine proton at δH 5.35, which placed it adjacent to the 
acetylene carbon atom at δC 80.6. The crosspeaks between the carbon at δC 65.3 
and the methylene protons at δH 1.82-1.77 and the methyl protons at δH 1.02 placed 
the methylene at δC 27.8 next to the acetate and the methyl at δC 9.3 next to the 
methylene. The hydroxyl-bearing methine at δC 62.9 showed crosspeaks with the 
methylene protons at δH 1.72-1.69 which placed the methylene-C at δC 37.5 next to 
the carbinol. This methylene-C correlated with the protons of a further methylene at 
δH 1.43, which placed that methylene-C at δC 25.0. Finaly the methylene-C at δC 31.9 
showed strong correlations with the methyl protons at δH 0.88 and with methylene 
protons of the methylene envelope at δH 1.28. Another methylene-C at δC 22.7 
showed also a strong correlation with the methyl protons at δH 0.88 but only a weak 
correlation with the protons of a methylene of the methylene envelope at δH 1.26. 
That placed the methylene-C at δC 31.9 next to that at δC 22.7 and that next to the 
terminal methyl group.  
 
The formula of MS-1 (25) with C→H correlations obtained from the HMBC 
experiment is shown in figure 13. 
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Figure 13 : C→H correlations obtained from the HMBC experiment of MS-1 (25) in CDCl3.  
(Optimized for nJCH = 7 Hz (n = 2 or 3)). 
 
On the basis of the above data MS-1 (25) was identified as 8-hydroxyheptadeca-4,6-
diyn-3-yl acetate. The comparison of the spectroscopic data with those of analogous 
structures from the literature : (+)-9(Z),17-octadecadiene-12,14-diyne-1,11,16-triol 
(43) [140]; oplopandiol (44), (+)-9(Z),17-octadecadiene-12,14-diyne-1,11,16-triol, 1-
acetate (45); oplopandiol acetate (46) [168]; and (9Z, 16S)-16-hydroxy-9,17-
octadecadiene-12,14-diynoic acid (47) [169] showed good correspondance.  
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5.2.2.2   8-Hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2  (26)), a novel diyne 
 
Preparative HPLC (see scheme 9 and 11) yielded 76.4 mg and 4.8 mg of a yellowish 
viscous oil with a negative optical rotation ([α]D –28.0). The oil was analyzed by FAB-
MS (NBA + KCl), EI-MS, HR-EI-MS, UV/VIS- and IR-spectroscopy, 1H-NMR, 13C-
NMR, DEPT135, 1H-1H COSY, HMQC and HMBC. 
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The FAB-MS (NBA + KCl) measurement of MS-2 (26) showed a [M+K]+ peak at m/z 
343, therefore the molecular mass must have been 304. The EI-MS measurement 
showed an [M-1]+ peak of m/z 303 and the molecular formula was determined as 
C19H27O3 from its HR-EI-MS measurement (m/z [M-1]+ calc.: 303.19602; found : 
303.19530). Therefore the correct molecular formula must have been C19H28O3. The 
UV spectrum suggested a conjugated diyne [158]. IR absorption bands indicated the 
presence of hydroxyl groups (3426 cm-1), alkenes (3088 cm-1 and 1650 cm-1), 
alkanes (2926 cm-1, 2856 cm-1, 1461 cm-1 and 1372 cm-1), acetylenes (2255 cm-1 and 
2157 cm-1) and esters/acetates (1746 cm-1 and 1225 cm-1). The 13C-NMR spectrum 
(figure 14) showed 19 resonances, which corresponded to the molecular formula 
derived from HR-EI-MS. The DEPT135 spectrum (figure 14) showed 14 resonances, 
five methyls or methines (δC 131.9, 64.5, 62.9, 20.9 and 14.1) and nine methylenes 
(δC 119.8, 37.4, 31.9, 29.51, 29.48, 29.29, 29.20, 25.0 and 22.7). Therefore it could 
be concluded that the molecule must contain five quaternary carbon atoms (δC 169.5, 
81.3, 74.4, 70.8 and 68.6) which also was confirmed by HMQC. The quaternary 
carbon atom at δC 169.5 was identified as that of a ester carbonyl group and the 
other four had to be connected by conjugated triple bonds due to comparison with 
MS-1 (25).  
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Figure 14 : 13C-NMR and DEPT135 of 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) in CDCl3.
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The suggestion of a diyne structure also was in agreement with the acetylene bands 
in the IR spectrum, the UV bands and the comparison with literature data [140]. The 
crosspeaks in the HMQC spectrum (figure 15) and the corresponding integrals from 
the 1H-NMR spectrum (figure 16) showed that the carbon atoms at δC 131.9, 64.5 
and 62.9 were methines and those at δC 20.9 and 14.1 were methyls. Therefore the 
molecule must contain the following structure components :  
1x COO 
4x C (conjugated triple bonds) 
3x CH 
2x CH3  
9x CH2  
= C19H27O2. The difference to the found molecular formula was OH which 
corresponded to the hydroxyl band in the IR spectrum.  
Furthermore the carbon atoms at δC 64.5 and 62.9 were identified as oxygen-bearing 
and those at δC 131.9 and 119.8 as a terminal olefin. 
 
The 1H-NMR spectrum (figure 16) showed signals for three olefinic protons at δH 
5.89-5.84 (m), 5.55 (d, J = 16.8) and 5.35 (d, J = 10.0), two oxygen-bearing methines 
at δH 5.93-5.90 (m) and 4.43 (broad t, J = 6.5), a hydroxyl at δH 1.81 (broad s), two 
methylenes at δH 1.75-1.66 (m) and 1.43 (broad q, J = 7.5), two methyls at δH 2.11 (s) 
and 0.88 (t, J = 7.0) and a methylene envelope at δH 1.31-1.22 (m). A 1H-1H COSY 
experiment (figure 17) showed three separate spin systems. The first began with an 
olefinic methylene at δH 5.55 (d) and 5.35 (d) which was coupled with an olefinic 
methine at δH 5.89-5.84 (m) that was further linked to an oxygen-bearing methine at 
δH 5.93-5.90 (m) marking the end of this spin system. The second spin system began 
at the second oxygen-bearing methine at δH 4.43 (broad t) which was coupled to a 
hydroxyl at δH 1.81 (broad s) and a methylene at δH 1.75-1.66 (m) that was coupled 
to a further methylene at δH 1.43 (broad q). Beyond this, the spin system extended to 
the overlapped methylene envelope at δH 1.31-1.22 (m) and could not be traced 
further with certainty.  
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Figure 15 : HMQC of 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) in CDCl3. 
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Figure 16 : 1H-NMR of 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) in CDCl3.
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Figure 17 : 1H-1H COSY of 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) in CDCl3. 
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Then the 13C resonances were correlated with the corresponding 1H resonances by 
HMQC (figure 15) and the structure components were linked using an HMBC 
experiment (figure 18). Key correlations were that of the carbonyl carbon atom at δC 
169.5 with the methyl protons at δH 2.11 which indicated an acetate. The correlation 
observed between the carbonyl carbon atom at δC 169.5 and the methine proton at 
δH 5.93-5.90 indicated an acetoxy group at the C-atom with δC 64.5. The acetylene 
carbon atom at δC 81.3 showed a correlation with the methylene protons at δH 1.75-
1.66 but none with the protons of the hydroxyl-bearing methine (δH 4.43). After 
comparison with the data of MS-1 (25) the carbon atom with δC 62.9 had to be placed 
next to the acetylene-C at δC 81.3. On the opposite side of the diyne, a correlation 
was observed between the acetylene carbon atom at δC 74.4 and the methine 
protons at δH 5.93-5.90 and 5.89-5.84 which placed this acetylene-C adjacent to the 
C at δC 64.5. The position of the inner alkyne carbons could not been determined with 
certainty because both showed correlations with the same methine proton at δH 5.93-
5.90 on the one side of the diyne and none with the protons of the hydroxyl-bearing 
methine (δH 4.43) on the other side of the diyne. But due to the comparison with the 
observed data of MS-1 (25) it could been suggested that the inner alkyne carbon at 
δC 70.8 was placed next to that at δC 74.4 and the other at δC 68.6 next to that at δC 
81.3. The crosspeaks between the C at δC 64.5 and the olefinic methine proton at δH 
5.89-5.84 and the olefinic methylene protons at δH 5.55 placed the olefinic methine at 
δC 131.9 adjacent to the C at δC 64.5 and the olefinic methylene at δC 119.8 next to 
the olefinic methine at δC 131.9. The hydroxyl-bearing methine at δC 62.9 showed 
crosspeaks with the methylene protons at δH 1.75-1.66 which placed the methylene-
C at δC 37.4 next to the carbinol. This methylene-C correlated with a further 
methylene proton at δH 1.43 which placed that methylene-C next to the C with δC 
25.0. Finaly the methylene-C at δC 31.9 showed strong correlations with the methyl 
protons at δH 0.88 and the protons of a methylene of the methylene envelope at δH 
1.28. Another methylene-C at δC 22.7 showed also a strong correlation with the 
protons at δH 0.88 but only a weak correlation with protons of the methylene envelope 
at δH 1.26. That placed the methylene-C at δC 31.9 next to that at δC 22.7 and that 
adjacent to the terminal methyl group.  
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Figure 18 : HMBC of 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) in CDCl3.
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The formula of MS-2 (26) with C→H correlations obtained from the HMBC 
experiment is shown in figure 19. 
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Figure 19 : C→H correlations obtained from the HMBC experiment of MS-2 (26) in CDCl3.  
(Optimized for nJCH = 7 Hz (n = 2 or 3)). 
        
 
On the basis of the above data MS-2 (26) was identified as 8-hydroxyheptadeca-1-
ene-4,6-diyn-3-yl acetate. The comparison of the spectroscopic data with those of 
analogous structures from the literature : 43 [140]; 44, 45, 46 [168]; and 47 [169] 
showed good correspondance.  
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5.2.2.3    16-Acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4  (27)), 
                a novel diyne 
 
Preparative HPLC (see scheme 13) yielded 221.7 mg of a yellowish viscous oil with a  
negative optical rotation ([α]D –26.4). The oil was analyzed by FAB-MS (NBA + KCl), 
HR-EI-MS, UV/VIS- and IR-spectroscopy, 1H-NMR, 13C-NMR, DEPT135, 1H-1H 
COSY, HMQC and HMBC. 
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The FAB-MS (NBA + KCl) measurement of MS-4 (27) showed a [M+K]+ peak at m/z 
415, therefore the molecular mass must have been 376. The molecular formula was 
determined as C22H32O5 from its HR-EI-MS measurement (m/z [M]+ calc.: 376.22497; 
found : 376.22369). The UV spectrum suggested a conjugated diyne [158]. IR 
absorption bands indicated the presence of hydroxyl groups (3444 cm-1), alkenes 
(3086 cm-1, 3031 cm-1 and 1644 cm-1), alkanes (2922 cm-1, 2844 cm-1, 1467 cm-1 and 
1367 cm-1), acetylenes (2256 cm-1 and 2156 cm-1) and esters/acetates (1739 cm-1 
and 1233 cm-1). The 13C-NMR spectrum (figure 20) showed 22 resonances, which 
corresponded to the molecular formula derived from HR-EI-MS. The DEPT135 
spectrum (figure 20) showed 16 resonances, five methyls or methines (δC 131.9, 
64.5, 62.8, 21.0 and 20.9) and 11 methylenes (δC 119.7, 64.7, 37.4, 29.44, 29.41, 
29.37, 29,21, 29.17, 28.6, 25.9 and 25.0). Therefore it could be concluded that the 
molecule must contain six quaternary carbon atoms (δC 171.3, 169.5, 81.4, 74.3, 70.9 
and 68.5) which also was confirmed by HMQC. The quaternary carbon atoms at δC 
171.3 and 169.5 were identified as those of ester carbonyl groups and the other four 
had to be connected by conjugated triple bonds due to the comparison with MS-1 
(25). The suggestion of a diyne structure also was in agreement with the acetylene 
bands in the IR spectrum, the UV bands and the comparison with literature data 
[140].
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Figure 20 : 13C-NMR and DEPT135 of 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) in CDCl3.
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The crosspeaks in the HMQC spectrum (figure 21) and the corresponding integrals 
from the 1H-NMR spectrum (figure 22) showed that the carbon atoms at δC 131.9, 
64.5 and 62.8 were methines and those at δC 21.0 and 20.9 were methyls. Therefore 
the molecule must contain the following structure components :  
2x COO 
4x C (conjugated triple bonds) 
3x CH 
2x CH3  
11x CH2  
= C22H31O4. The difference to the found molecular formula was OH which 
corresponded to the hydroxyl band in the IR spectrum.  
Furthermore the carbon atoms at δC 64.7, 64.5 and 62.8 were identified as oxygen-
bearing and those at δC 131.9 and 119.7 as a terminal olefin. 
 
The 1H-NMR spectrum (figure 22) showed signals for three olefinic protons at δH 
5.88-5.83 (m), 5.54 (d, J = 16.8) and 5.34 (d, J = 10.0), three oxygen-bearing 
methines at δH 5.92-5.89 (m), 4.42 (broad t, J = 6.3) and 4.04 (t, J = 6.8),  a hydroxyl 
at δH 2.02 (broad s), three methylenes at δH 1.73-1.68 (m), 1.61 (q, J = 7.2) and 1.43 
(broad q, J = 7.2) and two methyls at δH 2.10 (s) and 2.04 (s). A 1H-1H COSY 
experiment (figure 23) showed three separate spin systems. The first began with an 
olefinic methylene at δH 5.54 (d) and 5.34 (d) which was coupled with an olefinic 
methine at δH 5.88-5.83 (m) that was further linked to an oxygen-bearing methine at 
δH 5.92-5.89 (m) marking the end of this spin system. The second spin system began 
at the second oxygen-bearing methine at δH 4.42 (broad t) which was coupled to a 
hydroxyl proton at δH 2.02 (broad s) and a methylene at δH 1.73-1.68 (m) that was 
coupled to a further methylene at δH 1.43 (broad q). Beyond this, the spin system 
extended to the overlapped methylene envelope at δH 1.34-1.24 (m) and could not be 
traced further with certainty. The third spin system showed a correlation between the 
third oxygen-bearing methine at δH 4.04 (t) and a methylene at δH 1.61 (q), beyond 
this the spin system also extended to the overlapped methylene envelope at δH 1.34-
1.24 (m). 
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Figure 21 : HMQC of 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) in 
                    CDCl3. 
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Figure 22 : 1H-NMR of 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) in CDCl3.
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Figure 23 : 1H-1H COSY of 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) in CDCl3.
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Then the 13C resonances were correlated with the corresponding 1H resonances by 
HMQC (figure 21) and the structure components were linked using an HMBC 
experiment (figure 24). Key correlations were that of the first carbonyl carbon atom at 
δC 171.3 with the methyl protons at δH 2.04 and the second carbonyl carbon atom at 
δC 169.5 with the methyl protons at δH 2.10 which indicated two acetates. The 
correlation observed between the carbonyl carbon atom at δC 171.3 and the 
methylene protons at δH 4.04 indicated a first acetoxy group at the C-atom with δC 
64.7. The correlation observed between the carbonyl carbon atom at δC 169.5 and 
the methine proton at δH 5.92-5.89 indicated a second acetoxy group at the C-atom 
with δC 64.5. The acetylene carbon atom at δC 81.4 showed a correlation with the 
methylene protons at δH 1.73-1.68 and the proton of the hydroxyl-bearing methine at 
δH 4.42, which placed the carbinol-C with δC 62.8 adjacent to the acetylene carbon 
atom at δC 81.4. On the opposite side of the diyne, a correlation was observed 
between the acetylene carbon atom at δC 74.3 and the methine protons at δH 5.92-
5.89 and 5.88-5.83 which placed this acetylene carbon next to the acetoxy-bearing C 
at δC 64.5. A strong correlation between one of the inner alkyne carbon atoms at δC 
70.9 and the proton of the oxygen-bearing methine at δH 5.92-5.89 and a weak 
correlation with the proton of the hydroxyl-bearing methine at δH 4.42 placed this 
acetylene-C next to that at δC 74.3. The second inner alkyne carbon atom at δC 68.5 
correlated with the proton of the hydroxyl-bearing methine at δH 4.42 and the proton 
of the oxygen-bearing methine at δH 5.92-5.89. Therefore its position could not been 
determined with certainty but due to the determined positions of the other three 
acetylene carbons and the comparison with MS-1 (25) the second inner alkyne 
carbon atom must have been placed next to that at δC 81.4. The crosspeaks between 
the carbon at δC 64.5 and the olefinic methine proton at δH 5.88-5.83 and the olefinic 
methylene protons at δH 5.54 placed the olefinic methine at δC 131.9 next to the 
acetate and the olefinic methylene at δC 119.7 next to the olefinic methine at δC 
131.9. The hydroxyl-bearing methine at δC 62.8 showed crosspeaks with the 
methylene protons at δH 1.73-1.68 which placed the methylene-C at δC 37.4 next to 
the carbinol-C. This methylene-C correlated with further methylene protons at δH 1.43 
which placed that methylene-C next at δC 25.0. The crosspeak between the acetate 
at δC 64.7 and the methylene-C at δH 1.61 together with the 1H-1H-COSY correlation 
between the acetate at δH 4.04 and the methylene protons at δH 1.61 placed that 
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methylene-C at δC 28.6 next to the acetate. Another crosspeak between the 
methylene-C at δC 25.9 and the methylene protons at δH 1.61 placed that methylene-
C next to that at δC 28.6.  
 
 
Figure 24 : HMBC of 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) in 
                    CDCl3.
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The formula of MS-4 (27) with C→H correlations obtained from the HMBC 
experiment is shown in figure 25. 
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Figure 25 :  C→H correlations obtained from the HMBC experiment of MS-4 (27) in CDCl3.  
(Optimized for nJCH = 7 Hz (n = 2 or 3)). 
 
On the basis of the above data MS-4 (27) was identified as 16-acetoxy-11-
hydroxyoctadeca-17-ene-12,14-diynyl acetate. The comparison of the spectroscopic 
data with those of analogous structures from the literature : 43 [140]; 44, 45, 46 [168]; 
and 47 [169] showed good correspondance.
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5.2.2.3.1    Stereochemical analysis using the Mosher method 
 
The Mosher technique is an empirically derived method to determine the absolute 
configuration of stereogenic centers of secondary alcohols by measuring the 1H-NMR 
spectra [170] or 13C-NMR spectra [171] of their MTPA esters. The method is based 
on the observation, that MTPA esters prefer a conformation in which the carbinyl 
proton, the C-O carbonyl bond, and the trifluoromethyl group are located in the same 
plane, called the "MTPA plane" (figure 26[A]). Protons and carbons on the same side 
as the phenyl group experience an upfield shift, due to the anisotropic effect of the 
phenyl group. Therefore, in an MTPA ester with the absolute configuration shown in 
figure 26[B], protons HA,B,C and carbons CA,B,C should have positive ∆δ (∆δ = δ(S)-ester − 
δ(R)-ester) values, and protons HX,Y,Z and carbons CX,Y,Z should have negative ∆δ 
values. 
 
The chiral alcohol is first coupled with each of the individual enantiomers of the 
Mosher acid chloride. The optically pure Mosher acid of R configuration [(R)-MTPA] 
is converted to the acid chloride of S configuration [(S)-MTPA-Cl] (48) and then to the 
MTPA ester of R configuration [(R)-MTPA-Cl] (49). The 1H-NMR and 13C-NMR 
spectra of the Mosher esters are then measured. The absolute configuration of the 
carbinol center can then be deduced from the ∆δ values observed [172, 173]. 
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Figure 26 : [A] The MTPA plane of the (R)-MTPA ester of a secondary alcohol. [B] The rule for the 
determination of the absolute configurations of secondary alcohols (∆δ = δ(S)-ester − δ(R)-ester). 
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5.2.2.3.2    Stereochemical analysis of MS-4 (27) 
 
After the carrying out of the antiparasitic assays, the receptor binding studies and the 
electrophysiological investigations, only of MS-4 (27) the remaining amount was 
sufficient for stereochemical analysis.  
 
The stereochemical analysis was performed by esterification of the OH at C(11) of 
MS-4 (27) according to the procedure outlined above (scheme 16). The results are 
shown in table 17. 
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Scheme 16 : Synthesis procedure of the (R)-MTPA ester (50) and the (S)-MTPA ester (51)  
of MS-4 (27). 
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Table 17 : Results of the stereochemical analysis of the MTPA esters of MS-4 (27). 
H no. 
 δ(S) - ester δ(R) - ester             ∆δ  
(δ(S) - ester - δ(R) – ester) 
C no. 
 δ(S) - ester    δ(R) - ester             ∆δ  
(δ(S) – ester - δ(R) – ester) 
        12 76.03 75.88         + 0.15 
  10     1.79    1.85 
        − 0.06   10 34.17 34.13         + 0.04 
    9     1.29    1.43 
        − 0.14     9 24.61 24.88         − 0.27 
    8       a       a              -                       
a : Resonances not assignable in overlapped multiplets. 
∆δ measured in ppm at 500 MHz field strength. 
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The MTPA esters thus obtained showed negative ∆δ values for H-C(10) and H-C(9). 
This suggests the S-configuration for C(11) of MS-4 (27). The ∆δ values for C(12), 
C(10), and C(9) were not consistent. C(12) and C(10) showed positive and C(9) 
showed negative ∆δ values. Therefore, from the 13C-NMR data the configuration for 
C(11) could not be determined. 
 
For the determination of the absolute configuration at C(16) the Mosher method was 
not used because it was supposed that a deacetylation at C(16) would lead to a  
epimerization. Therefore the solid (S)-MTPA-ester (see p. 129) was recrystallized in 
order to elucidate the absolute configuration by X-ray structure determination. Only 
small crystals were obtained which could no be used for measurement. 
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5.2.2.4    11,16-Diacetoxyoctadeca-17-ene-12,14-diynyl acetate (MS-5 (28)),  
                a novel diyne 
 
Preparative HPLC yielded 1.4 mg of a yellowish viscous oil (see scheme 12). 
Because of its small quantity the structure was elucidated by FAB-MS (NBA + KCl) 
and mainly by comparison of its 1H-NMR, 13C-NMR, DEPT135, 1H-1H COSY, HMQC 
and HMBC data with that of MS-4 (27). 
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The FAB-MS (NBA + KCl) measurement of MS-5 (28) showed a [M+K]+ peak at m/z 
457, therefore the molecular mass must have been 418. The 13C-NMR spectrum 
(figure 27) showed 23 resonances, an additional resonance of a quaternary C-atom 
at δC 71.3 could only be seen in the HMBC (figure 27 detail). The DEPT135 spectrum 
(figure 27) showed 17 resonances, six methyls or methines (δC 131.8, 64.4, 64.1, 
21.05, 20.90 and 20.88) and 11 methylenes (δC 119.8, 64.7, 34.4, 29.45, 29.42, 
29.37, 29,22, 29.05, 28.6, 25.9 and 24.9). Therefore it could be concluded that the 
molecule must contain seven quaternary carbon atoms (δC 171.3, 169.8, 169.5, 77.7, 
74.5, 70.7 and 69.0) which also was confirmed by HMQC (not shown). The 
quaternary carbon atoms at δC 171.3, 169.8 and 169.5 were identified as those of 
ester carbonyl groups and the other four had to be connected by conjugated triple 
bonds due to the comparison with MS-4 (27). The crosspeaks in the HMQC spectrum 
and the corresponding integrals from the 1H-NMR spectrum (figure 28) showed that 
the carbon atoms at δC 131.8, 64.4 and 64.1 were methines and those at δC 21.05, 
20.90 and 20.88 were methyls.  
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Figure 27 : 13C-NMR, DEPT135 and HMBC (detail) of 11,16-diacetoxyoctadeca-17-ene-12,14-diynyl acetate (MS-5 (28)) in CDCl3.
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Figure 28 : 1H-NMR of 11,16-diacetoxyoctadeca-17-ene-12,14-diynyl acetate (MS-5 (28)) in CDCl3. (∗ impurity).
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Therefore the molecule must contain the following structure components :  
3x COO 
4x C (conjugated triple bonds) 
3x CH 
3x CH3  
11x CH2  
= C24H34O6 
Furthermore the carbon atoms at δC 64.7, 64.4 and 64.1 were identified as oxygen-
bearing and those at δC 131.8 and 119.8 as a terminal olefin. 
 
In the 1H-NMR spectrum (figure 28) the relevant differences to MS-4 (27) were a low 
field shift of the methine resonance at δH 5.37 (t, J = 7.4) (MS-4 (27) : δH 4.42 (t, J = 
6.3)), an additional methyl singlet at δH 2.08, and the absence of the hydroxy proton 
(MS-4 (27) : δH 2.02 (broad s)). 
 
The 13C-NMR spectrum (figure 27) showed an additional quaternary carbon atom of 
a carbonyl group at δC 169.8. The HMBC experiment showed crosspeaks between 
the carbonyl carbon atom at δC 169.8 and the methine proton at δH 5.37 and the 
methyl protons at δH 2.08. Therefore it was concluded that in this molecule – in 
comparison to MS-4 (27) – the hydroxyl group at C(11) was acetylated.  
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The formula of MS-5 (28) with C→H correlations obtained from the HMBC 
experiment is shown in figure 29. 
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Figure 29 : C→H correlations obtained from the HMBC experiment of MS-5 (28) in CDCl3.  
(Optimized for nJCH = 7 Hz (n = 2 or 3)). 
 
On the basis of the above data and the comparison with MS-4 (27), MS-5 (28) was 
identified as 11,16-diacetoxyoctadec-17-ene-12,14-diynyl acetate. The comparison of 
the spectroscopic data with that of analogous structures from the literature : 43 [140]; 
44, 45, 46 [168]; and 47 [169] showed good correspondance. 
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5.2.3    Identification of stigmasterol (42) 
 
Preparative HPLC (see scheme 12) yielded 17.3 mg of a white powder. This powder, 
compound 42, was identified as stigmasterol (24-ethyl-cholesta-5,22-dien-3β-ol) by 
comparison of its spectroscopic data (EI-MS, IR, 1H-NMR, 13C-NMR and DEPT135) 
with that of an authentic sample bought from Acros Organics. All spectroscopic data 
were in agreement. The 1H-, and 13C-NMR spectra of compound 42 and stigmasterol 
are shown in figure 30 and figure 31. 
 
     Compound 42 
           
Figure 30 : 1H-NMR spectra of compound 42 and stigmasterol (authentic sample).
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Figure 31 : 13C-NMR spectra of compound 42 and stigmasterol (authentic sample).
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6.    Commiphora fulvotomentosa Engl. 
 
6.1    Introduction  
 
6.1.1    Botany 
 
Commiphora fulvotomentosa Engl. belongs to the genus Commiphora of the family 
Burseraceae. Synonyms are C. boiviniana Engl., C. sp. near C. trollii Mattick sensu 
and C. torrei Mendes. It is a tree 4 - 12 m tall usually without spines on the branches, 
but sometimes with spines 4 - 7 cm long on the main stem. The trunk has up to 25 
cm diameter, the bark is coppery grey, smooth, sometimes papery, sometimes 
horizontally folded. The exudate is clear and scented. Flowers appearing with the 
leaves along with brownish tomentose ovate-oblong or spathulate prophylls up to 13 
mm long and 4 mm diameter on peduncles up to 5 cm long. The plant occurs in 
Tanzania (Kilosa-, Ulanga and Mikindani District) and Mozambique. It grows in 
woodland and dry forest, especially on rocky outcrops, 200 - 1050 m [123]. 
 
 
6.1.2    Use in traditional medicine 
 
In the Tanga District the decoction of the roots of C. boiviniana Engl. (syn.) is drunk 
against gonorrhoe [13]. The bark which is said to contain a mucilaginous resin is a 
Zigula dysenterie remedy.  
 
 
6.2    Fractionation 
 
The procedure of the bioassay-guided fractionation of the petroleum ether extract 
from Commiphora fulvotomentosa Engl. stembark is shown in schemes 17-19. The 
footnotes stand for the following : bold frames : fractions investigated further and 1 : 
fractions with activity against T. b. rhodesiense. For the activities of the crude extract 
and the fractions see chapter 4.2.1.2. For the isolation methods see chapter 5.2 in 
the experimental part. 
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              Extraction with petroleum ether 
 
crude extract 
5.8 g 
 
                  MPLC Method 1 
 
          
F1 
203.9 mg 
 F21 
1080.4 mg 
 F31 
521.5 mg 
 F4 
1021.0 mg 
 F5 
857.0 mg 
 F6 
369.5 mg 
 F7 
551.2 mg 
 F8 
238.3 mg 
 F9 
34.9 mg 
 F10 
305.0 mg 
 
  
   
      Scheme 18    Scheme 19 
 
Scheme 17 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Commiphora fulvotomentosa Engl. stembark (from plant material to fraction F2 and F3). 
 
 F21 
1034.4 mg 
 
                                                             MPLC Method 2 
 
              
F2.1 
3.0 mg 
 F2.2 
2.1 mg 
 F2.3 
1.4 mg 
 F2.4 
2.2 mg 
 F2.5 
571.5 mg 
 F2.6 
10.7 mg 
 F2.7 
13.1 mg 
 
              
              
F2.8 
53.9 mg 
 F2.9 
44.5 mg 
 F2.10 
38.6 mg 
 F2.11 
69.1 mg 
 F2.12 
73.6 mg 
 F2.13 
28.2 mg 
   
 
Scheme 18 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Commiphora fulvotomentosa Engl. stembark (from fraction F2 to fraction F2.1-F2.13). 
 
 F31 
500 mg 
 
                                                                                                         MPLC Method 3   
 
    
F3.1 
10.9 mg 
 F3.2 
239.2 mg 
 F3.3 
81.2 mg 
 F3.4 
19.2 mg 
 F3.5 
17.9 mg 
  
Scheme 19 : Procedure of the bioassay-guided fractionation of the petroleum ether extract from 
Commiphora fulvotomentosa Engl. stembark (from fraction F3 to fraction F3.1-F3.5). 
Commiphora 
fulvotomentosa 
stembark 
1039 g 
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B.    Experimental Part 
 
1.    General 
 
Hackling of dried plant material was performed with a Fuchs Mühle type MM 125 H. 
 
Powdering of hackled plant material was performed with a Miostar coffee grinder. 
 
Solvents used for extraction, MPLC and recrystallisation were technical, distilled 
solvents. Solvents used for extraction were distilled twice. Solvents used for 
analytical and preparative HPLC were of HPLC-quality. 
 
Solvent concentrations were performed on a Büchi Rotavapor RE 111 with a water 
bath at 40 °C; final pressure was 14 mbar. The high vacu um drying process was 
performed with an Edwards vacuum pump, final pressure was 4x10-2 mbar. 
 
MPLC was performed with a Büchi B-680 system, consisting of a Büchi B-688 
chromatography pump, a Büchi B-687 gradient former, a Knauer variable wavelength 
monitor, a Knauer strip chart recorder and a Büchi B-684 fraction collector. 
 
Adsorbents used for MPLC are described in the methods. 
 
Freeze drying was performed with a LSL secfroid, Lyolab B freeze dryer. 
 
Analytical HPLC was performed with a HP 1090 system from Hewlett Packard. The 
data were processed on a HP Chemstation from Hewlett Packard. 
 
Preparative HPLC was performed with a Waters 600 system consisting of a Waters 
600 multisolvent delivery system, a Waters 996 photodiode array detector, a Waters 
600 controller and a Waters fraction collector. The spectra were processed with the 
software millenium V3.1. from Waters. 
 
Columns used for analytical and preparative HPLC are described in the methods. 
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IR spectra were measured on a Perkin Elmer model 1600 FT-IR spectrophotometer 
using a substance film between NaCl plates or potassium bromide pellets. 
Resonance frequencies are given in cm-1; intensities : s = strong, m = medium and w 
= weak. 
 
UV/VIS spectra were obtained from a Perkin Elmer Lamda Bio 40 UV/VIS 
spectrometer. 
 
Optical rotation was measured on a Perkin Elmer polarimeter 341 in a 10 cm 
cuvette at 20 °C.  
 
Mass spectra were measured by Dr. H. Nadig at the Department of Chemistry of the 
University of Basel on a spectrometer VG 70S (EI) and a Finnigan MAT 312 (FAB). 
M/z values are reported with the corresponding relative intensities in parentheses. 
 
NMR spectra were measured on a Bruker Avance 400 (1H-NMR 400 MHz; 13C-NMR 
101 MHz) and a Bruker VRX 500 (1H-NMR 500 MHz; 13C-NMR 125 MHz) at the 
Department of Chemistry of the University of Basel with the assistance of Dr. K. 
Kulicke. The chemical shifts δ are given in ppm relative to the internal standard 
tetramethylsilane (δ = 0 ppm). The 13C-NMR spectra were measured using broad 
band decoupling with CDCl3 as the reference (δ = 77.0 ppm). The multiplicities 
derived from DEPT experiments are indicated as follow : s : singlet, d : doublet, t : 
triplet and q : quadruplet; br : broad. HMQC and HMBC experiments are reported as 
13C resonance → 1H resonance and COSY experiments 1H resonance → 1H 
resonance (intensity), where (+) : weak, (++) : medium and (+++) : strong. HMBC 
experiments were carried out using delays optimized for nJCH = 7 Hz (n = 2 or 3). 
 
Chemicals for derivatization were bought from Fluka AG. Stigmasterol (authentic 
sample) was bought from Acros Organics. Chemicals and materials used in the 
antiparasitic and cytotoxicity testings were standard materials used in the routine 
work of the laboratories of the Swiss Tropical Institute, Basel. Chemicals and 
materials for the performance of the GABAA receptor binding assays were standard 
materials in the routine work of the laboratories of the Institute of Pharmaceutical 
Biology of the University of Basel and the ones used for electrophysiological 
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investigations were standard materials in the routine work of the laboratories of the 
Institute of Pharmacology of the University of Bern. 
 
 
2.    Extraction 
 
The dried plant material was hackled with a chaffcutter and then powdered with a 
coffee grinder. For the production of the crude extracts for primary biological in vitro 
screening, samples of about 35 g of the ground plant material were consecutively 
extracted by stirring with two portions each of petroleum ether (40-60 °C), 
dichloromethane, methanol and water (see scheme 2). A ten-fold quantity of solvent 
in relation to plant material was used. The extraction was carried out at room 
temperature under stirring for 24 h per portion. After each aliquot the mixture was left 
to stand and then filtered. Petroleum ether and dichloromethane mixtures were 
filtered under normal pressure and methanol and water mixtures were filtered under 
vacuum. The extraction procedure continued with the next solvent. Same solvent 
filtrates were combined and concentrated at 40 °C. Lipophilic filtrates were dried 
under high vacuum and aqueous filtrates were freeze dried. The solvent-free crude 
extracts obtained were weighed (results see table 5) and then stored at 4 °C until 
use. 
 
 
3.    Biological tests 
 
3.1    Antiparasitic and cytotoxicity tests 
 
3.1.1    General 
 
The antiparasitic and the cytotoxicity assays were performed according to internal 
Standard Operation Procedures (SOP) of the Swiss Tropical Institute, Basel. Sample 
stock solutions of 10 mg/ml were prepared by dissolving the weighed samples in 
DMSO. The solutions were kept at room temperature until use. Each assay was 
performed in duplicate (n = 2). For the performance of the antiparasitic and 
cytotoxicity assays Costar 96-well microtiter plates were used (figure 32). 
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Figure 32 : Representation of a Costar 96-well microtiter plate. 
 
 
3.1.2    Antitrypanosomal tests 
 
3.1.2.1    African trypanosomes  
 
Crude plant extracts, fractions and the isolated pure compounds MS-1 (25), MS-2 
(26), and MS-4 (27) were tested. The highest sample concentration tested was 100 
µg/ml for extracts and fractions, 30 µg/ml for MS-1 (25) and 10 µg/ml for MS-2 (26) 
and MS-4 (27), respectively. Due to bacterial contamination of the crude plant 
extracts 1 % of an antibiotic mix, containing 6 mg/ml penicillin G, 10 mg/ml 
kanamycin sulfate, 5 mg/ml 5-fluorocytosin and 1 mg/ml chloramphenicol, 100 fold 
diluted with distilled water containing 1 % ethanol, was added to the background 
controls (no. 4 of the SOP), and to the trypanosome suspension (no. 5 of the SOP) 
so that the final volume (100 µl) contained an antibiotic mix-concentration of 0.5 %. 
After fractionation of the crude extracts, fractions and isolated pure compounds did 
not show any contamination. Therefore assays for fractions and pure compounds 
were performed without addition of antibiotic mix. 
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T. b. rhodesiense in vitro assay (LILIT: long incubation low inoculation test) 
 
Standard parasite strain : T. b. rhodesiense; STIB 900 
(stage trypomastigotes) 
 
Standard drug : Melarsoprol  start. conc. : 72 ng/ml  
Standard conditions : Medium : MEM with Earle’s salts 9.75 g/l 
HEPES 6.0 g/l 
Glucose 1.0 g/l 
NaHCO3 2.2 g/l 
MEM NEAA 10.0 ml/l 
Further supplemented with Baltz-Medium 
components : 
0.2 mM 2-mercaptoethanol 
2 mM Na-pyruvate 
0.1 mM hypoxanthine 
0.016 mM thymidine 
15 % heat inactivated horse serum 
Incubation : 37 °C, 5 % CO2  
 
Assay procedure  
 
1. The trypanosomes were diluted to 4x104 tryps. / ml medium. The trypanosome 
density was adjusted with a CASY (Cell Analysis System (Schaerfe System, 
Reutlingen, Germany)). 
2. Into the wells of row H, 75 µl of medium that contained two times the highest 
sample concentration were added.  
3.  Serial sample dilutions were pepared by using a 12-channel multi-pipette. First, 
25 µl were removed from wells of row H and put into row G and mixed well. Then 
25 µl were taken out of row G and put into row F and so on until row C. The last 
25 µl of row C were discarded. A serial dilution factor of 1:3 was thus obtained. 
Row A and B wells served as controls without samples. 
4. 50 µl of medium without trypanosomes containing 1 % of antibiotic mix (only for 
assays with crude extracts) were added to columns 3, 6, 9 and 12 (background 
controls).  
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5. 50 µl of trypanosome suspension containing 1 % of antibiotic mix were added 
into the remaining wells. 
6. The plates were incubated for 72 h. 
7. 10 µl of the fluorescent dye Alamar Blue (Laboserv GmbH, Art. Nr. DAL 1100) 
were added to each well and incubation resumed for an additional 2-6 h. 
8. The IC50 values were determined by reading the plates at excitation wavelength 
530 nm and emission wavelength 590 nm. A sigmoidal inhibition curve was thus  
obtained. 
9. IC50 values were calculated by linear interpolation between the two adjacent drug 
concentrations on the sigmoidal inhibition curve above and below the 50 % 
incorporation line. 
 
 
3.1.2.2    American Trypanosomes  
 
Only the isolated pure compounds MS-1 (25), MS-2 (26), and MS-4 (27) were tested. 
The highest sample concentration tested was 100 µg/ml for MS-1 (25) and 5 µg/ml 
for MS-2 (26) and MS-4 (27), respectively. 
 
T. cruzi  in vitro assay 
 
Standard parasite strain : T. cruzi Tulahuen C2C4  
transfected with the β-galactosidase gene 
(stage trypomastigotes) 
 
Standard cell line :         L-6 cells (mouse muscle fibroblasts)  
Standard drug : Benznidazole  
Start conc. :  30 µg/ml 
 
Standard conditions : Medium : RPMI 1640 + 10 % FCS  
+ 1.7 µM L-Glutamine 
Incubation : 37 °C, 5 % CO2  
Substrate : 2.5x CPRG/Nonidet solution : 5x stock = 500 µl Nonidet 
P40 + 30.38 mg CPRG in 100 ml 1x PBS 
The 5x stock was diluted 1:1 with 1x PBS 
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Assay procedure  
Day 1 :        All 96 wells were seeded with 100 µl of medium containing 2x103 L6 cells / 
well. 
Day 2 : 50 µl of a trypanosome suspension with a density of 5x103 tryps. / ml were 
added into columns 1 and 2, 4 and 5, 7 and 8, and 10 and 11. In columns 3, 
6, 9 and 12, 50 µl of medium were added. 
Day 4 : Medium from wells in row A to G was removed with the aspirator and 
replaced with 100 µl of medium. Medium was removed from row H and 
replaced with 150 µl of the highest sample concentration. Serial sample 
dilutions were prepared by using a 12-channel multi-pipette. First, 50 µl 
were removed from wells of row H and put into row G and mixed well. Next, 
50 µl were taken out of row G and put into row F and so on until row B. The 
last 50 µl of row B were discarded. A serial dilution factor of 1:3 was thus 
obtained. Wells in row A served as control wells without samples. 
Day 8 : 50 µl of 2.5x CPRG/Nonidet were added to all wells. After 2-6 h the plates 
were read in an Absorbance Reader at 540 nm. A sigmoidal inhibition curve 
was thus obtained.  
IC50 values were calculated by linear interpolation between the two adjacent 
drug concentrations on the sigmoidal inhibition curve above and below the 
50 % incorporation line. 
 
 
3.1.3    Antiplasmodial tests 
 
Crude plant extracts, fractions and the isolated pure compounds MS-1 (25), MS-2 
(26), and MS-4 (27) were tested. Because the medium itself contained an antibiotic, 
no antibiotic had to be added for the assays of the crude plant extracts. The highest 
sample concentration tested was 20 µg/ml for extracts, fractions and MS-1 (25), and 
5 µg/ml for MS-2 (26) and MS-4 (27), respectively. 
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P. falciparum in vitro assay ([3H]hypoxanthine incorporation) 
 
Standard parasite strain : P. falciparum, K1 strain 
(chloroquine and pyrimethamine resistant) 
 
Standard drugs : Chloroquine :  
Artemisinin  :  
start. conc. : 1000 ng/ml  
start. conc. : 10 ng/ml 
Standard conditions : Medium : RPMI 1640 (without hypoxanthine) 
supplemented with : 
5.94 g/l HEPES,   
2.1 g/l NaHCO3 
100 U/ml Neomycin 
5 g/l Albumax   
Human washed red blood cells (RBC) A+ 
Incubation : 48 h, followed by an additional 24 h in the presence of 
[3H]hypoxanthine 
Gas mixture : 4 % CO2, 3 % O2, 93 % N2, 37 °C  
 
Assay procedure 
1. Smears of the stock cultures of the K1 strain were prepared and the parasitaemia 
was determined. The dilution factor was calculated to obtain the starting 
conditions for the assay : 
Concentration of red cells : 
Initial parasitaemia            : 
2.5 % 
0.3 % 
2. 100 µl of medium were added to each well. 
3.  100 µl of medium, containing 4x the highest sample concentration, were added to 
wells in row B.  
4. Serial sample dilutions were prepared by using a 12-channel multi-pipette. 100 µl 
were taken from wells of row B and transferred, after gentle mixing, to wells of 
row C. After mixing, 100 µl were transferred from wells of row C to wells of row D 
and so on until row H. The 100 µl removed from row H were discarded. A serial 
dilution factor of 1:2 was thus obtained. Wells of row A served as controls without 
samples. 
5. 100 µl of a double-concentrated (5 %) red cell suspension with a parasitaemia of 
0.3 % were added to each well with the exception of A9 -A12 (negative controls). 
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6. The plates were incubated for 48 h. 
7. 50 µl [3H]hypoxanthine (0.5 µCi) were added to each well and the plates were 
incubated for an additional 24 h. 
8. The plates were harvested using a cell harvester (Wallac, Zürich, Switzerland), 
which transferred the red blood cells onto a glass fiber filter and washed with 
distilled water. The dried filters were inserted into a plastic foil with 10 ml of 
scintillation fluid, and counted in a liquid scintillation counter. A sigmoidal 
inhibition curve was thus obtained.  
9. IC50 values were calculated by linear interpolation between the two adjacent drug 
concentrations on the sigmoidal inhibition curve above and below the 50 % 
incorporation line. 
 
 
3.1.4    Antileishmanial tests 
 
3.1.4.1    Axenic 
 
Only the isolated pure compounds MS-1 (25), MS-2 (26), and MS-4 (27) were tested. 
The highest sample concentration tested was 30 µg/ml for MS-1 (25) and 1 µg/ml for 
MS-2 (26) and MS-4 (27), respectively. 
 
Axenic L. donovani in vitro assay  
 
Standard parasite strain : L. donovani MHOM-ET-67/L82 
(axenic amastigotes) 
 
Standard drug : Miltefosine  
Standard conditions : Medium : SM + SDM (1:1), pH 5.4  
+ 10 %  FCS, heat inactivated 
HEPES and MOPS are substituted with 
MES (40 mM final conc.) 
Incubation : 72  h at 37 °C and 5 % CO2  
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Assay procedure  
1. 50 µl of medium were added to all wells, except in row H. Row H received 75 µl, 
in triplicate, of two times the highest sample concentration. Serial sample 
dilutions were prepared in triplicate by using a 12-channel multi-pipette. First, 25 
µl were removed from wells of row H and put into row G and mixed well. Then 
25 µl were taken out of row G and put into row F and so on until row C. The last 
25 µl of row C were discarded. A serial dilution factor of 1:3 was thus obtained. 
Row A and B served as controls with no samples but parasites. 
2. 50 µl of amastigote suspension (1x105/well ; 2x106/ml) were added to the 
sample dilutions in columns 1 and 2, 4 and 5, 7 and 8, and 10 and 11. Columns 
3, 6, 9 and 12 received medium only and served as controls with samples but 
no parasites. 
3.  The plates were incubated for 72 h. 
4. 10 µl of Alamar Blue were added to each well and incubation was continued for 
another 3-4 h. 
5. Plates were read in the Cytofluor at excitation wavelength 530 nm and emission 
wavelength 590 nm. A sigmoidal inhibition curve was thus obtained. 
6. IC50 values were calculated by linear interpolation between the two adjacent 
drug concentrations on the sigmoidal inhibition curve above and below the 50 % 
incorporation line. 
 
 
3.1.4.2    In infected macrophages 
 
Only the isolated pure compounds MS-1 (25), MS-2 (26), and MS-4 (27) were tested. 
The highest sample concentration tested was 30 µg/ml for MS-1 (25) and MS-4 (27) 
and 1 µg/ml for MS-2 (26), respectively. 
 
L. donovani in vitro assay using macrophages infected with axenically grown 
amastigotes containing the Lac-Z gene marker 
 
Standard parasite strain : L. donovani MHOM-ET-67/L82-Lac Z  
Standard drug : Miltefosine  
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Standard conditions : Stock :   
 
 
Assay :   
Axenic amastigote stock in SM/SDM (1:1)  
pH 5.4, 20 % FCS 
37 °C, 5 % CO2   in Falcon 12.5 cm2  flasks 
RPMI 1640 without phenol red, 10 % FCS,  
pH 7.4 
Incubation : 37 °C, 5 % CO2 
96 h (4 days) sample exposure 
 
  
Assay procedure  
Day 1 : Two  mice were injected i.p. with 2 ml each of a 2 % starch in H2O 
suspension. 
Day 2 : Macrophages were harvested by peritoneal lavage. All wells were seeded 
with 50 µl containing 5x103 cells.   
Day 3 : An axenically growing amastigote culture was passed through a 26 gauge 
needle to break up clumps and counted by CASY (Cell Analysis System 
(Schärfe System, Reutlingen, Germany)). The macrophages on the plates 
were infected at a ratio of 1:3  (macrophgs. : amastig.) in columns 1 and 2, 4 
and 5, 7 and 8, and 10 and 11. Columns 3, 6, 9 and 12 served as controls of 
uninfected macrophages. After 6 h of infection excess amastigotes were 
washed away. 
Day 4 : The medium was removed from all wells and replaced with 100 µl of fresh 
RPMI, 10 % FCS in rows A to G. Row H received 150 µl of the highest 
sample concentration (in duplicate + background). Serial sample dilutions 
were made with 50 µl from row H into row G, then into row F etc. The last 50 
µl from row C were discarded. A serial dilution factor of 1:3 was thus 
obtained. Row A and B served as controls (infected cells with no samples). 
Day 8 : The plates were inspected visually to determine possible toxicity of the 
sample for the host cells in columns 3, 6, 9 and 12 (uninfected host cells + 
samples). 50 µl of CPRG/Nonidet (1:1 in PBS) were added to each well and 
the plates were incubated for another 2-6 h. 
 The plates were read in an Eliza reader. A sigmoidal inhibition curve was 
thus obtained. 
IC50 values were calculated by linear regression analysis. 
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3.1.5    Cytotoxicity tests 
 
Only extracts, which showed significant activity in the antitrypanosomal (African 
trypanosomes) and/or in the antiplasmodial testings (IC50 T. b. rhodesiense ≤ 10 
µg/ml, IC50 P. falciparum ≤ 5 µg/ml) and the isolated pure compounds MS-1 (25), MS-
2 (26), and MS-4 (27) were tested for cytotoxicity. The highest sample concentration 
tested was 100 µg/ml. The antibiotic mix (see chapter 3.1.2.1) was used for 
cytotoxicity assays with crude plant extracts. It was added to the fresh medium (no. 2 
of the SOP), and to the medium containing the highest sample concentration (no. 3 
of the SOP). Fractions and isolated pure compounds were testet without addition of 
antibiotic mix. 
 
In vitro cytotoxicity assay 
 
Standard cell line : L-6 cells (mouse muscle fibroblasts)  
Standard drug : Mefloquine  
Standard conditions : Medium : RPMI 1640  
+ 10 % FBS  
+ 1 % L-Glutamine (200 mM) 
Incubation : 37 °C, 5 % CO2 in air  
 
Assay procedure  
 
1. 100 µl of a cell suspension containing 4x104 cells / ml medium were added into 
columns 1 and 2, 4 and 5, 7 and 8, and 10 and 11. Cells were allowed to attach 
over night. 
2. The next morning the medium was removed completely, using the aspirator, and 
100 µl of fresh medium containing 0.5 % of antibiotic mix (only for assays with 
crude plant extracts) were added to all wells of the plate, except in row H. 
3.  150 µl of medium containing the highest sample concentration (100 µg/ml) and 
0.5 % of antibiotic mix were added to the wells of row H.  
4. Serial sample dilutions were prepared by using a 12-channel multi-pipette. First, 
50 µl were taken from wells of row H and put into row G, mixed well, then 50 µl 
were taken out of row G and put into row F and so on until row C. The last 50 µl 
of row C were discarded. A serial dilution factor of 1:3 was thus obtained. Wells in 
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of row C were discarded. A serial dilution factor of 1:3 was thus obtained. Wells in 
row A and B served as control wells without samples. 
5. The plates were incubated vor 72 h. 
6. 10 µl of Alamar Blue were added to each well and the plates were incubated for 
another 2 h. 
7. The plates were read at excitation wavelength 530 nm and emmision wavelength 
590 nm. A sigmoidal inhibition curve was thus obtained. 
8. IC50 values were calculated by linear interpolation between the two adjacent drug 
concentrations on the sigmoidal inhibition curve above and below the 50 % 
incorporation line. 
 
 
3.2    GABAA- receptor binding studies 
 
The GABAA-receptor binding studies were performed by Dr. U. Simmen and co-
workers in the laboratories of the Institute of Pharmaceutical Biology of the University 
of Basel. 
 
[3H]Flunitrazepam binding assay to rat cortex membranes 
 
Frozen cortex derived from rats was used to prepare membrane fractions. After 
separation of the cerebellum, cortex material was homogenised on ice with 50 mM 
Tris/HCl pH 7.4, 120 mM NaCl, 5 mM KCl using a Polytron homogeniser. The 
homogenate was centrifuged at 31’000 g for 10 min at 4 °C. The pellet was 
resuspended with 50 mM Tris/HCl pH 7.4 and centrifuged as described above for a 
total of three washing steps. The membrane fraction was stored at –80 °C. Binding 
equilibrium was performed under the following conditions: 200 µg of cortex 
membranes (determined with the BCA protein assay),  1 nM [3H]flunitrazepam in 50 
mM Tris/HCl pH 7.4, incubation for 1 h at r.t. in a total volume of 0.5 ml. Non-specific 
binding was defined in the presence of 100 µM diazepam. Stock solutions of crude 
plant extracts (20 mg/ml 50 % MeOH) and of the isolated pure compounds MS-1 
(25), MS-2 (26), and MS-4 (27) (5 mg/ml MeOH) were prepared. Binding was 
terminated by rapid filtration with GF/C filters under reduced pressure and three 
washes with cold 5 mM Tris/HCl buffer, pH 7.4. Radioactivity on filters was 
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determined by liquid scintillation counting (TRI-CARB 2100TR, Packard). Results are 
given by means  ± S.D. of triplicates.  
 
 
3.3    Electrophysiological investigations 
 
The electrophysiological investigations were performed by Prof. E. Sigel and co-
workers in the laboratories of the Institute of Pharmacology of the University of Bern.  
 
Xenopus laevis oocytes 
 
Briefly, oocytes were injected with 50 nl of capped, polyadenylated cRNA dissolved in 
5 mM K-HEPES (pH 6.8). For dual subunit combinations a concentration of 75 nM 
was used for each transcript. For triple subunit combinations 10 nM of the cRNA 
coding for the different α subunits (α1, α2, α3, α5, or α6), 10 nM for β2 and 50 nM for γ2 
were used. RNA transcripts were synthesized from linearized plasmids encoding the 
desired protein using the message machine kit (Ambion) according to the 
recommendations of the manufacturer. A poly (A) tail of ~300 residues was added to 
the transcripts by using yeast poly (A) polymerase (Amersham). The cRNA 
combinations were co-precipitated in ethanol and stored at −20 °C. Transcripts were 
quantified on agarose gels after staining with Radiant Red RNA Stain (Bio-Rad) by 
comparing staining intensities with various amounts of molecular weight markers 
(RNA Ladder, GibcoBRL). Electrophysiological experiments were performed by the 
two-electrode voltage clamp method at a holding potential of −80 mV. The medium 
contained 90 mM NaCl, 1 mM KCl, 1mM CaCl2, 1 mM MgCl2 and 5 mM HEPES-
NaOH (pH 7.4). GABA, diazepam, and test drugs were applied for 20 s and a 
washout period of 3-15 min was allowed to ensure full recovery from desensitization. 
Current responses have been fitted to the Hill equation: I = Imax / (1 + (EC50 / [A])
n) 
where I is the peak current at a given concentration of GABA [A], Imax is the maximum 
current, EC50 is the concentration of agonist eliciting half maximal current, and n is 
the Hill coefficient. Currents were measured using a modified OC-725 amplifier 
(Warner Instruments Corp.) in combination with a xy-recorder or digitized using a 
MacLab/200 (AD Instruments). 
 
 115 
The isolated pure compounds MS-1 (25), MS-2 (26), and MS-4 (27) were dissolved in 
DMSO. To minimize precipitation of the compounds the assay medium was 
complemented with 0.5 % DMSO. At this concentration DMSO had no significant 
effect on the current amplitude elicited by GABA. Relative current stimulation by the 
compounds was determined at a GABA concentration evoking 2-5 % of the maximal 
current amplitude in combination with increasing concentrations of compounds and 
expressed as ((I(GABA+MS) / I(GABA)) - 1) x 100 %. Only one cumulative concentration 
response curve was performed using the same oocyte, to avoid contamination, and 
the perfusion system was cleaned by washing with DMSO for the same reason. 
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4.    Constituents of Cussonia zimmermannii Harms 
 
4.1    The polyacetylenes and stigmasterol 
 
4.1.1    Isolation 
 
4.1.1.1    Extraction 
 
717 g of ground rootbark of Cussonia zimmermannii Harms were extracted by stirring 
with three portions of petroleum ether (40-60 °C). A five-fold quantity of solvent in 
relation to plant material was used. The extraction was carried out at room 
temperature under stirring for 24 h per portion. After each aliquot the mixture was left 
to stand and then filtered under normal pressure. The filtrates were combined, 
evaporated at 40 °C  and dried under high vacuum. 
 
 
4.1.1.2    Chromatography 
 
The isolation of the components from the crude plant extract was then carried out by 
MPLC followed by preparative scale HPLC. Fractions obtained with organic solvents 
were evaporated at 40 °C and then dried under high vacuum. From fractions obtained 
with organic solvent-water mixtures the organic solvent was removed by evaporation 
at 40 °C and the aquous residue was then freeze dried. After each fractionation step 
the fractions were checked for purity by analytical HPLC. 
 
MPLC Method 1 (crude extract) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 36 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time  
[min] 
% Hexane % Ethyl             
acetate 
% MeOH 
 Initial 100   0     0 
  10 100   0     0 
240   70 30     0 
360   70 30     0 
480     0   0 100 
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MPLC Method 2 (F3) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time  
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
 Initial  100   0     0 
240   90 10     0 
300   70 30     0 
360   70 30     0 
420     0   0 100 
 
Prep. HPLC Method 1 (F3.4.1) 
Column : Eurospher 100 C18 (Knauer), 7 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
  Time 
  [min] 
% Acetonitrile % Water 
  Initial 10 90 
   20 50 50 
   80 50 50 
     85 65 35 
   110 65 35 
   115 90 10 
   120 90 10 
 
MPLC Method 3 (F3.6) 
Column : Eurosil Bioselect 100-20 Diol 20 µm, 460 x 15 mm ID 
Detection : UV 254 nm 
Flow rate : 10 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time  
[min] 
% Hexane % Ethyl 
acetate 
Initial 98   2 
480 98   2 
540 90 10 
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Prep. HPLC Method 2 (F3.6.5) 
Column : Eurospher 100 C18 (Knauer), 7 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Acetonitrile % Water 
 Initial 60 40 
80 60 40 
95 80 20 
  115 80 20 
 
Prep. HPLC Method 3 (F3.6.5.6) 
Column : Eurospher 100 C18 (Knauer), 7 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Acetonitrile % Water 
Initial 65 35 
50 65 35 
60 90 10 
70 90 10 
 
Prep. HPLC Method 4 (F3.6.5.7) 
Column : Eurospher 100 C18 (Knauer), 7 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Acetonitrile % Water 
Initial 70 30 
50 70 30 
60 90 10 
70 90 10 
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MPLC Method 4 (F3.7) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 15 mm ID 
Detection : UV 254 nm 
Flow rate : 10 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
Initial 95   5 
480 95   5 
600 50 50 
 
Prep. HPLC Method 5 (F3.7.3) 
Column : Eurospher 100 C18 (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
  Time  
[min] 
% Acetonitrile % Water 
Initial 60 40 
  65 60 40 
  70 70 30 
110 70 30 
115 90 10 
120 90 10 
 
Prep. HPLC Method 6 (F3.7.3.5) 
Column : Eurospher 100 C18 (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time  
[min] 
% Methanol % Water 
Initial   75 25 
60   75 25 
65 100   0 
75 100   0 
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Prep. HPLC Method 7 (F3.7.4.1) 
Column : Eurospher 100 C18 (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Methanol % Water 
Initial 10 90 
  5 10 90 
15 20 80 
35 20 80 
45 45 55 
55 45 55 
65 98   2 
    120 98   2 
 
Prep. HPLC Method 8 (F3.7.4.2) 
Column : Eurospher 100 C18 (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Acetonitrile % Water 
Initial 55 45 
  80 55 45 
  90 70 30 
105 70 30 
110 90 10 
120 90 10 
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MPLC Method 5 (F4) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial  100   0     0 
240   80 20     0 
360   80 20     0 
420   50 50     0 
480   50 50     0 
540     0   0 100 
 
Prep. HPLC Method 9 (F4.7) 
Column : Eurospher 100 C18 (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Acetonitrile % Water 
Initial   55 45 
     65   55 45 
  70   65 35 
105   65 35 
110 100   0 
120 100   0 
 
Prep. HPLC Method 10 (F4.7.7) 
Column : LiChrospher 100 DIOL (Knauer), 10 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % CH2Cl2 
Initial 50   50 
20 50   50 
25   0 100 
35   0 100 
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MPLC Method 6 (F5) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial 100   0     0 
180   80 20     0 
360   80 20     0 
420   50 50     0 
480   50 50     0 
540     0   0 100 
 
MPLC Method 7 (F6) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial 100   0     0 
120   70 30     0 
240   70 30     0 
300   50 50     0 
360   50 50     0 
420     0   0 100 
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4.1.2    8-Hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 (25)) 
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tR : 32.9 min (prep. HPLC method 4). 
 
[α]20D = −94.5 (c = 0.78, CHCl3/0.75 % ethanol). 
 
UV/Vis (CHCl3/0.75 % ethanol) : λmax (ε) : 201.9 (282), 207.0 (308), 209.0 (350), 
219.8 (395), 223.9 (440), 244.7 (848), 258.3 (589), 281.8 (196). 
 
IR (NaCl) : 3424m, 2926s, 2855s, 2253w, 2156w, 1746s, 1464m, 1372m, 1231s. 
 
1H-NMR (500 MHz, CDCl3) : 5.35 (t, J = 6.5, 1 H, H-C(3)); 4.42 (t, J = 6.6, 1 H, H-
C(8)); 2.09 (s, 3 H, CH3COO); 1.82-1.77 (m, 2 H, H2C(2)); 1.75 (d, J = 5.8, 1 H, HO-
C(8)); 1.72-1.69 (m, 2 H, H2C(9)); 1.43 (br. quintet, J = 7.3, 2 H, H2C(10)); 1.31-1.26 
(m, 12 H, H2C(11/12/13/14/15/16)); 1.02 (t, J = 7.4, 3 H, H3C(1)); 0.88 (t, J = 7.0, 3 H, 
H3C(17)). 
 
13C-NMR (125 MHz, CDCl3) : 169.9 (s, COO); 80.6 (s, C(7)); 76.7 (s, C(4)); 69.3 (s, 
C(5)); 68.8 (s, C(6)); 65.3 (d, C(3)); 62.9 (d, C(8)); 37.5 (t, C(9)); 31.9 (t, C(15)); 
29.51, 29.48, 29.29, 29.21 (4t, C(11/12/13/14)); 27.8 (t, C(2)); 25.0 (t, C(10)); 22.7 (t, 
C(16)); 20.9 (q, CH3COO); 14.1 (q, C(17)); 9.3 (q, C(1)). 
 
COSY (500 MHz, CDCl3) : 5.35 → 1.82-1.77 (+++); 4.42 → 1.75 (+++) and 1.72-1.69 
(++); 1.82-1.77 → 1.02 (+++); 1.72-1.69 → 1.43 (+++); 1.43 → 1.31-1.26 (+++); 1.31-
1.26 → 0.88 (+++). 
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HMQC (125 MHz, CDCl3) : 65.3 → 5.35 (++); 62.9 → 4.42 (++); 37.5 → 1.72-1.69 
(+++); 31.9 → 1.26 (++); 29.51-29.21 → 1.31-1.26 (+++); 27.8 → 1.82-1.77 (+++); 
25.0 → 1.43 (+++); 22.7 → 1.28 (+++); 20.9 → 2.09 (+++); 14.1 → 0.88 (+++); 9.3 → 
1.02 (+++). 
 
HMBC (125 MHz, CDCl3) : 169.9 → 5.35 (+) and 2.09 (+++); 80.6 → 4.42 (+++) and 
1.72-1.69 (++); 76.7 → 5.35 (+++) and 1.82-1.77 (+++); 69.3 → 5.35 (+++) and 4.42 
(+); 68.8 → 5.35 (+) and 4.42 (+++); 65.3 → 1.82-1.77 (+++) and 1.02 (+++); 62.9 → 
1.72-1.69 (++); 37.5 → 4.42 (++); 31.9 → 1.28 (+++) and 0.88 (+++); 29.51-29.21 → 
1.43 (++) and 1.31-1.26 (++); 27.8 → 5.35 (++) and 1.02 (+++); 25.0 → 4.42 (+), 
1.72-1.69 (+) and 1.31-1.26 (+); 22.7 → 1.26 (+) and 0.88 (+++); 9.3 → 5.35 (+) and 
1.82-1.77 (+++). 
 
EI-MS (70 eV, ca. 200 °C) : 306 (84), M+; 291 (20), [M-15]+; 264 (6); 249 (26); 217 
(10); 175 (17); 161 (32); 133 (33); 119 (50); 91 (68); 57 (33); 55 (36); 43 (100). 
 
HR-EI-MS : 306.21971, M+; calc. for [C19H30O3]+ : 306.21950. 
 
 
4.1.3    8-Hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)) 
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26, MS-2
 
 
tR : 40.0 min (prep. HPLC method 3). 
 
[α]20D = −28.0 (c = 0.85, CHCl3/0.75 % ethanol). 
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UV/Vis (CHCl3/0.75 % ethanol) : λmax (ε) : 201.1 (369), 204.0 (351), 208.0 (495), 
209.9 (455), 214.0 (567), 216.0 (548), 219.1 (527), 222.1 (642), 245.9 (1245), 259.6 
(955), 283.1 (456). 
 
IR (NaCl) : 3426m, 3088w, 2926s, 2856s, 2255w, 2157w, 1746s, 1650w, 1461m, 
1372m, 1225s. 
 
1H-NMR (500 MHz, CDCl3) : 5.93-5.90 (m, 1 H, H-C(3)); 5.89-5.84 (m, 1 H, H-C(2)); 
5.55 (d, J = 16.8, 1 H, Ha-C(1)); 5.35 (d, J = 10.0, 1 H, Hb-C(1)); 4.43 (br. t, J = 6.5, 1 
H, H-C(8)); 2.11 (s, 3 H, CH3COO); 1.81 (br. s, 1 H, HO-C(8)); 1.75-1.66 (m, 2 H, 
H2C(9)); 1.43 (br. quintet, J = 7.5, 2 H, H2C(10)); 1.31-1.22 (m, 12 H, 
H2C(11/12/13/14/15/16)); 0.88 (t, J = 7.0, 3 H, H3C(17)). 
 
13C-NMR (125 MHz, CDCl3) : 169.5 (s, COO); 131.9 (d, C(2)); 119.8 (t, C(1)); 81.3 (s, 
C(7)); 74.4 (s, C(4)); 70.8 (s, C(5)); 68.6 (6)); 64.5 (d, C(3)); 62.9 (d, C(8)); 37.4 (t, 
C(9)); 31.9 (t, C(15)); 29.51, 29.48, 29.29, 29.20 (4t, C(11/12/13/14)); 25.0 (t, C(10)); 
22.7 (t, C(16)); 20.9 (q, CH3COO); 14.1 (q, C(17)). 
 
COSY (500 MHz, CDCl3) : 5.93-5.90 → 5.89-5.84 (+++); 5.89-5.84 → 5.55 (+++) and 
5.35 (+++); 4.43 → 1.81 (+) and 1.75-1.66 (+++); 1.75-1.66 → 1.43 (+++); 1.43 → 
1.31-1.22 (+++); 1.31-1.22 → 0.88 (+++). 
 
HMQC (125 MHz, CDCl3) : 131.9 → 5.93-5.90 (+) and 5.89-5.84 (+); 119.8 → 5.55 
(++) and 5.35 (++); 64.5 → 5.93-5.90 (+++); 62.9 → 4.43 (+++); 37.4 → 1.75-1.66 
(+++); 31.9 → 1.26 (+++); 29.51-29.20 → 1.31-1.22 (+++); 25.0 → 1.43 (+++); 22.7 
→ 1.28 (+++); 20.9 → 2.11 (+++); 14.1 → 0.88 (+++). 
 
HMBC (125 MHz, CDCl3) : 169.5 → 5.93-5.90 (++) and 2.11 (+++); 131.9 → 5.93-
5.90 (+++) and 5.55 (++); 119.8 → 5.93-5.90 (+++); 81.3 → 1.75-1.66 (+++); 74.4 → 
5.93-5.90 (++) and 5.89-5.84 (+++); 70.8 → 5.93-5.90 (+++); 68.6 → 5.93-5.90 (++); 
64.5 → 5.89-5.84 (++) and 5.55 (+++); 62.9 → 1.75-1.66 (+++) and 1.43 (+); 37.4 → 
1.43 (+); 31.9 → 1.28 (+++) and 0.88 (+++); 29.51-29.20 → 1.43 (+++) and 1.31-1.22 
(+++); 25.0 → 1.75-1.66 (+) and 1.30 (++); 22.7 → 1.26 (+) and 0.88 (+++). 
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FAB-MS (NBA + KCl) : 343 (36), [M+K]+; 287 (12); 245 (12); 227 (8); 137 (17); 91 
(33); 43 (100). 
 
EI-MS : 303 (20), [M-1]+; 201 (14); 178 (78); 159 (44); 135 (47); 107 (65); 79 (38); 43 
(100). 
 
HR-EI-MS : 303.19530, [M-1]+; calc. for [C19H27O3]+ : 303.19602. 
 
4.1.4    16-Acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)) 
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tR : 11.0 min (prep. HPLC method 10). 
 
[α]20D = −26.4 (c = 0.81, CHCl3/0.75 % ethanol). 
 
UV/Vis (CHCl3/0.75 % ethanol) : λmax (ε) : 202.0 (254), 207.0 (302), 209.1 (353), 
212.9 (352), 245.8 (984), 259.7 (601). 
 
IR (NaCl) : 3444m, 3086w, 3031w, 2922s, 2844s, 2256w, 2156w, 1739s, 1644w, 
1467w, 1367w, 1233s. 
 
1H-NMR (500 MHz, CDCl3) : 5.92-5.89 (m, 1 H, H-C(16)); 5.88-5.83 (m, 1 H, H-
C(17)); 5.54 (d, J = 16.8, 1 H, Ha-C(18)); 5.34 (d, J = 10.0, 1 H, Hb-C(18)); 4.42 (br. t, 
J = 6.3, 1 H, H-C(11)); 4.04 (t, J = 6.8, 2 H, H2C(1)); 2.10 (s, 3 H, H3C(2'')); 2.04 (s, 3 
H, H3C(2')); 2.02 (br. s, 1 H, HO-C(11)); 1.73-1.68 (m, 2 H, H2C(10)); 1.61 (quintet, J 
= 7.2, 2 H, H2C(2)); 1.43 (br. quintet, J = 7.2, 2 H, H2C(9)); 1.34-1.24 (m, 12 H, H2C 
(3/4/5/6/7/8)). 
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13C-NMR (125 MHz, CDCl3) : 171.3 (s, C(1')); 169.5 (s, C(1'')); 131.9 (d, C(17)); 
119.7 (t, C(18)); 81.4 (s, C(12)); 74.3 (s, C(15)); 70.9 (s, C(14)); 68.5 (s, C(13)); 64.7 
(t, C(1)); 64.5 (d, C(16)); 62.8 (d, C(11)); 37.4 (t, C(10)); 29.44, 29.41, 29.37, 29.21, 
29.17 (5t, C(4/5/6/7/8)); 28.6 (t, C(2)); 25.9 (t, C(3)); 25.0 (t, C(9)); 21.0 (q, C(2')); 
20.9 (q, C(2'')). 
 
COSY (500 MHz, CDCl3) : 5.92-5.89 → 5.88-5.83 (++); 5.88-5.83 → 5.54 (++) and 
5.34 (++), 4.42 → 2.02 (+) and 1.73-1.68 (+++); 4.04 → 1.61 (+++); 1.73-1.68 → 1.43 
(++); 1.61 → 1.34-1.24 (+++); 1.43 → 1.34-1.24 (+++). 
 
HMQC (125 MHz, CDCl3) : 131.9 → 5.92-5.89 (++) and 5.88-5.83 (++); 119.7 → 5.54 
(+++) and 5.34 (+++); 64.7 → 4.04 (+++); 64.5 → 5.92-5.89 (+++); 62.8 → 4.42 
(+++); 37.4 → 1.73-1.68 (+++); 29.44-29.17 → 1.34-1.24 (+++); 28.6 → 1.61 (+++); 
25.9 → 1.32 (+++); 25.0 → 1.43 (+++); 21.0 → 2.04 (+++); 20.9 → 2.10 (+++). 
 
HMBC (125 MHz, CDCl3) : 171.3 → 4.04 (+++) and 2.04 (+++); 169.5 → 5.92-5.89 
(++) and 2.10 (+++); 131.9 → 5.92-5.89 (++) and 5.54 (++); 119.7 → 5.92-5.89 (++); 
81.4 → 4.42 (++) and 1.73-1.68 (+++); 74.3 → 5.92-5.89 (+++) and 5.88-5.83 (+++); 
70.9 → 5.92-5.89 (+++) and 4.42 (+); 68.5 → 5.92-5.89 (++) and 4.42 (++); 64.7 → 
1.61 (+++) and 1.31 (+); 64.5 → 5.88-5.83 (++) and 5.54 (+++); 62.8 → 1.73-1.68 
(+++) and 1.43 (+); 37.4 → 4.42 (++) and 1.43 (+); 29.44-29.17 → 4.04 (++), 1.73-
1.68 (+), 1.61 (+++), 1.43 (+++) and 1.34-1.24 (+++); 28.6 → 4.04 (+++) and 1.34-
1.24 (+++); 25.9 → 4.04 (+++), 1.61 (+++) and 1.34-1.24 (+++); 25.0 → 4.42 (++), 
1.73-1.68 (++) and 1.34-1.24 (++). 
 
FAB-MS (NBA + KCl) : 415 (32), [M+K]+; 377 (2); 359 (5); 317 (11); 299 (12); 136 
(13); 91 (24); 55 (35); 43 (100). 
 
HR-EI-MS : 376.22369, M+; calc. for [C22H32O5]+ : 376.22497. 
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4.1.4.1    Stereochemical analysis of MS-4 (27) using the Mosher method  
 
Both the (R)-MTPA ester (50) from (S)-MTPA-Cl (48) and (S)-MTPA ester (51) from 
(R)-MTPA-Cl (49) were prepared from 16-Acetoxy-11-hydroxyoctadeca-17-ene-
12,14-diynyl acetate (MS-4 (27)).       
 
(R)-MTPA ester (50) 
 
A granule (4 mg) of catalytic DMAP was dissolved in 500 µl of absolute pyridine at r.t. 
This solution was added to 5.4 mg (0.0144 mmol) of MS-4 (27) under argon. To this 
solution 14.5 mg (0.0574 mmol, 4 eq.) of (S)-MTPA-Cl (48) were added and the 
mixture was stirred at r.t. for 24 h under argon. After the addition of 5 ml diethyl ether, 
the solution was washed with water. After separation, the resulting organic phase 
was dried over MgSO4, filtered and the solvent evaporated. Preparative HPLC 
purification afforded 4.9 mg (0.0083 mmol, 58 %) of 50 as a pale yellow oil. 
 
Prep. HPLC purification 
Column : Eurospher 100 Si (Knauer), 5 µm, 250 x 16.0 mm ID 
Detection : DAD Waters 996 
Flow rate : 12 ml/min 
Fraction collecting : 1 fraction every 30 seconds 
Gradient table :  
Time 
[min] 
% CH2Cl2 % MeOH 
Initial           100           0 
15           100           0 
25             80  20 
40             80  20 
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1H-NMR (500 MHz, CDCl3) : 7.52-7.51 (m, 2 H, H-C(6''')); 7.43-7.40 (m, 3 H, H-C(7'''), 
H-C(8''')); 5.92-5.90 (m, 1 H, H-C(16)); 5.88-5.84 (m, 1 H, H-C(17)); 5.55 (t, J = 6.7, 1 
H, H-C(11)); 5.54 (d, J = 16.4, 1 H, Ha-C(18)); 5.36 (d, J = 9.7, 1 H, Hb-C(18)); 4.05 (t, 
J = 6.8, 2 H, H2C(1)); 3.55 (s, 3 H, H-C(3''')); 2.11 (s, 3 H, H3C(2'')); 2.04 (s, 3 H, 
H3C(2')); 1.87-1.83 (m, 2 H, H2C(10)); 1.63-1.59 (m, 2 H, H2C(2)); 1.43 (m, 2 H, 
H2C(9)); 1.34-1.27 (m, 12 H, H2C(3/4/5/6/7/8)). 
 
13C-NMR (125 MHz, CDCl3) : 171.3 (s, C(1')); 169.4 (s, C(1'')); 165.6 (s, C(1''')); 
131.8 (s, C(5''')); 131.7 (d, C(17)); 129.7-127.4 (3d, C(6'''/7'''/8''')); 123.2 (q, C(4'''), JCF 
= 289); 119.9 (t, C(18)); 84.5 (s, C(2''')); 75.88 (s, C(12)); 75.2 (s, C(15)); 70.4 (s, 
C(14)); 70.2 (s, C(13)); 66.38 (d, C(11)); 64.6 (t, C(1)); 64.3 (d, C(16)); 55.6 (q, 
C(3''')); 34.13 (t, C(10)); 29.42, 29.37, 29.30, 29.22, 28.90 (5t, C(4/5/6/7/8)); 28.6 (t, 
C(2)); 25.9 (t, C(3)); 24.88 (t, C(9)); 21.05 (q, C(2')); 20.88 (q, C(2'')). 
 
(S)-MTPA ester (51) 
 
A granule (3 mg) of catalytic DMAP was dissolved in 500 µl of absolute pyridine at r.t. 
This solution was added to 7.8 mg (0.0207 mmol) of MS-4 (27) under argon. To that 
solution 21.0 mg (0.083 mmol, 4 eq.) of (R)-MTPA-Cl (49) were added and the 
mixture was stirred at r.t. for 24 h under argon. After the addition of 5 ml diethyl ether, 
the solution was washed with water. After separation, the resulting organic phase 
was dried over MgSO4, filtered and the solvent evaporated. Preparative HPLC 
purification (see above) afforded 6.8 mg (0.0115 mmol, 55 %) of 51 as a pale yellow 
solid. 
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The two derivatives were analyzed by 500 MHz 1H- and 125 MHz 13C NMR. The 
absolute konfiguration at C(11) was determined according to the formula ∆δ = δ(S)-ester 
− δ(R)-ester. Results are summarized under 5.2.2.3.2 in the theoretical part. 
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1H-NMR (500 MHz, CDCl3) : 7.53-7.51 (m, 2 H, H-C(6''')); 7.42-7.39 (m, 3 H, H-C(7'''), 
H-C(8''')); 5.92-5.90 (m, 1 H, H-C(16)); 5.89-5.84 (m, 1 H, H-C(17)); 5.59 (t, J = 6.7, 1 
H, H-C(11)); 5.55 (d, J = 16.3, 1 H, Ha-C(18)); 5.36 (d, J = 9.8, 1 H, Hb-C(18)); 4.05 (t, 
J = 6.8, 2 H, H2C(1)); 3.58 (s, 3 H, H-C(3''')); 2.11 (s, 3 H, H3C(2'')); 2.05 (s, 3 H, 
H3C(2')); 1.81-1.76 (m, 2 H, H2C(10)); 1.65-1.56 (m, 2 H, H2C(2)); 1.33-1.22 (m, 12 
H, H2C(3/4/5/6/7/8)); 1.29 (m, 2 H, H2C(9)). 
 
13C-NMR (125 MHz, CDCl3) : 171.3 (s, C(1')); 169.5 (s, C(1'')); 165.7 (s, C(1''')); 
132.1 (s, C(5''')); 131.7 (d, C(17)); 129.7-127.3 (3d, C(6'''/7'''/8''')); 123.2 (q, C(4'''), JCF 
= 288); 119.9 (t, C(18)); 84.5 (s, C(2''')); 76.03 (s, C(12)); 75.3 (s, C(15)); 70.4 (s, 
C(14)); 70.2 (s, C(13)); 65.97 (d, C(11)); 64.7 (t, C(1)); 64.3 (d, C(16)); 55.6 (q, 
C(3''')); 34.17 (t, C(10)); 29.71, 29.42, 29.33, 29.25, 29.22 (5t, C(4/5/6/7/8)); 28.8 (t, 
C(2)); 25.9 (t, C(3)); 24.61 (t, C(9)); 21.05 (q, C(2')); 20.88 (q, C(2'')). 
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4.1.5    11,16-Diacetoxyoctadeca-17-ene-12,14-diynyl acetate (MS-5 (28)) 
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tR : 105.0 min (prep. HPLC method 8). 
 
1H-NMR (500 MHz, CDCl3) : 5.91-5.89 (m, 1 H, H-C(16)); 5.87-5.83 (m, 1 H, H-
C(17)); 5.54 (d, J = 16.4, 1 H, Ha-C(18)); 5.37 (t, J = 7.4, 1 H, H-C(11)); 5.35 (d, J = 
9.7, 1 H, Hb-C(18)); 4.05 (t, J = 6.8, 2 H, H2C(1)); 2.10 (s, 3 H, H3C(2''')); 2.08 (s, 3 H, 
H3C(2'')); 2.05 (s, 3 H, H3C(2')); 1.78-1.74 (m, 2 H, H2C(10)); 1.63-1.59 (m, 2 H, 
H2C(2)); 1.46-1.37 (m, 2 H, H2C(9)); 1.33-1.23 (m, 12 H, H2C (3/4/5/6/7/8)). 
 
13C-NMR (125 MHz, CDCl3) : 171.3 (s, C(1')); 169.8 (s, C(1'')); 169.5 (s, C(1''')); 
131.8 (d, C(17)); 119.8 (t, C(18)); 77.7 (s, C(12)); 74.5 (s, C(15)); 70.7 (s, C(14)); 
69.0 (s, C(13)); 64.7 (t, C(1)); 64.4 (d, C(16)); 64.1 (d, C(11)); 34.4 (t, C(10)); 29.45, 
29.42, 29.37, 29.22, 29.05 (5t, C(4/5/6/7/8)); 28.6 (t, C(2)); 25.9 (t, C(3)); 24.9 (t, 
C(9)); 21.05 (q, C(2')); 20.90 (q, C(2'' or 2''')); 20.88 (q, C(2'' or 2''')). 
 
COSY (500 MHz, CDCl3) : 5.91-5.89 → 5.87-5.83 (++); 5.87-5.83 → 5.54 (++) and 
5.35 (++); 5.37 → 1.78-1.74 (+++); 4.05 → 1.63-1.59 (+++); 1.78-1.74 → 1.46-1.37 
(+++); 1.63-1.59 → 1.33-1.23 (+++); 1.46-1.37 → 1.33-1.23 (++). 
 
HMQC (125 MHz, CDCl3) : 119.8 → 5.54 (+) and 5.35 (+); 64.7 → 4.05 (++); 64.4 → 
5.91-5.89 (+); 64.1 → 5.37 (++); 34.4 → 1.78-1.74 (+); 29.45-29.05 → 1.33-1.23 
(+++); 28.6 → 1.63-1.59 (+); 25.9 → 1.33 (+); 24.9 → 1.46-1.37 (+); 21.05 → 2.05 
(+++); 20.90 or 20.88 → 2.10 (+++); 20.88 or 20.90 → 2.08 (+++). 
 132 
HMBC (125 MHz, CDCl3) : 171.3 → 4.05 (++) and 2.05 (+++); 169.8 → 5.37 (+) and 
2.08 (+++); 169.5 → 5.91-5.89 (+) and 2.10 (+++); 131.8 → 5.91-5.89 (+); 77.7 → 
5.37 (++) and 1.78-1.74 (+); 69.0 → 5.37 (+); 64.7 → 1.63-1.59 (+); 64.4 → 5.87-5.83 
(+); 64.1 → 1.78-1.74 (+); 34.4 → 5.37 (+); 29.45-29.05 → 1.78-1.74 (+), 1.63-1.59 
(+) and 1.33-1.23 (++); 28.6 → 4.05 (++) and 1.33-1.23 (+); 25.9 → 4.05 (+++) and 
1.63-1.59 (+). 
 
FAB-MS (NBA + KCl) : 457 (94), [M+K]+; 419 (8), [M+1]+; 359 (99); 317 (19); 171 (9); 
115 (15); 55 (35); 43 (100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 133 
4.1.6    Stigmasterol (42) 
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Table 18 : Comparison of the spectroscopic data of compound 42 with stigmasterol  
(authentic sample). 
Analytical method  Compound 42  Authentic sample 
EI-MS  
(70 eV, ca. 200 °C) 
 412 (90), [M]+; 369 (23); 351 (39); 
300 (40); 271 (53); 255 (83); 213 
(32); 159 (56); 133 (52); 83 (89);  
55 (100). 
 
 412 (100), [M]+; 369 (25); 351 (38); 
300 (40); 271 (50); 255 (74); 213 
(28); 159 (45); 133 (40); 83 (57); 55 
(59). 
 
IR 
(KBr pellet) 
 3346m, 2935s, 2866s, 1458m, 
1440m, 1382m, 1368m, 1331w, 
1193w, 1055m, 1022w, 970m, 
961m, 838w, 799w. 
 
 3346m, 2935s, 2867s, 1458m, 
1442m, 1382m, 1368m, 1331w, 
1193w, 1054m, 1022w, 971m, 
960m, 838w, 799w. 
1H-NMR*  
(500/400 MHz, 
CDCl3) 
 5.35-5.34 (m); 5.15 (dd, J = 8.6, 
8.7); 5.01 (dd, J = 8.8, 8.7); 3.54-
3.50 (m); 2.31-2.23 (m); 2.06-1.94 
(m); 1.87-1.82 (m); 1.72-1.66 (m); 
1.58-1.39 (m); 1.30-1.25 (m); 1.23-
1.14 (m); 1.12-1.04 (m); 1.03 (s); 
1.01 (s); 1.00-0.91 (m); 0.85 (d, J = 
6.4); 0.80 (t, J = 7.5); 0.70 (s). 
 
 5.36-5.34 (m); 5.15 (dd, J = 8.6, 
8.7); 5.01 (dd, J = 8.6, 8.6); 
3.56-3.48 (m); 2.32-2.23 (m);  
2.07-1.95 (m); 1.87-1.81 (m);  
1.73-1.66 (m); 1.59-1.38 (m);  
1.30-1.24 (m); 1.22-1.13 (m);  
1.11-1.05 (m); 1.03 (s); 1.01 (s); 
1.00-0.90 (m); 0.85 (d, J = 6.6);  
0.80 (t, J = 7.2); 0.70 (s). 
 
13C-NMR**  
(125/101 MHz, 
CDCl3) 
 140.8; 138.3; 129.3; 121.7; 71.8; 
56.9; 55.9; 51.2; 50.2; 42.3; 42.2; 
40.5; 39.7; 37.3; 36.5; 31.90; 31.90; 
31.7; 28.9; 25.4; 24.4; 21.2; 21.1; 
21.08; 19.4; 19.0; 12.3; 12.1. 
 140.9; 138.5; 129.4; 121.9; 71.9; 
57.0; 56.1; 51.4; 50.3; 42.4;  
42.3; 40.7; 39.8; 37.4; 36.7;  
32.0; 32.0; 31.8; 29.1; 25.6;  
24.5; 21.4; 21.24; 21.21; 19.5;  
19.1; 12.4; 12.2. 
*  : 500 MHz 1H-NMR spectrum of compound 42 / 400 MHz 1H-NMR spectrum of authentic sample 
**  : 125 MHz 13C-NMR spectrum of compound 42 / 101 MHz 1H-NMR spectrum of authentic sample 
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5.    Fractionation of Commiphora fulvotomentosa Engl. extract 
 
5.1    Extraction 
 
1039 g of ground stembark of Commiphora fulvotomentosa Engl. were extracted by 
stirring with three portions of petroleum ether (40-60 °C). A five-fold quantity of 
solvent in relation to plant material was used. The extraction was carried out at room 
temperature under stirring for 24 h per portion. After each aliquot the mixture was left 
to stand and then filtered under normal pressure. The filtrates were combined, 
evaporated at 40 °C and dried under high vacuum. 
 
 
5.2    Chromatography 
 
The fractionation of the crude plant extract was carried out by MPLC followed by 
preparative scale HPLC. After each fractionation step the fractions were checked for 
purity by analytical HPLC. 
 
MPLC Method 1 (crude extract) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 36 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial 100   0     0 
  10 100   0     0 
240   50 50     0 
360   50 50     0 
480     0   0 100 
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MPLC Method 2 (F2) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial 100   0     0 
240   95   5     0 
360   95   5     0 
420   80 20     0 
480   80 20     0 
540     0   0 100 
 
MPLC Method 3 (F3) 
Column : LiChroprep Si 60 (Merck), 15-25 µm, 460 x 26 mm ID 
Detection : UV 254 nm 
Flow rate : 15 ml/min 
Fraction collecting : 1 fraction every min 
Gradient table :  
Time 
[min] 
% Hexane % Ethyl 
acetate 
% MeOH 
Initial  100   0     0 
240   90 10     0 
360   90 10     0 
420   70 30     0 
480   70 30     0 
540     0   0 100 
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C.    Summary 
 
For the present thesis 22 samples of seven African medicinal plants, the extracts of 
which had previously proved to possess an in vitro activity against T. b. rhodesiense 
and/or P. falciparum and 13 samples of six randomly selected plant species based on 
availability were collected in Tanzania.  
 
Of these 35 samples, 140 crude extracts were produced with four solvents of 
different polarity, and the extracts were tested for in vitro antitrypanosomal and 
antiplasmodial activity and for cytotoxicity. In addition the extracts were tested for the 
affinity to the GABAA receptor performed by radioligand binding experiments. 
 
Based on the considerable antitrypanosomal and antiplasmodial activity and the 
affinity to the GABAA receptor, two extracts were selected for bioassay-guided 
fractionation : the petroleum ether extract of the stembark of Commiphora 
fulvotomentosa Engl. because of its promising IC50 value of 2.1 µg/ml against T. b. 
rhodesiense and the high selectivity index of 21.4, and the petroleum ether extract of 
the rootbark of Cussonia zimmermannii Harms because of its IC50 value of 4.8 µg/ml 
against T. b. rhodesiense, its IC50 value of 3.3 µg/ml against P. falciparum, and the 
potent modulatory effect at the GABAA receptor of 151 %. 
 
After three fractionation steps the fractions of the petroleum ether extract of the 
stembark of Commiphora fulvotomentosa Engl. did not show any inhibitory activity 
against T. b. rhodesiense and were therefore not investigated further. 
 
Bioassay-guided fractionation of the petroleum ether extract of the rootbark of 
Cussonia zimmermannii Harms lead to the isolation of four polyacetylenes. By the 
application of MS, HR-MS, UV/VIS and IR methods and NMR experiments (1H-NMR, 
13C-NMR, DEPT135, 1H-1H COSY, HMQC and HMBC) the structures of the four 
novel diynes were established : 8-Hydroxyheptadeca-4,6-diyn-3-yl acetate (MS-1 
(25)), 8-Hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate (MS-2 (26)), 16-Acetoxy-11-
hydroxyoctadeca-17-ene-12,14-diynyl acetate (MS-4 (27)), and 11,16-Diacetoxyocta-
deca-17-ene-12,14-diynyl acetate (MS-5 (28)).  
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Additionally, stigmasterol (42) was isolated and identified by comparison of its 
spectroscopic data with those of an authentic sample.  
 
For the determination of the absolute configuration of MS-4 (27) at C(11) the Mosher 
method was used. The negative ∆δ values for the neighbouring protons suggested 
the S-configuration. But this result could not be confirmed by the 13C-NMR data since 
both positive and negative ∆δ values were obtained for the neighbouring carbons. 
Due to the fact, that the results for the protons and the carbons were not consistent 
the S-configuration for C(11) of MS-4 (27) could not be assigned with certainty.   
 
The isolated compounds MS-1 (25), MS-2 (26), and MS-4 (27) were tested for in vitro 
inhibitory activity against additional parasites like T. cruzi and L. donovani (axenic 
and in infected macrophages). 42 was not tested because it was a well known 
phytosterol which is ubiquitous in plants. Neither was MS-5 (28) tested, since the 
isolated amount was not sufficient. 
 
It was found that MS-1 (25) showed in all antiparasitic in vitro assays no higher 
inhibitory activity than the crude extract. MS-2 (26) showed promising activities in the 
T. cruzi and L. donovani (axenic and in infected macrophages) assay with IC50 values 
of 0.2, 0.039, and 0.098 µg/ml, respectively. The respective IC50 values of the 
standard drugs were 0.62, 0.18, and 0.29. The cytotoxicity was relatively high; 
therefore the selectivity with SI values of 18.0 and 36.7, respectively (T. cruzi, L. 
donovani in inf. mac.), was in a moderate range. MS-4 (27) showed also interesting 
activities in the T. cruzi and L. donovani (axenic) assays with IC50 values of 0.15 and 
0.054 µg/ml. The SI value of 145.3 (T. cruzi) was high. Compared with the standard 
drugs the activities of MS-2 (26) and MS-4 (27) against T. b. rhodesiense and P. 
falciparum were in a moderate range.  
 
MS-1 (25), MS-2 (26), and MS-4 (27) were also tested in the GABAA receptor binding 
assay. Here MS-4 (27) showed the highest relative specific binding of 158 % at a 
concentration of 20 µg/ml, followed by MS-2 (26) with 152 % and MS-1 (25) with   
138 %.  
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In order to investigate whether the modulatory effect at the GABAA receptor leads to 
a chanel opening, the isolated compounds were investigated electrophysiologically. It 
was found that MS-1 (25), MS-2 (26), and MS-4 (27) act as potent positive allosteric 
modulators at GABAA receptors with a half maximal stimulation at a concentration of 
0.6-3.5 µM and a maximal stimulation of 110-450 %. The compounds also showed 
unique subunit selectivity profiles, the stimulation was independend from the 
presence of the γ subunit and resistant to the benzodiazepine antagonist Ro15-1788.  
 
These in vitro data suggested that MS-1 (25), MS-2 (26), and MS-4 (27) may be used 
to treat diseases of the central nervous system, specifically they may be used to treat 
states of anxiety, as sedatives/hypnotics, as muscle relaxants and as anticonvulsives 
(e.g. in epilepsy), and in the treatment of drug addiction. Therefore it was decided to 
patent the compounds for these indications [174].  
 
All data are on the in vitro level. For a pharmaceutical application in vivo data are 
needed. Therefore MS-1 (25), MS-2 (26), and MS-4 (27) need to be synthesized in 
order to get more material for subsequent in vivo experiments. 
 
 139 
D.    Bibliography 
 
[1] G. M. Cragg, D. J. Newman, in `Ethnomedicine and drug discovery´, Ed. M. M. Iwu, J. C. 
Wootton, Elsevier, Amsterdam, London, New York, 2002, p. 23-38. 
[2] A. D. Buss, R. D. Waigh, in `Burgers medicinal chemistry and drug discovery´, Ed. M. E. Wolff, 
Wiley, New York, 1995, Vol. 1, p. 983-1033. 
[3] N. Neuss, M. N. Neuss, in `The Alkaloids´, Ed. A. Brossi, M. Suffness, Academic Press, New 
York, 1990, p. 229-240. 
[4] D. L. Klayman, in `Human medicinal agents from plants´, Ed. A. D. Kinghorn, M. F. Balandrin, 
American Chemical Society, Washington DC, 1993, p. 242-255. 
[5] K. Hostettmann, A. Marston, J.-L. Wolfender, in `Phytochemistry of plants used in traditional 
medicine´, Ed. K. Hostettmann, A. Marston, M. Maillard, M. Hamburger, Clarendon Press, 
Oxford, 1995, p. 17-45. 
[6] M. Hamburger, K. Hostettmann, Phytochem., 1991, 30, 3864-3874. 
[7] M. M. Iwu, in `Ethnomedicine and drug discovery´, Ed. M. M. Iwu, J. C. Wootton, Elsevier, 
Amsterdam, 2002, p. 309-320. 
[8] M. J. O’Neill, J. A. Lewis, in `Human medicinal agents from plants´, Ed. A. D. Kinghorn, M. F. 
Balandrin, American Chemical Society, Washington DC, 1993, p. 48-55. 
[9] J. G. Bruhn, F. Sandberg, in `The medical plant industry´, Ed. R. O. B. Wijesekera, CRC Press, 
Ann Arbor, 1991, p. 223. 
[10] O. Akerele, Int. Trad. Health. New., 1985, 1, 1. 
[11] F. Haerdi, in `Afrikanische Heilpflanzen´ Ed. A. Buehler, R. Geigy, A. Gigon, F. Meier, Acta 
Tropica, 1964, Supplement 8. 
[12] J. O. Kokwaro, `Medicinal plants of East Africa´, East African Literature Bureau, Kampala, 
1976. 
[13] I. Hedberg, O. Hedberg, P. J. Madati, K. E. Mshigeni, E. N. Mshiu, G. Samuelsson, J. 
Ethnopharm., 1982, 6, 29-60. 
[14] I. Hedberg, O. Hedberg, P. J. Madati, K. E. Mshigeni, E. N. Mshiu, G. Samuelsson, J. 
Ethnopharm., 1983, 9, 105-128. 
[15] I. Hedberg, O. Hedberg, P. J. Madati, K. E. Mshigeni, E. N. Mshiu, G. Samuelsson, J. 
Ethnopharm., 1983, 9, 237-260. 
[16] S. C. Chhabra, R. L. Mahunnah, E. N. Mshiu, J. Ethnopharm., 1987, 21, 253-277. 
[17] S. C. Chhabra, R. L. Mahunnah, E. N. Mshiu, J. Ethnopharm., 1989, 25, 339-359. 
[18] H. Weenen, M. H. H. Nkunya, D. H. Bray, L. B. Mwasumbi, L. S. Kinabo, V. A. E. B. Kilimali, 
Plant. Med., 1990, 56, 368-370. 
[19] H. Weenen, M. H. H. Nkunya, D. H. Bray, L. B. Mwasumbi, L. S. Kinabo, V. A. E. B. Kilimali, 
Plant. Med., 1990, 56, 371-373. 
[20] M. Gessler, `The antimalarial potential of medicinal plants traditionally used in Tanzania, and 
their use in the treatment of Malaria by traditional healers´, Ph.D. Thesis, University of Basel, 
1995. 
 
 140 
[21] F. Freiburghaus, `African medicinal plants used in the treatment of sleeping sickness – an 
evaluation´, Ph.D. Thesis, University of Basel, 1996. 
[22] B. Räz, `Isolation and evaluation of antiparasitic lead compounds from African medicinal 
plants´, Ph.D. Thesis, University of Basel, 1998. 
[23] J. D. Phillipson, C. W. Wright, G. C. Kirby, D. C. Warhurst, in `Phytochemistry of Plants Used in 
Traditional Medicine´, Ed. K. Hostettmann, A. Marston, M. Maillard, M. Hamburger, Clarendon 
Press, Oxford, 1995, p. 94-135. 
[24] P. I. Trigg, in `Economic and medicinal plant research´, Ed. H. Wagner, H. Hikino, N. R. 
Farnsworth, Academic Press, London, 1989, Vol. 3, p. 1-56. 
[25] J. D. Phillipson, M. J. O’Neill, in `Biologically active natural products, Proceedings of the 
Phytochemical Society of Europe´, Ed. K. Hostettmann, P. J. Lea, Clarendon Press, Oxford, 
1987, Vol. 27, p. 49-64. 
[26] M. H. H. Nkunya, `Progress in the search for antimalarials´, NAPRECA Monograph Series, 
NAPRECA, Addis Ababa University, Addis Ababa, 1992, No. 4, p. 1-36. 
[27] G. L. Sharma, K. K. Bhutani, Plant. Med., 1988, 54, 120-122. 
[28] M. Hooper, G. C. Kirby, M. M. Kulkarni, S. N. Kulkarni, B. A. Nagasampagi, M. J. O’Neill, J. D. 
Phillipson, S. R. Rojatkar, D. C. Warhurst, J. Med. Chem., 1990, 25, 717-723. 
[29] A. Fournet, V. Muñoz, F. Roblot, R. Hocquemiller, A. Cave, J. C. Gantier, Phyto. Res., 1993, 7, 
111-115. 
[30] J. D. Phillipson, C. W. Wright, G. C. Kirby, D. C. Warhurst, in `Phytochemical potential of 
tropical plants´, Ed. K. R. Downum, J. T. Romeo, H. A. Stafford, Plenum Press, New York, 
1993, p. 1-40. 
[31] L. -Z. Lin, H. -L. Shieh, C. K. Angerhofer, J. M. Pezzuto, G. A. Cordell, L. Xue, M. E. Johnson, 
N. Ruangrungsi, J. Nat. Prod., 1993, 56, 22-29. 
[32] J. C. Cavin, S. M. Krassner, E. Rodriguez, J. Ethnopharm., 1987, 19, 89-94. 
[33] M. Sauvin, J. -P. Dedet, N. Kunesch, J. Poisson, J. C. Gantier, P. Gayral, G. Kunesch, Phyto. 
Res., 1993, 7, 167-171. 
[34] K. C. Liu, S. -L. Yang, M. F. Roberts, B. C. Elford, J. D. Phillipson, Plant Cell Rep., 1992, 11, 
637-640. 
[35] World Health Organisation, `Fighting disease, fostering development´, Report  WHO, Geneva, 
1996b, Fact sheet no. 134. 
[36] D. T. Okpako, Trends pharmacol. Sci., 1999, 20, 482-485. 
[37] D. T. Okpako, `Principles of Pharmacology. A tropical approach´, Cambridge University Press, 
New York, 1991. 
[38] World Health Organisation, `Fighting disease, fostering development´, Report  WHO, Geneva, 
1996. 
[39] World Health Organisation, `Life in the 21st Century – A vision for all´, Report  WHO, Geneva, 
1998. 
[40] K. Vickermann, Int. J. Parasitol., 1994, 24, 1317-1331. 
[41] A. Stich, M. P. Barrett, S. Krishna, Trends Pharmacol., 2003, 19, 195-197. 
  
 141 
[42] D. Legros, G. Ollivier, M. Gestellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, P. Buescher, The 
Lancet Infect. Dis., 2002, 2, 437-440. 
[43] World Health Organisation, WHO Tech. Rep. Ser. 881, 1998, 1-114. 
[44] E. K. Markell, M. Voge, `Medical Parasitology´, W. B. Saunders Comp., Philadelphia, 1981. 
[45] D. D. Despommier, J. W. Karapelou, `Parasite Life Cycles´, Springer-Verlag, Berlin, 1987. 
[46] H. Mehlhorn, `Encyclopedic Reference of Parasitology, Diseases, Treatment, Therapy´, 
Springer-Verlag, Berlin, 2001. 
[47] A. H. Fairlamb, Trends Parasito., 2003, 19, 488-494. 
[48] J. Pépin, F. Milford, Adv. Parasitol., 1994, 33, 1-47. 
[49] N. S. Carter, J. Biol. Chem., 1995, 270, 28153-28157. 
[50] H. P. De Koning, Mol. Pharmacol., 2001, 59, 586-592. 
[51] T. A. Shapiro, P. T. Englund, Proc. Natl. Acad. Sci. USA, 1990, 87, 950-954. 
[52] O. Heby, Biochem. Soc. Trans., 2003, 31, 415-419. 
[53] P. G. Bray, Mol. Biochem. Parasitol., 1994, 63, 87-94. 
[54] J. A. Urbina, R. Docampo, Tr. Parasitol., 2003, 19, 495-501. 
[55] World Health Organisation, WHO Tech. Rep. Ser. 905, 2002, 1-109. 
[56] C. M. Morel, Parasitol. Today, 2000, 16, 522-525. 
[57] G. A. Schmuñis, in `Trypanosoma cruzi e Doença de Chagas´, Ed. Z. Brener et al., Guanabara 
Koogan, Rio de Janeiro, 2000, p. 1-15. 
[58] A. Prata, The Lancet Inf. Dis., 2001, 1, 92-100. 
[59] D. S. Fries, A. H. Fairlamb in `Burgers medicinal chemistry and drug discovery´, Ed. D. J. 
Abraham, Wiley, New York, 2003, p. 1033-1087. 
[60] R. Docampo, Chem. Biol. Interact., 1990, 73, 1-27. 
[61] J. R. Cançado, Mem. Inst. Oswaldo Cruz, 1999, 94, 331-336. 
[62] L. V. Kirchhoff, in `Emergin Infections 3´, Ed. W. M. Scheld, ASM Press, Boston, 1999, p. 111-
134. 
[63] S. G. Andrade, Trans. R. Soc. Trop. Med. Hyg., 1992, 86, 624-626. 
[64] J. Sachs, P. Malaney, Nature, 2002, 415, 680-685. 
[65] P. J. Guerin, P. Olliaro, F. Nosten, P. Druilhe, R. Laxminarayan, F. Binka, W. L. Kilama, N. 
Ford, N. J. White, The Lancet Infect. Dis., 2002, 2, 564-573. 
[66] R. W. Snow, M. H. Craig, U. Deichmann, U. Marsh, Bull. WHO, 1999, 77, 624-640. 
[67] J. G. Breman, Am. J. Trop. Med. Hyg., 2001, 64, 1-11. 
[68] K. Marsh, Lancet, 1998, 352, 924-925. 
[69] F. M. A. Ukoli, `Introduction to Parasitology in Tropical Africa´, John Wiley, Chichester, 1984. 
[70] P. A. Nogueira, Res. Microbiol., 2001, 152, 141-147. 
[71] C. G. Nevill, Soc. Sci. Med., 1990, 6, 667-669. 
[72] W. A. Krotoski, Am. J. Trop. Med. Hyg., 1982, 31, 1291-1293. 
[73] World Health Organisation, Trans. R. Soc. Trop. Med. Hyg., 1990, 84, 1-65. 
[74] K. Marsh, Parasitol., 1992, 104, 53-69. 
[75] S. R. Meshnick, Med. Trop., 1998, 58, 13-17. 
  
 142 
[76] M. Korsinczky, N. Chen, B. Kotecka, A. Saul, K. Rieckmann, Q. Cheng, Antimic. A. Chemo., 
2000, 44, 2100-2108. 
[77] A. Sabchareon, P. Attanath, P. Phanuaksook, Trans. R. Soc. Trop. Med. Hyg., 1998, 92, 201-
206. 
[78] P. Winstanley, The Lancet Infect. Dis., 2001, 1, 242-250. 
[79] P. M. O’Neill, P. G. Bray, S. R. Hawley, S. A. Ward, B. K. Park, Pharmacol. Ther., 1998, 77, 29-
58. 
[80] P. A. Phillips-Howard, F. O. ter Kuile, Drug. Saf., 1995, 12, 370-383. 
[81] A. L. Bittencourt, A. Barral, Mem. Inst. Oswaldo Cruz Rio J., 1991, 86, 51-56. 
[82] World Health Organisation, `Zoonoses and veterinary public health´, 2005. 
[83] M. Siddig, H. Galid, D. Shillington, A. Petesen, S. Khidir, Trop. Geogr. Med., 1990, 42, 107-112. 
[84] K. S. Warren, A. A. F. Mahmoud, `Tropical and Geographical Medicine´, McGraw-Hill, New 
York, 1990. 
[85] S. F. Moody, Acta. Trop. Basal, 1993, 53, 185-205. 
[86] D. G. Russel, T. Talamas-Rhoana, Immunol. Today, 1989, 10, 328-334. 
[87] S. J. Turco, Biochem., 1990, 118, 74-78. 
[88] M. K. Wasseff, D. M. Dywer, J. Biol. Chem., 1985, 264, 6711-6715. 
[89] E. Braunwald, F. C. Isselbacher, R. G. Petersdor, J. D. Wilson, `Harrison’s Principals of Internal 
Medicine´, McGraw-Hill, New York, 1987. 
[90] D. T. Hart, `Leishmaniasis, The Currant Status and New Strategies for Control´, Plenum Press, 
New York, 1987. 
[91] B. C. Walton, L. L. Valvuerde, Ann. Trop. Med. Parasitol., 1979, 73, 23-27. 
[92] S. L. Croft, Mol. Biochem. Parasitol., 2003, 126, 165-172. 
[93] World Health Organisation, `WHO Model prescribing information : drugs used in parasitic 
disease´, WHO, Geneva, 1995. 
[94] C. P. Thakur, Trans. R. Soc. Trop. Med. Hyg., 1999, 93, 319-323. 
[95] W. Sieghart, Pharmacol. Rev., 1995, 47, 182-234. 
[96] G. B. Smith, R. W. Olsen, Trends Pharmacol. Sci., 1995, 16, 162-168. 
[97] D. R. Burt, G. L. Kamatchi, FASEB J., 1991, 5, 2916-2923. 
[98] R. L. Mcdonald, T. P., Cell Physiol. Biochem., 1993, 3, 352-373. 
[99] P. J. Whiting, R. M. McKernan, K. A. Wafford, Int. Rev. Neurobiol., 1995, 38, 95-138. 
[100] I. Mody, Y. DeKoninck, T. S. Otis, I. Soltesz, Trends. Neurosci., 1994, 17, 517-525. 
[101] Y. Okada, H. Taniguchi, C. Shimada, Science, 1976, 194, 620-622. 
[102] H. Taniguchi, Y. Okada, H. Seguchi, C. Shimada, M. Seki, A. Tsutou, S. Baba, Diabetes, 1979, 
28, 629-633. 
[103] H. Betz, Neuron, 1990, 5, 383-392. 
[104] J. L. Galzi, J. P. Changeux, Curr. Opin. Struct. Biol., 1994, 4, 554-565. 
[105] H. Moehler, J. M. Fritschy, B. Luescher, U. Rudolph, J. Benson, D. Benke, in `Ion Channels´, 
Ed. T. Narahashi, Plenum, New York, 1995, vol. 4, p. 89-113. 
[106] S. Mertens, D. Benke, H. Moehler, J. Biol. Chem., 1993, 268, 5965-5973. 
[107] S. Bohlhalter, O. Weinmann, H. Moehler, J. M. Fritschy, J. Neurosci., 1996, 16, 283-297. 
 143 
[108] K. H. Backus, M. Arigoni, U. Drescher, L. Scheurer, P. Malherbe, H. Moehler, Neuroreport, 
1993, 5, 285-288. 
[109] E. A. Barnard, in `GABAA Receptors and Anxiety. From Neurobiology to Treatment, Advances 
in Biochemical Psychopharmacology´, Ed. G. Biggio, E. Sanna, M. Serra, E. Costa, Raven, 
New York, 1995, vol. 48, p. 1-16. 
[110] G. Richards, P. Schoch, W. Haefely, Semin. Neurosci., 1991, 3, 191-203. 
[111] W. Haefely, in `The Challenge of Neuropharmacology. A Tribute to the Memory of Willy 
Haefely´, Ed. H. Moehler, M. Da Prada, Editiones Roche, Basel, 1994, p. 15-40. 
[112] R. E. Study, J. L. Baker, Neurons. Proc. Natl. Acad. Sci. USA, 1981, 78, 7180-7184. 
[113] E. Sigel, A. Buhr, Trends Pharmacolog. Sci., 1997, 18, 425-429. 
[114] M. D. Majewska, Prog. Neurobiol., 1992, 38, 379-395. 
[115] K. A. Wafford, D. M. Burnett, T. V. Dunwiddie, R. A. Harris, Science, 1990, 249, 291-293. 
[116] E. Sigel, R. Baur, P. Malherbe, FEBS Lett., 1993, 324, 140-142. 
[117] A. R. Smith, `Flora of tropical East Africa. Euphorbiaceae (Part 1)´, A. A. Balkema, Rotterdam, 
Boston, 1988. 
[118] J. P. M Brenan, `Flora of tropical East Africa. Leguminosae, subfamily Mimosoideae´, Crown 
agents for oversea governments and administrations, Millbank, London, 1959. 
[119] B. Verdcourt, Kew Bulletin, 1985, 40, 635-636. 
[120] N. K. B., Robson, B. Mathew, `Flora of tropical East Africa. Celastraceae´, A. A. Balkema, 
Rotterdam, Brookfield, 1994. 
[121] B. Verdcourt, `Flora of tropical East Africa. Annonaceae´, Crown agents for oversea 
governments and administrations, Millbank, London, 1971. 
[122] J. R. Tennant, `Flora of tropical East Africa. Araliaceae´, Crown agents for oversea 
governments and administrations, Millbank, London, 1968. 
[123] J. B. Gillett, `Flora of tropical East Africa. Araliaceae´, A. A. Balkema, Rotterdam, Brookfield, 
1991. 
[124] B. Verdcourt, `Flora of tropical East Africa. Rubiaceae (Part 3)´, A. A. Balkema, Rotterdam, 
Brookfield, 1991. 
[125] L. B. Mwasumbi, University of Dar Es Salaam, Tanzania, personal communication. 
[126] R. Brun, Z. V. Lun, Vet. Parasitol.,1994, 52, 37-46. 
[127] B. Raez, M. Iten, B. Y. Grether, R. Kaminsky, R. Brun, Act. Trop., 1997, 68, 139-147. 
[128] R. Kaminsky, R. Brun, Antimicrob. Agents Chemother., 1998, 42, 2858-2862. 
[129] M. Hills, C. Hudson, P. G. Smith, `WHO working paper no. 2.8.5´, WHO, 1986, Geneva. 
[130] R. E. Desjardins, C. J. Canfield, J. D. Haynes, J. D. Chulay, Antimicrob. Agents Chemother., 
1979, 16, 710-718. 
[131] R. A. Neal, S. L. Croft, Antimicrob. Agents Chemother., 1984, 14, 463-475. 
[132] B. Pagé, M. Pagé, C. Noel, C. Int. J. Oncol., 1993, 3, 473-476. 
[133] S. A. Ahmed, R. M. Gogal, J. E. Walsh, J. Immunol. Methods, 1994, 170, 211-224. 
[134] M. Karobath, G. Sperk, Proc. Natl. Acad. Sci USA, 1979, 76, 1004-1006. 
[135] U. Simmen, C. Saladin, P. Kaufmann, M. Poddar, C. Wallimann, W. Schaffner, Plant. Med., 
2005. In press. 
 144 
[136] E. Sigel, J. Physiol., 1987, 386, 73-90. 
[137] E. Sigel, R. Baur, G. Trube, H. Moehler, P. Halherbe, Neuron, 1990, 5, 703-711. 
[138] P. B. Wingrove, K. A. Wafford, C. Bain, P. J. Whiting, Proc. Natl. Acad. Sci. USA, 1994, 91, 
4569-4573. 
[139] E. Sigel, R. Baur, R. Furtmueller, R. Razet, R. H. Dodd, W. Sieghart, Mol. Pharmacol., 2001, 
59, 1470-1477. 
[140] S. Papajewski, `Isolierung und Strukturaufklärung von biologisch aktiven Pflanzeninhaltsstoffen 
aus Cussonia barteri Seemann (Araliaceae)´, Ph.D. Thesis, University of Hohenheim, 2000. 
[141] S. Papajewski, B. Vogler, J. Conrad, I. Klaiber, G. Roos, C. U. Walter, R. Suessmuth, W. 
Kraus, Plant. Med., 2001, 67, 732-736. 
[142] L. A. Tapondjou, D. Lontsi, B. L. Sondengam, F. Shaheen, M. I. Choudhary, R. Atta-ur, F. R. 
Van Heerden, H. -J. Park, K. -J. Lee, J. Nat. Prod., 2003, 66, 1266-1269. 
[143] L. A. Tapondjou, D. Lontsi, H. Bouda, B. L. Sondengam, R. Atta-ur,  M. I. Choudhary, F. R. Van 
Heerden, Chem. Res. Comm., 2002, 15, 11-19. 
[144] L. Harinantenaina, R. Kasai, K. Yamasaki, Chem. Pharm. Bull., 2002, 50, 1290-1293. 
[145] J. Gunzinger, J. D. Msonthi, K. Hostettmann, Phytochem., 1986, 25, 2501-2503. 
[146] M. A. Dubois, M. Ilyas, H. Wagner, Plant. Med., 1986, 2, 80-83. 
[147] T. G. Fourie, E. Matthee, F. O. Snyckers, Phytochem., 1989, 28, 2851-2852. 
[148] H. Weidong, L. Van Puyvelde, L. Maes, J. Bosselaers, N. De Kimpe, Nat. Prod. Res., 2003, 17, 
127-133. 
[149] F. Trotin, L. Bezanger-Beauquesne, M. Pinkas, A. Robelet, Ann. Pharm. Franc., 1972, 30, 555-
560. 
[150] H. Dadoun, A. Cave, Plant. Med. Phyto., 1972, 6, 223-227. 
[151] L. Harinantenaina, R. Kasai, K. Yamasaki, Phytochem., 2002, 61, 367-372. 
[152] L. Harinantenaina, R. Kasai, K. Yamasaki, Chem. Pharm. Bull., 2002, 50, 1122-1123. 
[153] L. Harinantenaina, R. Rakotondraibe, R. Kasai, K. Yamasaki, Chem. Pharm. Bull., 2002, 50, 
268-271. 
[154] L. Harinantenaina, R. Kasai, K. Yamasaki, Phytochem., 2002, 60, 339-343. 
[155] `Roempp encyclopedia natural products´, Ed. W. Steglich, B. Fugmann, S. Lang-Fugmann, 
Thieme, Stuttgart, 2000. 
[156] J. Bruneton, `Pharmacognosy, Phytochemistry, Medicinal Plants´, Intercept Ltd., Andover, 
1995. 
[157] R. Haensel, O. Sticher, E. Steinegger, `Pharmakognosie – Phytopharmazie´, Springer, Berlin, 
1999. 
[158] F. Bohlmann, T. Burkhardt, C. Zdero, `Naturally Occuring Acetylenes´, Academic Press, 
London, 1973. 
[159] P. B. Kaufman, L. J. Cseke, S. Warber, J. A. Duke, H. L. Brielmann, `Natural Products from 
Plants´, CRC Press, Boca Raton, 1999. 
[160] L. Hansen, P. M. Boll, Phytochem., 1985, 25, 285-293. 
[161] B. M. Hausen, J. Broehan, W. A. Koenig, H. Faasch, H. Hahn, G. Bruhn, Contact Derm., 1987, 
17, 1-9. 
 145 
[162] J-M. Kim, J-E. Shin, M. J. Han, N-I. Baek, D-H. Kim, Nat. Prod. Sci., 2003, 9, 158-160. 
[163] J. Lutomski, T. C. Luan, T. T. Hoa, Herb. Polon., 1992, 38, 137-140. 
[164] J. H. Liu, S. Zschocke, E. Reininger, R. Bauer, Pharma. Biol., 1998, 36, 207-216. 
[165] J. Lutomski, T. C. Luan, Herb. Polon., 1991, 37, 113-123. 
[166] A. F. Magalhaes, E. G. Magalhaes, H. F. Leitao Filho, V. Nunes Junior, Biochem. Syst. Ecol., 
1992, 20, 783-784. 
[167] D. Chapman, M. T. Kramers, C. J. Restall, in `Sterols and Bile Acids´, Ed. H. Danielsson, J. 
Sjoevall, Elsevier, New York, 1985, p. 151-174. 
[168] M. Kobaisy, Z. Abramowski, L. Lermer, G. Saxena, R. E. Hancock, G. H. Towers, J. Nat. Prod., 
1997, 1210-1213. 
[169] B-Y. Park, B-S. Min, S-R. Oh, J-H. Kim, T-J. Kim, D-H. Kim, K-H. Bae, H-K. Lee, J. 
Ethnopharm., 2004, 404-408. 
[170] J. A. Dale, H. S. Mosher, J. Am. Chem. Soc. 1973, 95, 512-519. 
[171] G. L. Lemière, J. J. Willaert, R. A. Dommisse, J. A. Lepoivre, F. C. Alderweireldt, Chirality, 
1990, 2, 175-184. 
[172] M. J. Rieser, Y. Hui, K. K. Rupprecht, J. F. Kozlowski, K. V. Wood, J. L. McLaughlin, P. R. 
Hanson, Z. Zhuang, T. R. Hoye, J. Am. Chem. Soc., 1992, 114, 10203-10213. 
[173] I. Ohtani, T. Kusumi, Y. Kashman, H. Kakisawa, J. Org. Chem., 1991, 56, 1296-1298. 
[174] M. Senn, U. Simmen, E. Sigel, U. Séquin, R. Brun, U.K. Pat. 04 281 64.8, 2004. 
 
 
 146 
E.    Curriculum vitae 
 
Personal data  
Name : Senn Martin Werner 
Date and place of birth : April, 17th 1968 in Dornach (SO) 
Place of origine : Buus (BL) 
Nationality : Swiss 
Marital status : married (2 children) 
 
School education 
1975 - 1980 Primary school, Reinach (BL) 
1980 - 1984 Secundary school, Reinach (BL) 
4/1984 - 4/1987 Apprenticeship as laboratory technician  
1989 - 1992 Eidg. Matura in Economy 
 
University education (University of Basel, Switzerland) 
1993 - 1994 Basic studies I in Pharmaceutical Sciences 
1994 - 1995 Basic studies in Medicine 
1995 - 1996 Basic studies II in Pharmaceutical Sciences 
9/1996 - 11/1996 Practical training at the hospital pharmacy of 
Kantonsspital Aarau 
(as part of the studies in Pharmaceutical Sciences) 
12/1996 - 9/1997 Practical training at Kronen-Apotheke, Binningen 
(as part of the studies in Pharmaceutical Sciences) 
9/1997 Federal diploma as assistant pharmacist 
1997 - 1999 Specialised studies in Pharmaceutical Sciences 
11/1999 Federal diploma in Pharmaceutical Sciences 
9/2000 - 12/2004 Ph.D. thesis in Phytochemistry and Medicinal 
Parasitology : ′Structures and Evaluation of 
Biologically Active Constituents of Cussonia 
zimmermannii Harms′, supervised by Prof.  
U. Séquin, Department of Chemistry, University  
of Basel and Prof. R. Brun, Swiss Tropical Institute, 
Basel. 
 
 147 
Professional experience 
4/1987 - 12/1988 Employment as laboratory technician 
1/1989 - 7/1989 Employment as laboratory technician 
1997 - 1999 Deputyship as assistant pharmacist  
2000 - 2004 Deputyships as pharmacist  
 
Teaching experience 
2002 - 2004 Teaching assistant  
Department of Chemistry, University of Basel 
 
 
 148 
Lectures and courses of the following professors were attended during the 
pharmaceutical education at the University of Basel : 
 
J-P. Barras, H. Durrer, J. Drewe, U. Eppenberger, A. Fahr, T. Günthert, D. Haag, A. 
Hädener,  W. Häfeli, K. Hersberger, R. Hof, A. Kress, L. Landmann, H. Leuenberger, 
B. Meier, J. Meier, P. Oelhafen, H.-R. Olpe, M. Rüegg, H. Seiler, W. Schaffner, A. 
Scholer, U. Séquin, I. Sick, H. Sigel, P. Strazewski, P. Wolf, A. Zuberbühler. 
 
Lectures and courses of the following professors were attended during the medicinal 
education at the University of Basel : 
 
R. Baur, L. Hösli, Th. Kaden, D. Ladewig, L. Landmann, H. Mäcke, P. Oelhafen, U. 
Séquin, H. Sigel, W. Weber. 
 
Lectures and courses of the following professors were attended during the post-
graduate education at the University of Basel : 
 
Th. Boller, H. Gampp, B. Giese, J. Meier, M. Oehme, U. Séquin, M. Tanner, N. 
Weiss, W. Woggon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
